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1. Introduction 
 
1.1. The stomach  
 
1.1.1. Development of the stomach 
Early in embryonic development of vertebrates the mono-layered blastula 
evolves into the so called gastrula. During this process called gastrulation, totipotent 
cells of the epiblast are partitioned into the three germ layers, i.e. ectoderm, mesoderm 
and endoderm. The ectoderm gives rise to skin and central nervous system, the 
mesoderm forms blood, bone and muscle and the endoderm forms glands of thyroid, 
thymus, pancreas and liver as well as epithelium of lung, esophagus, stomach, intestines, 
and colon. The latter group is usually referred to as the gut [1].  
During early development the gut is arranged into four axes, namely the anterior-
posterior (AP) axis, the dorsal-ventral (DV) axis, the left-right (LF) axis and the radial 
(RAD) axis. Through further differentiation and regional specific morphological 
development, the AP axis later on forms three different regions: The foregut will develop 
into pharynx, esophagus and stomach, the midgut will give rise to the small intestine and 
the hindgut will form the colon [2]. 
Expression of several transcription factors as well as activity of different signaling 
pathways during fetal development is influencing the specification of endoderm. Among 
others SOX genes, HOX genes, GATA5 and FGF10 as well as the canonical 
WNT/Catenin, Hedgehog, Notch, and BMP pathway play a crucial role in foregut and 
stomach formation. Also, enduring epithelial-mesenchymal crosstalk is mandatory for 
several steps of stomach development, such as gland formation, regionalization and cell 
differentiation [3-5]. Disorders in these tightly regulated systems frequently lead to 
tumorigenesis in the adult stomach. 
 
1.1.2. Anatomy and function of the stomach 
The vertebrate gastrointestinal (GI) tract is a specialized vital organ derived from 
an ordinary tube-like structure and consists of GI tract derivatives, namely thyroid, lung, 
pancreas, liver and the gut (esophagus, stomach, intestine and colon). The main function 
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of the gut is to digest and absorb nutrients. After mastication the second phase of 
digestion proceeds in the stomach where food is enzymatically converted into chyme.  
The stomach is located between esophagus and small intestine and is connected 
to both by cardia or pylorus, respectively. It can be divided into three parts, i.e. fundus, 
body (or corpus) and antrum (Fig.1).   
 
Fig. 1: Anatomy of the stomach (modified from Peek and Blaser [6]) 
The gastric wall consists of five different layers. The inner lining, namely the 
mucosa contains the gastric glands. Underneath the mucosa lies the submucosa, 
followed by a muscle layer and the subserosa. The outer layer is the so called serosa [7]. 
The gastric mucosa consists of multiple gastric units, comprised of gastric glands. 
Glands feed into gastric pits that open through a single layer of epithelial cells into the 
stomach lumen. Depending on anatomical regions of the stomach the gastric units vary 
in structure and composition [8]. The continuously renewing epithelium of the stomach 
corpus consists of four different main cell types: Surface mucus faveolar (pit) cells, 
parietal (oxyntic) cells, zymogenic (chief) cells, and hormone-secreting enteroendocrine 
cells (Fig.2). In comparison, glands of the stomach antrum have only few parietal and 
zymogenic cells but a separate population of mucus-secreting cells near the base of the 
glands [9].  
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Fig.2: Scheme of a corpus stomach gland [10]. The yellow cell in the isthmus depicts a 
presumable gastric stem cell.  
 
1.1.3. Gastric stem cells 
Almost every tissue of an organism is renewed during lifetime. Differentiated 
cells are replaced by new mature cells which originate from tissue specific adult stem 
cells. In several different tissues, e.g. in the intestine, self renewal has been extensively 
studied. However, only little is known about adult stem cells in the stomach. There is 
consensus that most adult stomach glands are monoclonal, meaning each gland derives 
from its own stem cells [11, 12]. According to numerous independent studies using 
labeled nucleotide incorporation assays and ultrastructural investigations, immature 
presumable gastric adult stem cells, that maintain and regenerate gastric epithelium, 
might be located in the isthmus of gastric glands. Characteristics of those cells were high 
nucleus-to-cytoplasm ratio, lack of granules, open chromatin, undeveloped rough 
endoplasmatic reticulum, many free ribosomes, and few mitochondria [13-19]. The 
isthmus lies in the upper third of typical corpus glands and in the lower third of glands of 
the stomach antrum. Cellular migration takes place bidirectional from this area. Cells 
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differentiate into gastric surface mucus cells coating the gastric pits and gastric 
zymogenic and parietal cells at the base of the glands. Zymogenic cells are supposed to 
be progeny of glandular mucous neck cells. Stem cells are also self-renewing and give 
rise to enteroendocrine cells (Fig.3) [9, 20, 21]. 
 
Fig.3: Stem cell theory in corpus epithelial glands [10]. The presumable stem cell is self-renewing and 
gives rise to all other epithelial lineages. 
 
In contrast to this dogma, studies by Barker et al. more recently postulated 
presumable gastric stem cells being located much lower in the glands, i.e. in the 
glandular base of stomach antrum and pylorus. Using lineage tracing experiments in 
mice, they found a Lgr5 expressing cell population that could give rise to all antral and 
pyloric unit cells and expressed several proliferation markers. In stomach corpus 
epithelium, however, Lgr5+ cells are only detected in neonatal mice and disappear soon 
after birth (Fig.4) [22]. Therefore, the gastric stem cell maintaining the adult gastric units 
still need to be identified and specific markers defined. 
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Fig.4: The gastric stem cell; two schools of thought (modified from Vries et al. [23]) Proposed localization 
of adult stem cells in gastric glands. 
 
Furthermore, contrary to current assumptions that adult stem cells remain in a 
quiescent state, Barker et al. reported that Lgr5+ cells are rapidly dividing under 
homeostatic conditions. Their findings were based on their earlier lineage tracing 
studies, in which they identified Lgr5 to be a putative intestinal stem cell marker [24]. 
Lineage tracing is, since several years, an excellent tool to test for actual “stemness” of 
cells. The approach is based on genetic labeling of stem cells. Stem cells are assumed to 
pass their genetic background to all progeny, thus labeling all daughter cell population 
which then can be traced in vivo. Barker et al. used mice harboring a Lgr5-GFP-IRES-
CreERT2 in which CreERT2 is expressed at all Lgr5 sites [24]. The CreERT2 is an inducible 
version of Cre-recombinase [25]. The Cre enzyme is inactive in the cytoplasm, being 
fused to a mutated human estrogen receptor (ER) binding-domain. Upon induction with 
tamoxifen, a synthetic estrogen antagonist, Cre recombinase can translocate into the 
nucleus and excise DNA flanked by loxP recognition sites [26]. Lgr5-CreERT2 mice where 
crossed into Rosa26-LacZ Cre-reporter mice [27]. A loxP flanked stop codon in front of 
the LacZ gene of the Rosa26-LacZ Cre-reporter inhibits LacZ expression until tamoxifen is 
applied to the system, which then subsequently results in irreversible genetic labeling of 
Cre-expressing Lgr5+ cells and all their progeny by excision of the stop cassette (Fig.5). 
The labeling can be visualized by an enzymatic blue staining of the tissue [24, 28]. 
Observation of blue cell clones over time thus gives insight into growth kinetics, 
multipotency and longevity of the original marked cell [29].  
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Fig.5: In vivo lineage tracing approach (modified from Snippert et al. [29]) A) In not induced stem cells 
only GFP and an inactive Cre recombinase are expressed B) After induction with tamoxifen Cre 
recombinase can enter the nucleus and excise loxP sites, thus LacZ can be transcribed C) Daughter cells do 
no longer express GFP and Cre, however, LacZ expression remains 
 
A further lineage tracing approach in the murine stomach was made by Qiao et 
al. by marking cells expressing the villin promoter. Villin is intestine specific and usually 
not expressed in the stomach. Nevertheless, single villin promoter positive cells in 
varying positions between isthmus and base of antral glands were identified, that gave 
rise to all cells within an antral gland after stimulation with interferon gamma (IFNy). As 
these cells seem to replicate only after cytokine stimulation, they are not likely to be real 
stem cells, but rather a stem-cell like population regulating epithelium renewal, e.g. 
after injury [21].  
In the glands of stomach corpus, Trefoil factor family 2 (Tff2) positive cells were 
found to give rise to a limited spectrum of lineages. TFF2 is a regulator of mucosal repair 
in the stomach and is also used as an indicator of metaplastic changes [30]. Tff2 mRNA is 
expressed in cells in the isthmus of corpus glands. Lineage tracing experiments in mice 
revealed that parietal cells, as well as mucus neck cells and zymogenic cells are progeny 
of Tff2+ cells. Yet, mucous pit cells and enteroendocrine cells were never labeled and 
Tff2+ cells and their progeny never survived more than 200 days. These findings 
emphasize that Tff2+ cells are not true gastric stem cells [31].  
MIST-1 (chief cells of corpus gland base) [32], CD44 (corpus and antrum gland 
base) [33], DCAMKL1 (corpus gland isthmus) [34] and PROM1 (Prominin-1) (antral gland 
base) [35] are other candidates for presumable markers for gastric stem cells, but have 
only marginally been investigated so far and roles need to be clarified. 
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The transcription factor SOX2 is, in concert with OCT4 and NANOG, an essential 
factor for pluripotency in ES cells (see Introduction 3.3). While analyses of OCT4 and 
NANOG in reporter animals and knock out studies failed to confirm their contribution to 
pluripotency in adult stem cells, evidences have accumulated that SOX2 plays an 
important role in these cells [36]. Lately SOX2 has been reported in various adult 
progenitors (see Introduction 3.3). Therefore, we suspected a role for SOX2 in gastric 
stem cells. While this thesis work was in progress Arnold et al. published their work on 
adult stem cells. Here Sox2 was investigated via lineage tracing experiments in several 
different mouse tissues. In glands of stomach corpus as well as pylorus, Sox2+ cells gave 
rise to all mature glandular cells. Sox2+ cells were mostly located in the glandular base, 
but co-staining experiments revealed that they were rare and not identical with Lgr5+ 
cells. Villin-expressing cells in antral glands, however, might coincide with Sox2+ cells, 
but further studies need to be done [37]. These findings suggest that there might be 
several different types of adult stem cells in the stomach, which are, among other 
factors, dependent on the stomach region. This idea resembles the recently postulated 
hypothesis for intestinal stem cell markers which also seem to label different cell 
populations [24, 38-40].  
Furthermore, in contrast to intestinal stem cells, gastric stem cells have an 
essential challenge to overcome: there is a substantial difference in turnover rates of 
epithelial stomach cells, as surface-associated mucous cells have a life span of 3 – 5 days, 
whereas the life span of zymogenic cells is several months [13]. Thus, gastric stem cells 
must generate many more precursor cells of pit cells than of chief cells in every 
differentiation cycle. How stomach stem cells accomplish to drive their progeny toward 
the different lineages is not clear yet. 
Taken all this together, it is obvious that the characteristics, the markers and the 
niche of gastric stem cells have not been entirely identifed to date. 
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1.2. Gastric cancer 
 
1.2.1. Epidemiology of gastric cancer 
Gastric cancer (GC) is the fourth most common cancer and the second most 
common cause of cancer-related death worldwide, as its average 5-year-survival rate is 
only 25 % [41]. The risk of developing GC is 6 to 10 times higher in undeveloped 
countries like Latin America and parts of Eastern Europe compared to Northern America 
and Western Europe [41] and it is more prevalent in African-Americans, Hispanics and 
Native Americans than in Caucasians [42]. Occurrence of GC shows also a distinct gender 
specific distribution, as males develop GC about twice as often as females [43]. Highest 
risk comes with age. 80 % of patients are between 50 and 70 years old [44]. GCs have 
also strongly been linked to several environmental factors, among others up-take of 
high-salted food and tobacco smoking, which might nearly double the risk compared to 
non-smoking population [45, 46]. Helicobacter pylori (H. pylori) is one of the most 
important high risk factors for GC [47]. Although early preventions and eradications of H. 
pylori have increased during the last years and therefore incidence of GC has declined 
[43], every year approximately 500 000 people worldwide newly developed GC [48]. 
Diagnosis is often made very late, as symptoms (e.g. abdominal pain, blood in stool, 
weight loss) occur mainly after the tumor has reached an advanced stage and infiltrated 
the muscularis propria. This results in poor prognosis and low survival rates [49]. 
 
1.2.2. Classification of gastric cancer 
Different types of gastric tumors can occur in the stomach, e.g. gastrointestinal 
stromal tumors (GIST), mucus-associated-lymphoid-tissue- (MALT-) lymphomas or 
squamous epithelial lymphomas, sarcomas, that arise from cells of the muscle layer and 
carcinoid tumors, arising from neuroendocrine cells [50]. However, the most prevalent 
gastric tumors are adenocarcinomas (95 % of all gastric tumors) [51] which derive from 
glandular epithelium of gastric mucosa and are highly malignant.  
Many approaches have been made to classify gastric adenocarcinomas, such as 
the Ming [52] or the World Health Organization (WHO) classification. Another widely 
used characterization is the DIO system firstly proposed by Laurén in 1965 based on 
 Introduction                             
 
25 
 
tumor histology. According to this system gastric adenocarcinomas are classified as 
diffuse (D), intestinal (I) or other (O). Intestinal-type tumors are highly differentiated and 
cohesive neoplastic cells show gland-like tubular structures. In contrast, the diffuse-type 
GC is less differentiated and cells are not cohesive, infiltrating and thickening the 
stomach wall. Furthermore, in this subtype signet ring-cells are found in the gastric 
mucosa. The diffuse-type tumor has higher metastatic potential and thus shows poorer 
prognosis than the intestinal-type tumor. About 10 – 15 % of gastric adenocarcinomas 
show characteristics of both subtypes and therefore are declared as mixed-type tumors 
[53, 54].  
 
1.2.3. Development of gastric cancer 
Several environmental factors and susceptible genetic variants as well as various 
genetic and epigenetic alterations in cell cycle regulators, oncogenes, tumor suppressor 
genes, growth factor systems, DNA repair genes, cell adhesion molecules and 
telomerase activations are supposed to be involved in the multiple-step development of 
GC. However, intestinal- and diffuse-type GC seem to differ substantially in decisive 
combinations of these alterations, suggesting two different carcinogenesis pathways for 
the two subtypes [55-57]. 
 Intestinal-type gastric cancer 
Gastric tumors are not a result of one specific event but develop out of multiple 
combinations of factors. In 1975 Correa and coworkers for the first time postulated a 
model which proposed sequential steps leading to changes in histomorphology of the 
gastric mucosa and eventually to GC. In their model, the so called Correa-pathway, pre-
cancerous lesions (gastritis/atrophy) are followed by intestinal metaplasia, dysplasia and 
finally gastric carcinogenesis (Fig.6) [58]. However, there are two further possible routes 
leading to intestinal-type gastric carcinomas postulated. Intestinal metaplasia may 
resume directly in GC and GC may develop de novo with no foregoing steps needed [57].  
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Fig.6: Histology of the Correa-pathway A) Normal gastric mucosa B) Gastritis C) Complete intestinal 
metaplasia D) Dysplasia E) Intestinal-type adenocarcinomas (kindly provided by R. Mejias-Luque) 
 
The first step of the Correa-pathway is usually chronic active non-atrophic 
gastritis which is typically triggered by H. pylori infection and characterized by 
infiltration of the mucosa by white blood cells (lymphocytes, plasma cells, 
macrophages). Additionally, eosinophiles, mast cells and polymorphoculear neutrophils 
can be detected.  
The second stage, atrophic gastritis, is typified by changes in the cell cycle which 
lead to proliferation and apoptosis and results in atrophy (loss of glands) and 
replacement of parietal cells by mucous secreting cells [59].  
This step can be followed by intestinal metaplasia (IM). IM shows cells 
characteristic for the intestine, namely absorptive enterocytes with a brush border, 
goblet cells containing mucins and paneth cells harboring eosinophilic granules in their 
cytoplasm. They are typically found at the base of the glands [60]. Accordingly, genes 
specific for the intestine have been identified in intestinal metaplasia, e.g. MUC2 and 
MUC4 in goblet cells [61], Villin in enterocytes or DEF (defensines) in paneth cells [62]. 
Several genes, functions and regulators are known to be deregulated in intestinal 
metaplasia. Among others these are CCND2 (Cyclin D2), COX2, telomerases, 
microsatellite instability, reduced expression of CDKN1B (p27), APC (Adenomatous 
polyposis coli) loss, mutation/LOH in TP53 [50, 63]. Furthermore, numerous researchers 
stated a correlation of deregulation of specific transcription factors and intestinal 
metaplasia. The intestine specific transcription factor Caudal type homeobox 2 (CDX2) 
for example is a master regulator in mammalian gut and important for intestinal 
development and differentiation [64]. Loss of CDX2 leads to gastric differentiation in the 
colon [65]. Accordingly, aberrant expression of CDX2 in the stomach results in 
intestinalization and is a key event for intestinal metaplasia [66].  
Dysplasia is the next step in the Correa-pathway cascade. As it results in pre-
invasive neoplastic changes in the gastric glands it is also called intraepithelial neoplasia. 
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This lesion is characterized by atypical changes in cells and tissue architecture. Nuclei are 
often enlarged and hyperchromatic, due to a higher proliferation rate in an increased 
number of cells. Glands are distributed abnormally with irregular lumens. Dysplasia is 
classified as low- or high-grade depending on the degree of atypia in nuclei and gland 
deformation [59]. Molecular characteristics of dysplasia are similar to those detected in 
GC. Typically this is loss of heterozygosity in the APC gene, as well as aberrant expression 
of TP53 (p53), CDKN1A (p21) and BCL2 [63].  
In intestinal-type adenocarcinomas numerous genetic and epigenetic alterations 
can be observed. As mentioned above these are LOH or missense mutations in the APC 
gene as well as reduced expression in tumor suppressor genes, namely TP53, TP73 (p73), 
CDKN1B (p27) and TFF1 [50]. TP53 and TP73 are usually inactivated by LOH whereas loss 
of TFF1 expression is believed to arise due to DNA methylation in its promoter region 
[57]. In addition, TFF1 has been described to be down-regulated by STAT3 in a mouse 
model bearing a mutation in the GP130 receptor. These mice develop tumors after 4 
weeks of age, due to hyperactivated STAT3 signaling, indicating a key role of STAT3 in 
gastric oncogenesis [67]. Loss of APC expression enhances the expression of CTNNB1 (-
Catenin), which acts as an oncogene. Other alterations known to be involved in 
development of intestinal type adenocarcinomas are loss of RUNX3 expression, LOH on 
chromosome 7q, amplification of  ERBB2 and CCNE1 (cyclin E), CD44 and CD46 aberrant 
transcripts, epigenetic alterations in MLH1, a mismatch repair gene, DS191 instability 
and over expression of several growth factors (EGF, TGFa, IGFII, bFGF) (Fig.7) [50]. 
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Fig.7: Genetic and epigenetic alterations in intestinal-type GC modified from Smith et al. [50] 
 Diffuse-type gastric cancer 
Although particularly intestinal-type GC has been associated with H. pylori 
infection, there have been some recent studies, showing also a link between diffuse-
type GC and H. pylori [68, 69]. However, in pathogenesis of diffuse-type GC preceding 
steps like they are known in intestinal-type cancer are not well understood yet. It is 
assumed that diffuse-type GC rather arises from single-cell changes in the mucus-neck 
region of gastric glands. These cells then may proliferate and invade from the crypt in 
the lamina propria.  
Several molecular mechanisms are known to be involved in the generation of 
diffuse-type GC, including alterations in tumor suppressor genes, activation of proto-
oncogenes, aberrant expression of cell cycle regulators and growth factors. 
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Fig.8: Genetic and epigenetic alterations in diffuse-type GC modified from Smith et al. [50] 
 
A well studied example of alterations in tumor suppressor genes is the autosomal 
dominantly inherited germ line mutation of CDH1 (E-cadherin) in patients with 
hereditary diffuse gastric cancer (HDGC). Carriers of the germ line mutation have a more 
than 70 % life time risk of developing GC [70]. Furthermore, it is also strongly associated 
with the risk of women to develop breast cancer [71]. Interestingly, also in 40 - 83 % of 
sporadically occurring diffuse-type adenocarcinomas of the stomach a somatic mutation 
of CDH1 gene has been observed, but was never identified in intestinal-type GC [72]. 
Additionally, E-cadherin loss can also be found in mixed-type GC, but only in the diffuse 
section, suggesting it to be a possible genetic variable driving gastric cancer towards 
diffuse or intestinal differentiation [73]. Another tumor suppressor gene mutated in GC 
is TP53. It is prevalently inactivated by loss of heterozygosity (LOH), missense mutations 
and framshift deletions, frequently GC-AT transitions in diffuse-type GC [74]. Other 
tumor suppressor genes that appear to be affected in diffuse-type GC are loss of RUNX3 
and histone H4 deacetylation [50].  
Furthermore, several proto-oncogenes are activated in diffuse-type GC. In 39 % 
of cases this is MET (c-met), a tyrosine kinase receptor gene encoding for hepatocyte 
growth factor receptor. 33 % of diffuse-type GC show over expression of type II FGFR3 
oncogene, a receptor for keratinocyte growth factor.  
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Other known important factors influencing the development of diffuse GC are 
CD44 and CD46 aberrant transcripts, CCNE1 (Cycline E) amplification, reduced 
expression of the CDK inhibitor TP27, reduced expression of NME1 (nm23), LOH on 
17q21, including BRCA1 gene, LOH on 7q, and over expression of growth factors (TGFb, 
bFGF, IGF II) (Fig.8) [50]. 
 
1.2.4. Helicobacter pylori and gastric cancer 
H. pylori is a gram negative, motile, microaerophilic bacterium. It can colonize the 
human stomach and is responsible for development of atrophic gastritis and peptic ulcer 
which can later on lead to GC [47]. Therefore, in 1994 the WHO defined H. pylori as a 
type I carcinogen. Prevalence of H. pylori infection differs highly among populations [75] 
and increases with age [76]. Severity of gastric damage and clinical outcome are 
supposed to be dependent on bacterial virulence factors as well as genetic background 
of the host. 
 Bacterial virulence factors 
The best studied virulence factor in H. pylori is the cag pathogenicity island (PAI) 
Type IV secretion system. CagA, the product of the terminal gene in the island, is 
translocated into epithelial cells by this system [77], where it is phosphorylated at 
certain glutamate-isoleucine-thyrosine-alanine (EPIYA) motifs by Src-kinases. CagA can 
then activate the Ras-mitogen activated protein kinase (MAPK) pathway and the EGF 
receptor and thus leads to changes in intracellular signaling and morphological changes 
in the epithelium. CagA can also bind to numerous host proteins, like SHP-2 and MET 
thereby inducing subsequent aberrant signaling which leads to apoptosis and increase 
cell turnover of epithelial cells [78, 79]. Another known pathway influenced by CagA is 
the E-cadherin/-catenin pathway, which regulates junction formation, cell adhesion 
and cell growth [80]. Interaction of CagA with this system can also lead to direct 
transactivation of CDX1 and thus to mucosal metaplastic changes [81]. Furthermore, 
CagA can activate NF- leading to IL-8 secretion [82].  
Another major virulence factor in H. pylori is the secreted pore-forming protein 
vacuolating cytotoxin A (VacA). VacA gene structure can be divided into a signaling (s), a 
middle (m) and a recently identified intermediate (i) region. The majority of H. pylori 
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strains express VacA, but variations in the subtype result in differences of cytotoxicity. 
VacA s1 and VacA m1 were assumed to be most cytotoxic and thus highly associated 
with GC, however, recently also VacA i1 was identified to contribute to malignant 
invasive tissue formation [83, 84]. VacA induces vacuole formation in epithelial cells, 
leading to altered antigen presentation [85]. Moreover, disruption of the epithelial 
barrier as well as pore-formation in mitochondrial membranes which may lead to the 
activation of apoptosis has been reported [86, 87]. Besides, it interferes with GSK3 
pathway which leads to -Catenin release and modulation of apoptosis and cell cycle 
regulation [88, 89]. 
The outer-membrane protein BabA (Blood group antigen binding) binds to the 
Lewis b antigen on the surface of gastric epithelial cells and facilitates entering of the 
host epithelium by the bacteria [90]. BabA expressing strains of H. pylori promote a 
more pathogenic phenotype and presence of BabA is significantly associated with higher 
incidence of gastric adenocarcinomas. H. pylori strains expressing BabA concomitant 
with VacA and CagA are associated with highest risk for developing GC [91]. 
 Genetic background of the host 
Not only bacterial virulence factors but also host genetic factors are profoundly 
influencing the outcome of an H. pylori infection and progression to GC. It is known that 
H. pylori triggers chronic inflammation in the gastric mucosa through several pro- and 
anti-inflammatory cytokines, though alterations in genes involved in immune response 
have been reported to cause an increased risk for the host. IL-1a strong inhibitor of 
acid secretion, is one of the most important pro-inflammatory cytokines produced in 
response to H. pylori infection [92]. Specific single nucleotide gene polymorphisms (SNP) 
in the IL1B locus are associated with a higher risk for developing GC. For example, higher 
rates of atrophy and gastritis are found in patients with the genotype IL1B 511 T/T 
correlating with an increase in pH of gastric juices [93, 94].  
TNF-, a pro-inflammatory cytokine mainly produced by activated macrophages 
in immune response is also secreted in response to H. pylori infection. It is an 
endogenous pyrogen and induces inflammation. Like IL-1, it also has an acid inhibitory 
effect. Polymorphisms in TNFa are reported to correlate with many inflammatory 
conditions and thus promote the risk of GC [95].  
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IL-8 is a further important cytokine associated with H. pylori pathogenesis. Its 
primary function is to recruit neutrophiles at the site of inflammation during innate 
immune response. Promoter polymorphisms at the -251T allele influence neutrophil 
infiltration in the gastric mucosa and increase the risk of atrophic gastritis and GC [96]. 
IL-10 is an anti-inflammatory cytokine that down-regulates pro-inflammatory 
cytokines, e.g. IL-1 and TNF-. Polymorphisms that result in low production of IL-10 
elevate the risk of developing GC after H. pylori infection. 
Furthermore, changes in pattern recognition factors, like TLR4, NOD1, and NOD2 
as well as aberrant gene expression of proteases, mucins, HLA molecules, xenobiotic 
metabolism enzymes, cell cycle regulators, and DNA repair enzymes play a major role in 
H. pylori induced disease [81].  
 Inflammatory response induced by H. pylori 
Inflammatory response of H. pylori includes the release of pro-inflammatory 
cytokines such as IL-1 and IL-6. To analyze the etiological role of IL-1 in gastric 
carcinogenesis a transgenic mouse model over expressing Il1b in the stomach was 
established. Il1b transgenic mice developed spontaneous inflammation, metaplasia, 
dysplasia and carcinoma of the stomach, demonstrating that increased levels of IL-1 
can be sufficient to induce neoplasia [97].  
Increased levels of IL-6 have been described in the gastric mucosa of H. pylori 
infected subjects [98, 99]. IL-6 signaling is mainly mediated by STAT3. A significant 
increase in STAT3 activation has been detected in H. pylori infected patients as well as in 
adenocarcinomas [100]  and it has been proposed as a prognostic factor for poor 
survival of GC patients [101]. STAT3 activation involves binding of the cytokine to a 
membrane bound IL-6 receptor, triggering heterodimerization with GP130 and 
activation of GP130-associated Janus kinases (JAK). Latent STAT3 monomers are then 
recruited to the phosphorylated residues of the GP130 receptor and phosphorylated by 
JAK1 and JAK2, resulting in their dimerization and translocation to the nucleus where the 
STAT3 DNA-binding domain interacts with STAT binding sites in target gene promoters 
[102]. 
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1.2.5. The Cancer stem cell theory  
The cancer stem cell (CSC) theory is based on the hypothesis that a 
subpopulation of cells within a tumor is the origin of the tumor, responsible for 
persistence and spreading. CSCs therefore have characteristics of adult or embryonic 
stem cells, namely self-renewal, a proliferative ability to drive continuous growth and 
the generation of differentiated cells [103]. They are supposed to be responsible for 
tumor initiation, invasion, metastasis and chemoresistance [104]. CSCs may arise from 
tissue specific adult stem cells or originate through degeneration of somatic progenitors 
within the tissue (Fig. 9) [105].  
                                              
Fig.9: Cancer stem cell theory (modified from Jordan [105]) Normal adult tissue arises from adult stem 
cells that differentiate in progenitor cells which give rise to mature cells. Throughout mutations in normal 
stem cells or progenitor cells cancer stem cells can develop, self-renew, grow and differentiate into 
primary tumors. 
 
CSCs have been characterized in many tumors including breast [106], ovary [107], 
brain [108], pancreas [109], head and neck [110], colon [111], and cancer of the blood 
[112, 113]. However, only little is known about cancer stem cells in gastric 
adenocarcinomas. In 2009 Takaishi at al. identified a CD44+ self-renewing cell fraction in 
GCs which possessed the ability to give rise to differentiated daughter cells and was 
chemo- and radioresistant. Nevertheless, CD44 is not specific for GC stem cells and 
further markers need to be identified [33]. Recently Rocco at al. disproved CD44+ cells 
to have cancer stem cell properties in primary human gastric tumors [114]. A further 
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suggestion of the origin of GC stem cells was given by Barker et al. They postulated that 
deletion of APC in putative LGR5+ gastric cancer stem cells in the stomach leads to rapid 
development of gastric adenomas, thus implicating that LGR5+ gastric stem cells might 
be the origin of APC driven adenomas in GC. However, this is only proven for cells at the 
base of the pyloric glands in the distal stomach [22].  
 
 
1.3. The transcription factor SOX2 
 
1.3.1. General characteristics of SOX (Sry box) proteins 
In 1990 SRY (Sex determing region Y) was the first member of SOX proteins 
identified [115]. SOX proteins build a group of transcription factors which are all largely 
conserved in their high mobility group (HMG) domain, which is their DNA binding 
domain of approximately 79 amino acids. The conserved amino acid motif in the HMG 
box is RPMNAFMVW. An exception is the first identified SOX protein SRY, which shares 
only a part (RPMNAF) of the conserved motif [116]. Furthermore, all SOX proteins bind 
to variants of the DNA sequence 5’- (A/T)(A/T)CAA(A/T)G -3’ [117]. The SOX superfamily 
can be further divided into two groups: The SOX/TCF/MATA family binds specific DNA 
motifs, whereas members of the HMG/UBF group bind less specific [118]. Members of 
the SOX/TCF/MATA group usually bind to the minor groove of the DNA double helix. 
Binding causes a strong DNA bending which might bring distal proteins on gene 
promoters and enhancer closer together, facilitating functional interaction [119]. SOX 
proteins are restricted to animal kingdom and can be subdivided according to 
phylogenetic analysis of their HMG box domain. 10 subgroups (A-J) are identified so far, 
of which 8 groups (A-H) are present in mice and humans. All SOX proteins share around 
50 % homology within their HMG box with SRY, however, group internal amino acid 
homology can be up to 90 % [116, 120]. Even though classification is solely based on 
sequence comparison, SOX proteins in the same group have similar biochemical 
properties and biological functions [121]. SOX transcription factors are expressed in 
embryos as well as in adults and are known to be involved in many different 
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developmental and proliferative processes in different tissues. They are also implicated 
in the etiology of different diseases and certain cancers [116, 122]. 
 
1.3.2. Classification and localization of SOX2 
The transcription factor SOX2 belongs to the group B of SOX proteins. This group 
can be further divided into two subgroups, namely group B1 and group B2. SOX2 
belongs, among SOX1 and SOX3, to the subgroup B1. Group B2 consists of SOX14 and 
SOX21 and their protein interaction domain acts as a transcription repressor. In contrast, 
the protein interaction domain of SOX1, SOX2 and SOX3 acts as an activator of 
transcription [123].  
 
Fig.10: Homology of chicken SOX proteins in group B (modified from Kamachi [124]). The scheme shows 
similarity of HMG domain amino acids in chicken, relative to SOX2. Color code: Red - group B homology, 
light red - group B1 homology, purple - group B2 homology, orange - poly alanine sites, brown - PRD 
repeats 
 
Expression of members of the SOX B1 family is prevalent in early embryo, 
developing testis, and nervous system and plays a crucial role in cell fate determination 
and cell differentiation during mouse development [125-127]. SOX2 is the best studied 
and probably also the most important gene in the SOX B1 family. It is located at the 
short arm of chromosome 3 at position 3q26.3 – q27. Human SOX2 (hSOX2) gene 
consists of a coding nucleotide sequence of 2511 bp length, is intronless and highly 
conserved in vertebrates. The SOX2 gene encodes a 317 aa long SOX2 protein with a 
molecular mass of about 34 kDa. The chicken homologue cSox2 has 95 % total amino-
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acid identity to hSOX2. Mouse Sox2 (mSox2) shows even 97 % of similarity to hSOX2 
amino acid sequence [128].  
 
1.3.3. SOX2 in pluripotency and development 
Embryonic stem (ES) cells emerge from the inner cell mass (ICM) of blastocysts 
and proliferate while sustaining pluripotency, thus contributing to all three germ layers 
and the respective tissues of an embryo [129]. Because of their origin they are not only 
interesting in regard to cellular processes of development but also for therapeutical 
approaches in respect to malignancies. SOX2 is, among OCT4 (POU5F1) and NANOG, one 
of the main regulators of pluripotency in ES cells [130-132]. The current model suggests 
that, on the one hand, SOX2, OCT4 and NANOG bind to promoter regions of genes 
associated with pluripotency and on the other hand to promoters of genes involved in 
differentiation. Thereby they operate as activators of transcription of pluripotency genes 
and repressors of genes for differentiation (Fig. 11) [133].  
 
                                         
Fig.11: Model of maintenance of pluripotency in ES cells (modified from Chickarmane [134]) OCT4, SOX2 
and NANOG build a core unit of a transcriptional network for maintaining pluripotency. They bind to the 
regulatory region of a number of genes, therefore operating as activators or repressors. They can target 
genes individually as well as jointly. A and B represent extrinsic and intrinsic factors influencing the 
system.  
 
But not only in ES cells is SOX2 a marker for pluripotency. A study by Takahashi 
and coworkers in 2006 for the first time described that ectopic co-expression of four 
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transcription factors is enough to induce mouse fibroblast to dedifferentiate into 
pluripotent stem cells, so called induced pluripotent stem cells (iPS). Those four factors 
were SOX2, OCT4, KLF4 and C-MYC [135]. In the mean time several somatic cells in 
different species have been reported to dedifferentiate into iPS with similar 
reprogramming strategies all including SOX2 [136-138]. These studies again elucidate 
the exceptional role of SOX2 in pluripotency. 
Yet, it is known that SOX2 does not influence pluripotency and expression of 
target genes on its own, but needs binding partners to activate specific transcription of 
genes. Cooperative binding of SOX-partners depends significantly on the stage of 
development. In implantation phase of embryos SOX2 binds to OCT4 and activates e.g. 
FGF4, NANOG and UTF1. Interestingly the SOX2/OCT4 protein complex is also self-
activating, thus inducing an auto-regulatory loop [131]. However, in later phases of 
embryogenesis when OCT4 is no longer expressed, SOX2 can build hetero-dimeric 
complexes with different partners [139]. One example is the SOX2-PAX6 complex which 
activates the CRYBB2 (-crystalline) gene during retina development [140]. Moreover, it 
has been shown lately that the regulation of Sox2 by the transcription factor Stat3 is 
necessary in early stages of mouse neural development for differentiation of ES cells into 
neuronal precursor cells (NPC), suggesting a novel signaling pathway [141]. Hence the 
combination of SOX2 and partner factors provides a code for activation of target genes 
and specification of cells.  
In early phase of development SOX2 expression is limited to cells with stem cell 
characteristics like germ line cells or trophoblast stem cells. Accordingly, SOX2 is down-
regulated in all cells with limited developmental potential [127, 142]. SOX2 is essential 
during embryogenesis. Homozygous Sox2 knock out mouse embryos are not able to 
build the epiblast or the extraembryonic ectoderm and die shortly after implantation. A 
specific knock-down of Sox2 in ES cells in vitro via dominant negative SOX2 or siRNA 
results in loss of pluripotency and induces differentiation towards trophoectoderm [127, 
143]. Heterozygous loss of SOX2 provokes several defects in mice and human, one of 
which is abnormal anterior pituitary development and endocrine deficits [144], which 
may be linked to the malformation of sensory organs of the inner ear [145]. Mutation of 
SOX2 causes also Anophthalmia-Esophageal-Genital- (AEG) Syndrome, which was first 
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named by Shah et al. in 1997. AEG is an association of anophthalmia/microphthalmia 
(bilateral absence or malformation of the eye), esophageal atresia with or without 
tracheo-esophageal fistula (trachea and esophagus fail to separate) and urogenital 
abnormalities (cryptorchidism, micropenis) [146, 147]. In 2007 Que and coworkers 
defined a dose depended role for SOX2 in patterning and differentiation of mouse 
foregut. They demonstrated that heterozygous loss of Sox2 does not influence foregut 
development, however, further reductions of Sox2 using Sox2 hypomorphic alleles result 
in various abnormalities according to dose of expression. Complete knock-outs fail to 
separate trachea and esophagus and die postnatally [148].  
Lately SOX2 has been shown to be expressed in some mammalian adult tissue 
such as progenitors of the brain [149], retina [150], progenitors of pituitary glands [151], 
trachea [152], tongue epithelium [153], dermal papilla of the hair follicle [154], 
epithelium of seminiferous and lens, squamous epithelia lining the esophagus, 
forestomach, anus, and cervix as well as glandular stomach [37]. In most of these tissues 
SOX2+ cells seem to have stem cell properties, thus implicating that SOX2 might be a 
common marker of pluripotency that activates general pathways essential for self-
renewal and differentiation and consequently is crucial for tissue homeostasis.  
 
1.3.4. SOX2 and cancer 
The improper expression of SOX genes has been implicated in numerous severe 
clinical disorders including human tumors [122]. In prostate [155] and pancreatic cancer 
[156] SOX2 was observed to be amplified and might be involved in later events of 
carcinogenesis, such as invasion and metastasis. SOX2 was also seen to be over 
expressed in 43 % of basal-like sporadic breast cancers and in tumors arising from BRCA1 
germ line mutation [157]. In vitro studies in breast cancer cells revealed that SOX2 
promotes cell cycle progression and tumorigenesis by facilitating G1/S- transition [158]. 
Accordingly, in tumor-initiating cells (TIC) derived from glioblastoma, the most 
aggressive cerebral tumor, silencing of SOX2 via miRNA resulted in stop of proliferation 
and loss of tumorgenicity [159]. In lung and esophageal squamous cell carcinomas, SOX2 
is highly amplified and acts as a lineage survival oncogene, promoting cell migration and 
anchorage-independend growth in vitro [160, 161]. In a very recent report by Xiang and 
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co-workers, SOX2 was seen to be over expressed in presumable lung cancer stem cells. 
Down-regulation of SOX2 via RNA silencing resulted in inhibition of growth and 
migration and an increase of apoptosis of cells, suggesting a key role for SOX2 signaling 
pathway in lung cancer stem cells [162]. Furthermore, a correlation of poorer overall 
survival and SOX2 expression was found in oral tongue squamous cell carcinomas [163]. 
In Merkel cell carcinomas nuclear SOX2 expression correlated with tumor thickness. In 
vivo studies in a xenograft model showed that SOX2 knock down resulted in decrease in 
mean tumor volume [164]. Furthermore, a recent study identified SOX2 to contribute to 
melanoma invasion [165]. Interestingly, SOX2 was also lately detected to be expressed in 
colorectal cancer (CRC) and was associated with poorer outcome and reduced overall 
survival due to correlating lymph-node and distant metastases [166, 167]. The majority 
of CRCs typically develop via an activation of WNT/Catenin signaling pathway and 
accumulation of nuclear Catenin is associated with poorer prognosis. Contrary to 
these results SOX2 was shown to down-regulate Catenin/TCF transcriptional activity 
in vitro [168]. However, knock-down of SOX2 in a colorectal cancer cell line decreased 
growth rate in vitro and in an in vivo xenograft model [169]. The results suggest that 
there is a definite influence of the regulatory feedback mechanism between SOX2 and 
the Catenin/TCF complex in CRC that remains unclear and needs to be clarified. SOX2 
was also found to play a role in GC. A recent study showed that SOX2 was regulated by 
IL-4 through STAT6 signaling in gastric epithelial cells and that SOX2 expression was 
blocked in H. pylori-mediated intestinal metaplasia, triggering Correa’s sequence [170]. 
In vitro studies revealed that SOX2 was down-regulated in some GC cell lines and that 
exogenous expression led to inhibition of cell growth and apoptosis of cells, suggesting 
SOX2 to be a tumor suppressor gene [171]. Tsukamoto et al. reported that SOX2 was 
gradually down-regulated in intestinal metaplasia and intestinal-type gastric 
adenocarcinomas, inversely correlated with expression of CDX1/CDX2. However, they 
found SOX2 to be expressed in diffuse- and mixed-type GC being there important for 
maintenance of the gastric phenotype [172, 173]. Additionally, Matsuoka et al. affirmed 
that SOX2 positive expression might be associated with the invasion of GC [174]. 
Immunohistochemical experiments conducted in CEA/SV40 transgenic mice [175], which 
develop gastric tumors, clearly showed SOX2 expression in tumorigenic tissues (Fig.12).  
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Fig.12: H&E staining of gastric tumors derived from CEA/SV40 transgenic mice. Expression of SOX2 
correlates with the expression of the proliferation marker KI67. 
 
In numerous GC cell lines SOX2 seems to be up-regulated and considering the 
role for SOX2 in maintenance of pluripotency in embryonic and adult stem cells and the 
current cancer stem cell theory it might not be surprising for SOX2 to have a tumor 
initiating character in gastric adenocarcinomas. 
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1.4. Aims of the study  
Gastric cancer (GC) arises throughout the influence of different environmental 
factors and/or the genetic predisposition of the patient. Developing a therapy for the 
treatment of malignant tumors however, can only be achieved when selective pathways 
or target genes leading to carcinogenesis are identified.  
SOX2 is a very important factor in pluripotency of embryonic stem cells, 
influencing cell growth and differentiation. Moreover, it is also known to be highly over 
expressed in different kind of tumors such as breast cancer, glioblastoma and lung 
cancer, being responsible for their tumorigenicity. Furthermore, SOX2 was also found to 
be over expressed in some gastric tumors, indicating it might here be also tumorigenic. 
Thus, the first objective was to analyze the role of SOX2 in tumorigenesis of the 
stomach. 
In order to evaluate the influence of SOX2 in aggressiveness and invasive 
characteristics of the tumor, GC cells were investigated for changes in proliferation, 
apoptosis, migration and in vivo metastatic behavior after inhibition of SOX2.  
Additionally, to depict the mechanism underlying possible growth inhibition, changes in 
cell cycle were also investigated.  
To date pathways influencing development of GC are only poorly understood. 
Furthermore, not many target genes of SOX2 are known up to now. A second objective 
was to identify genes regulated by SOX2 and related to GC. Therefore, gene expression 
in GC cells was analyzed at certain time points after SOX2 inhibition using an mRNA 
microarray approach. Identifying differentially expressed genes might unravel target 
genes and pathways influenced by SOX2 in gastric carcinogenesis.  
To date there are not much data available concerning regulation of SOX2 in 
gastric tumors. Thus, another objective was to analyze the influence of the transcription 
factor STAT3 on SOX2 in GC since STAT3 is known to regulate SOX2 expression in 
neuronal development. Furthermore, it was aimed to identifiy how SOX2 could be 
regulated by H. pylori in GC cells, as H. pylori infection is an important key factor in the 
development of stomach cancer. 
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SOX2 is not only an important factor concerning tumorigenesis but also 
important during development of the stomach. Finally, to investigate the role of SOX2 in 
gastric development, Sox2 depletion in a conditional knock-out mouse was analyzed. 
Different knock-out systems as well as different Cre mouse lines were analyzed and 
compared. Results would give valuable hints how the regulation of SOX2 could influence 
stomach development. Furthermore, studying the adult stomach would give deeper 
insight into identification of adult stomach stem cells which still are not fully identified. 
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2. Methods 
 
2.1. Molecular cloning 
 
2.1.1. Cloning strategies 
 Insert DNA was amplified by PCR using primer pairs containing enzyme restriction 
sites to generate segments of inserts with cohesive ends. PCR products were digested 
with respective restriction enzymes and ligated into the vector system of interest 
(Tab.1). 
Tab.1: List of vectors and primers for cloning strategies 
Construct Vector Primers Restriction 
sites 
SOX2 full flag tag pcDNA4-TO se 5’ GCAGGTACCATGGATTACAAGGATGACGGACGATTAA 
GATGTACAACATGATGGAGACGGAG 3’  
as 5’ CAGGGATCCTCACTTATCGTCGTCATCCTTGTAATCCATGT 
GTGAGAGGGGCAG 3’ 
Kpn I 
BamHI 
dnSOX2 1-129 
HA tag 
pcDNA4-TO se 5’ CCAGGATCCATGTACAACATGATGGAGACGGAG 3‘ 
as 5’GCAGCGGCCGCTCAAGCGTAATCTGGAACATCGTAT 
GGGTAACCCCCGCCGGGCAGCGTGTAC 3‘ 
BamH I 
Not I 
dnSOX2 1-158 
HA tag 
pcDNA4-TO se 5’ CCAGGATCCATGTACAACATGATGGAGACGGAG 3‘ 
as 5’ GCAGCGGCCGCTCAAGCGTAATCTGGAACATCGTAT 
GGGTAACCACTGTCCATGCGCTGGTTCAC 3‘ 
BamH I 
Not I 
shRNA Vector Oligonucleotides Restriction 
sites 
shSOX2 pLVTHM se 5’ CGCGTCCCCGGTTGATATCGTTGGTAATTTCAAGAGATT 
ACCAACGATATCAACCTTTTTGGAAAT 3‘ 
as 5’ CGATTTCCAAAAAGGTTGATATCGTTGGTAATTCTCTTG 
AAATTACCAACGATATCAACCGGGGA 3’ 
Mlu I 
Cla I 
shControl pLVTHM se 5’ CGCGTCCCCGTACAGCCGCCTCAATTCTTTCAAGAGAAG 
AATTGAGGCGGCTGTACTTTTTGGAAAT 3’ 
Mlu I 
Cla I 
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as 5’ CGATTTCCAAAAAGTACAGCCGCCTCAATTCTTCTCTTGA 
AAGAATTGAGGCGGCTGTACGGGGA 3’ 
 
2.1.2 Restriction digestion of DNA 
 DNA (0.5 ng - 5 µg) was digested for 1 to 2 h with 1 unit of appropriate restriction 
enzyme (Promega) per µg DNA in the respective restriction enzyme buffer (Promega) 
following supplier’s instructions. To verify successful digestion, restricted DNA was 
analyzed by agarose gel electrophoresis. Correct fragments were excised from the gel 
and purified using Illustra GFX PCR and Gel Band Purification Kit (GE Healthcare) 
according to manufacturer’s recommendations. 
2.1.3 Ligation 
 For ligation of cohesive ends a molar ration of 1:8 of digested and purified vector 
DNA and digested insert were used. All ligations were set up using 1 µl (2 µl) T4 DNA 
ligase and respective ligation buffer in a total volume of 10 µl (20 µl). Ligation reaction 
was incubated over night at 16 °C. 
 
2.1.4 Competent E. coli cells 
 Bacteria which are able to uptake DNA are called “competent”. Bacterial 
competence can be achieved by treating E. coli cells with calcium chloride in the early 
log-phase of growth. Cells can uptake chloride ions but their membrane is not 
permeable for calcium ions. While positive charged chloride ions enter the cells, they are 
accompanied by water molecules. This water influx causes the cells to swell which 
induces uptake of DNA. The exact mechanism of this phenomenon is not yet identified, 
however, it is known, that a heat shock step (42 °C) is necessary for DNA uptake.  
A single bacterial colony of the E. coli strain K-12 was transferred into an 
inoculation tube containing 5 ml TYM medium and cultured over night at 37 °C. The next 
day culture was transferred into 500 ml TYM medium and growth was monitored every 
20 min until OD600 of 0.5 -0.6 was reached. Cells were incubated on ice for 30 min and 
subsequently pelleted by centrifugation (3000 x g, 10 min, 4 °C) and washed with 15 ml 
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ice cold Tfb-I Buffer. Cells were centrifuged again (3000 x g, 10 min, 4 °C) and 
resuspended in ice cold 20 ml Tfb-II Buffer. Cell suspension was aliquoted in 100 µl 
fractions and immediately frozen in liquid nitrogen. Long term storage was done at – 80 
°C. 
 
2.1.5 Transformation of DNA in bacteria 
 For transformation 100 µl competent E. coli were thawed on ice for 5 min. DNA 
(50 – 200 ng) was added and mixture was incubated on ice for 20 min. Subsequently 
cells were heat-pulsed at 42 °C for 45 sec and immediately cooled down on ice for 1 - 2 
min. 1 ml LB medium (37 °C) was added to each tube and cells were incubated for 1 h at 
37 °C while shaking continuously. Bacteria were pelleted by centrifugation (5000 x g, 5 
min) and plated on prewarmed LB plates (LB medium with 1.5 % Agar) containing the 
appropriate antibiotics (50 µg/ml ampicillin or kanamycin). Plates were incubated over 
night at 37 °C. 
 
2.1.6 Preparation of plasmid DNA 
 Single E. coli colonies were transferred from the agar plate into 5 ml LB medium 
with antibiotics and were grown over night at 37 °C while shaking. For Mini preparations 
this over night culture was used directly. For Midi preparations an aliquot of this culture 
was transferred to 100 ml LB medium with appropriate antibiotics and again grown over 
night at 37 °C while shaking. All plasmid DNA preparations were carried out with either 
SV Minipreps Wizard Plus Kit (Promega) or PureYield plasmid Midiprep Kit (Promega) 
according to manufacturer’s recommendations. 
 
2.1.7 shRNA cloning 
shRNA oligonucleotides of SOX2 were cloned into the vector pLVTHM according 
to manufacturer’s protocol. In contrast to general cloning procedure, purified 
oligonucleotides must be annealed prior to ligation. For annealing 1 µl (100 ng) oligos for 
top and bottom strand were mixed together with 48 µl annealing buffer and boiled for 5 
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min to remove secondary structure and disrupt hairpin. The mixture was cooled down 
slowly on ice and stored at -20 °C until ligation.  
Before ligation, oligos were phosphorylated. 5 µl (500 ng) of oligos was mixed 
with 12 µl of dH2O, 2 µl T4 ligation buffer and 1 µl T4 polynucletide kinase (PNK). 
Mixture was incubated at 37 °C for 30 min followed by heat inactivation of PNK at 70 °C 
for 10 min. For ligation, 5 µl (125 ng) of annealed phosphorylated oligos was mixed with 
20 – 100 ng of digested and purified pLVTHM vector, as a large excess of oligo will inhibit 
ligation. Ligation took place at RT for 3 - 4 h. Oligos and digested vector were ligated 
according to supplier’s recommendations and transformed into competent E. coli DH5 
as described above. After plasmid preparation, the desired recombinant plasmid was 
identified by screening PCR using the primer H1 (5’ - TCG CTA TGT GTT CTG GGA AA – 3’). 
Insert was verified by sequencing with the same primer. Transduction in the lentiviral 
system was done as described below. 
 
2.1.8 Agarose gel electrophoresis 
Electrophoresis through a horizontal agarose gel of 0.7 % - 2 % (depending on 
MW of the sample) was used to separate, identify and purify DNA fragments. Gels were 
prepared by mixing appropriate portions of agarose with 1 x TAE buffer. The mixture 
was cooked and Roti®-Safe GelStain (Roth) was added in a concentration of 5µl/100ml. 
Agarose gels were poured with a thickness of 6 - 7 mm in a precast agarose gel chamber 
and added to a running chamber containing 1 x TAE buffer. DNA was mixed with loading 
dye and 20 µl of the mix was added to gel pockets. An electric field of 80 - 120 mV was 
applied for 30 – 45 min to separate DNA fragments. A DNA 1 kb ladder was used for size 
determination under an UV Transilluminator, Eagle Eye Gel Doc. 
 
2.2 Cell culture 
 
In this work several human tumor cell lines where used. AZ-521 cells were 
purchased from the Japanese Collection of Research Biosources (JCRB, Osaka, Japan) 
and cultivated in 75 cm2 culture flasks in Minimum Essential Medium containing 
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glutamine (MEM-GlutaMax) supplemented with 10 % tetracycline-free fetal bovine 
serum and 1 % penicillin/streptomycin. AGS, Kato III, MKN7, MKN45, NUGC4, N87, 
SNU1, St2957, St3051 and St23132 cells were purchased from the American Type 
Culture Collection (ATCC). All of these cell lines were cultivated in RPMI-1640 with 10 % 
FCS and 1 % penicillin/streptomycin. All cells were maintained at 37 °C and 5 % CO2 in a 
95 % air-humidified incubator. Cells were routinely checked for Mycoplasma 
contamination. 
 
2.2.1. General cell culture methods 
2.2.1.1. Cell counting 
Cell suspension was diluted 1:10 with PBS and 10 µl of this suspension was 
diluted 1:2 with trypan blue. 10 µl were counted in a Neubauer hematocytometer. 
Trypan blue is a vital dye that stains broken cell membrane. Thus, stained (dead) cells 
are not counted. Cells were counted in each of the four corner quarters. One corner 
quarter represents the area of 1 mm2 and the height of 0.1 mm, thus holds 0.1 µl cell 
suspension. The mean of the cell number per quarter was calculated. Mean cell number 
multiplied by 104 (volume of the chamber) and the dilution factor (10 x 2) resulted in the 
number of cells per ml. 
2.2.1.2. Freezing cells 
Cell suspensions of approximately 1 x 107 cells were centrifuged at 1000 x g for 8 
min. Cell pellets were resuspended in 10 ml ice cold FCS containing 5 % DMSO and 1 ml 
aliquots were prepared in sterile polypropylene tube for cryogenic storage. Tubes were 
slowly cooled down over night at -80 °C in a polystyrene box. Long term storage took 
place in liquid nitrogen. 
2.2.1.3. Thawing and maintaining cells 
Frozen cell suspensions were thawed in a water bath at 37 °C and were added to 
50 ml cell growth medium immediately to dilute toxic DMSO. Cells were subsequently 
centrifuged at 1000 x g for 8 min. Cell pellets were resolved in 12 ml growth medium 
containing 10 % FCS and seeded into a sterile 75 cm2 plastic flask. Cells were split every 3 
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– 5 days, depending on confluence. For splitting old medium was removed and cells 
were washed once with PBS. Cells were subsequently incubated for 2 – 5 min with 2 ml 
Trypsin/EDTA at 37 °C. When all cells were detached from the surface, fresh medium 
was added to the suspension. Cells were transferred to a 15 ml tube and spun down for 
5 min at 1000 x g. Supernatant was discarded and cell pellet was resuspended in 5 ml 
growth medium and seeded at adequate cell density. 
 
2.2.2. Transfection of cells 
Cell lines were transfected by lipofection or electroporation. Lipofection is a 
method to introduce nucleic acids into cells by using vesicles, so called liposomes. 
Liposomes are positively charged and entrap the negatively charged genetic material. 
They are made of a phospholipid bilayer, thus they can easily pass the cell membranes as 
it also consists of lipid bilayer and is negatively charged. Electroporation is a very 
effective method of transfection. The permeability of the cell plasma membrane is 
increased by applying an electric field. After disruption of the phospholipid bilayer DNA 
can penetrate the cells. The membrane spontaneously reassembles and leaves the cell 
intact. However, many cells die during this method. 
2.2.2.1. Transient transfection by lipofection 
Cells were seeded in a density of 5 x 104 cells per well in a 24-well plate and 
incubated over night for attachment. Plasmids harboring the gene of interest or a 
control empty vector were diluted in serum-free OPTIMEM in a final concentration of 20 
ng/ml. For reporter assays reporter plasmids containing promoter binding sites and 
firefly luciferase (200 ng/ml) and transfection control plasmids containing renilla 
luciferase (20 ng/ml) were added to the mix and cells were transfected with 15 µl 
Lipofectamine 2000 (Invitrogen) per 24-well plate according to manufacturer’s 
recommendations. For transfection cells were cultured in serum-free OPTIMEM for 24 h. 
Medium was changed to normal growth medium the day after transfection. Lysates for 
analysis were taken 48 h to 72 h after transfection, depending on experimental 
procedures. 
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2.2.2.2. Transient transfection by electroporation  
1 x 106 cells in 500 µl OPTIMEM were inserted to a 0.4 cm gap electroporation 
cuvette together with a plasmid containing the gene to analyze (20 ng/ml), reporter 
plasmids (200 ng/ml) and transfection control plasmids harboring renilla luciferase (20 
ng/ml). Electroporation was carried out in a BioRad electroporator applying 165 V and 
1000 µF. 25 µl of cell suspension was subsequently seeded in each well of a 24-well-
plate and 500 µl serum-free OPTIMEM was added. Medium was changed to normal 
growth medium the day after transfection. Lysates for analysis were taken 48 h to 72 h 
after transfection. 
2.2.2.3. Titration of antibiotics (Killing curve)  
To determine the optimal concentration for selection of stable cell clones (see 
below) killing curve experiments were performed. Different cell lines were seeded in 24-
well-plates in a density of 5 x 104 cells per well. Antibiotics were applied to the cells after 
attachment. Zeocin was added in concentrations from 100 µg/ml to 1000 µg/ml, 
blasticidin was added in concentrations from 10 µg/ml to 100 µg/ml. Cell viability was 
analyzed microscopically after three and seven days. Optimal selection concentration 
was defined as the lowest concentration of antibiotic in which all cells were dead by 
seven days at the latest. 
2.2.2.4. Stable transfection of cells  
Cells were seeded in a 6-well-plate in a concentration of 1 x 105 cells per well and 
incubated over night for attachment. Transfection of cells with a plasmid containing the 
gene of interest and a eukaryotic antibiotic resistance cassette was achieved by 
lipofection or electroporation (see above). Each well was transfected with 1 µg of 
plasmid DNA in OPTIMEM. 24 h after transfection cells were trypsinized, diluted 1:2, 1:5 
and 1:10 and seeded into 150 mm cell culture dishes containing 20 ml growth medium 
and the selective drug. Growth medium and antibiotic was changed every 3 to 7 days. 
After 2 to 3 weeks, single colonies began to appear and could be harvested. For isolation 
of colonies, growth medium was removed and cells were rinsed twice with PBS. Cell 
separating cylinders were dipped into autoclaved vaseline to make the rim sticky. 
Subsequently, cylinders were put over a cell colony and gentle pressure was applied to 
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prevent movement. 50 µl of Trypsin/EDTA was added into cylinders and cell culture 
plates were incubated for 2 min at 37 °C to allow cells to detach. Each trypsin-treated 
colony was placed into one well of a 24-well-plate containing growth medium and 
selective antibiotic. Cells were grown until 80 % confluence and split into 24-well-plates 
and 6-well-plates to check if the gene of interest was present via promoter analysis and 
protein expression. Positive cell clones were expanded and frozen. 
2.2.2.5. Inducible cell clones 
The Tet-On system was used to express dnSOX2 at certain time points after 
induction. The Tet-On system is an aberrant version of the initially established Tet-Off 
system invented by Bujard and colleges in 1992. In this dual system the regulatory 
plasmid is a constitutively expressed tetracycline-responsive transcriptional activator 
(tTA), a fusion protein of tetracycline repressor (TetR) found in Escherichia coli and the 
VP16 domain of herpes simplex virus under the control of a CMV promoter. The second 
plasmid of the system, a responsive plasmid, harbors the gene of interest under the 
control of a tetracycline responsive element (TRE). In absence of tetracycline, tTA binds 
to TRE and activates transcription of the gene of interest. When tetracycline is added to 
the cells it binds to tTA. This complex can no longer bind the TRE and thus transcription 
is inhibited [176]. The Tet-On system is based on a mutated version of tTA (reverse tTA). 
It only binds to TRE in presence of tetracycline or a tetracycline derivate, e.g. doxycycline 
(Dox) and thus induces expression of the gene of interest [177].  
A vector containing rtTA was stably transfected into cell lines (see above). 
Selection took place via transient transfection of clones with a reporter plasmid for rtTA 
(TO-Luc) and subsequent reporter assays (see below). Successfully transfected stable cell 
clones were expanded and again stably transfected with a plasmid containing the TRE 
and dnSOX2 cDNA. Stable clones were selected by reporter assay. Therefore, cells were 
transiently transfected with a SOX2 reporter plasmid (SOP-Flash), induced with 
doxycycline 3 h after transfection and analyzed 48 h later. 
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2.2.3. shRNA mediated RNA interference 
To analyze the function of a specific gene product the endogenous mechanism of 
RNA interference is widely used since the last decade. The knock down of specific 
mRNAs reduces the expression of the respective protein. RNA interference (RNAi) can be 
set up by transient transfection of small interfering RNAs (siRNAs) or by stable 
expression of small hairpin RNAs (shRNAs). The latter are integrated in the genome and 
processed intracellularly to siRNAs. The stable expression allows a constitutive mRNA 
knock down. 
A lentiviral transfer approach was used to set up stable shSOX2 cell clones in AZ-
521 cells. Lentiviruses are a subclass of retroviruses, which means they integrate their 
genome into the DNA of their host cells. To ensure safe application these viral vectors 
never carry genes for their spontaneous self-assembly and thus are unable to self-
replicate. In the commonly used lentiviral systems of the so called 2nd and 3rd generation 
the least necessary number of viral genes therefore is distributed to several plasmids. 
Producer cell lines, e.g. HEK 293T cells, are transiently transfected with several plasmids 
(vector, packaging system, envelope plasmid) to initiate assembly of the virus. They 
secrete the virus into the supernatant where it can be collected and used for 
transduction.  
shSOX2 was cloned into pLVTHM vector as described above. HEK 293T cells were 
transiently transfected with the recombinant pLVTHM vector, the 2nd generation 
packaging vector psPAX2, containing a CMV promoter and the 2nd generation envelope 
vector pMD2.G to produce lentiviral particles. AZ-521 cells were seeded to culture plates 
and infected with the virus. The production of lentivirus and the infections were done by 
Dr. Martina Anton (Klinikum rechts der Isar, department for experimental oncology, 
München, Germany).  
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2.3. Biological assays 
 
2.3.1. Luciferase reporter gene assay 
Luciferase activity was measured using the Dual-luciferase reporter assay system 
(Promega). In this assay two individual reporters are simultaneously expressed within a 
single system. The first reporter is typically correlated with an effect of experimental 
conditions, whereas the second co-transfected reporter serves as internal transfection 
control that gives a baseline signal. Variances caused by differences in transfection 
efficiency, pipetting volume or cell lysis efficiency can be minimized by normalizing 
activity of the first reporter to the activity of the internal control. In this system the first 
reporter was coupled to firefly (Photinus pyralis) luciferase. As a control reporter renilla 
(Renilla reniformis) luciferase driven by a CMV reporter was used. Both luciferases have 
distinct luminescence characteristics which allow discrimination. 
Cells were transfected with the plasmids of interest and reporter plasmids as 
described above. Growth medium was removed from transfected cells and cells were 
rinsed with PBS. 100 µl of 1 x passive lysis buffer was added to each well. Plates were 
shock-frozen for 30 min at -20 °C and subsequently incubated 30 min on a shaker at 
room temperature for complete lysis. 20 µl of cell suspension was transferred in 
duplicates to a white 96-well-round bottom plate. Firefly luciferase and renilla luciferase 
activity was quantified in an Orion microplate luminometer using Dual-luciferase 
reporter assay system (Promega). 25 µl of Luciferase Assay Reagent II (LARII) was added 
to each well and relative light units (RLU) of firefly luciferase were measured. The second 
substrate, Stop & Glo Reagent, quenched firefly luminescence and initiated renilla 
luciferase activity which was quantified immediately. Ratio of firefly luciferase to renilla 
luciferase was calculated for quantification of relative promoter activity. 
The WNT-responsive, TCF-dependent luciferase constructs, pTOPFlash and the 
control plasmid pFOPFlash, and the SOX2-responsive pSOPFlash and the control 
pNOPFlash have were kindly provided by Prof. Hans Clevers (NIOB, Utrecht, the 
Netherlands) and have been described previously [178]. 6x O/S LUC was a kind gift from 
Dr. Lisa Daily (New York University, New York, USA). pCMV-Renilla was purchased from 
Promega. 
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2.3.2. Proliferation analysis 
Proliferation of cells was measured using CellTiter-Glo Luminescent Cell Viability 
Assay (Promega) and Cell proliferation Dye eFluor 670 (eBioscience) according to 
manufacturer’s recommendations.  
The CellTiter-Glo system is based on the quantification of ATP of metabolic cells 
via a luminescence signal. ATP-yield is directly proportional to the number of viable cells 
in culture. Cells were plated in triplicates in a 96-well-plate in a density of 5x 103 cells per 
well. Cells were serum starved for 24 h to synchronize cell cycle. After synchronization 
cells were treated with 1 µg/ml doxycycline (see above). Measurement was performed 
in a Berthold Mithras plate reader after 24 h, 48 h, 72 h and 6 days. Cell numbers were 
normalized to the parental control cell line.  
Cell Proliferation Dye eFluor 670 is used to monitor individual cell divisions. The 
red fluorescent dye binds to primary amines of cellular protein and is distributed equally 
between daughter cells during cell division, halving the fluorescence intensity. 105 cells 
were seeded into 10 cm dishes and serum starved for synchronization. After 24 h cells 
were stained with 2.5 µM eFluor Proliferation Dye according to recommendations of the 
supplier and seeded into 10 cm dishes with serum. 1 µg/ml doxycycline was added the 
same day and FACS analysis using APC channel were done after 24 h, 48 h and 72 h in a 
CyAn FACS sorter. 
 
2.3.3. Analysis of apoptosis 
Apoptosis of cells was measured with Caspase-Glo 3/7 Assay System (Promega) 
and by Annexin V binding. Caspase-Glo 3/7 Assay is based on the measurement of 
Caspase-3 and -7 activities of cells. A luminogenic substrate is cleaved by Caspase 3/7 
and releases aminoluciferin which generates a luminescence signal. This signal is directly 
proportional to the amount of Caspase 3/7 present.  
5 x 103 cells were seeded in triplicates in each well of a96-well-plate and serum 
starved over night for synchronization. After synchronization cells were treated with 1 
µg/ml doxycycline for 13 h, 24 h and 48 h. Assay was performed according to 
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manufacturer’s protocol and luminescence signal was measured in a Berthold Mithras 
plate reader. A final concentration of 1 µM Staurosporine was used as a positive control 
for apoptosis. Staurosporine treatment was done for 8 h.  
In viable eukaryotic cells, phosphatidylserine (PS), which is a negatively charged 
phospholipid, is located at the intracellular site of the plasma membrane. However, 
when membranes get disrupted during cell death, PS is translocated to the outer 
membrane. Annexin V has high binding affinity to PS. Therefore, FITC-labeled Annexin V 
can be used to detect apoptotic cells via FACS. During necrosis cell membranes get 
disrupted and Annexin V can also bind to PS. To discriminate necrosis from apoptosis 
cells are co-stained with 7AAD which can only penetrate into necrotic cells. Thus, cells 
positive for Annexin V and negative for 7AAD are apoptotic cells [179]. For Annexin V 
staining 2 x 105 cells were seeded in a 10 cm dish. After synchronization by serum 
starvation for 24 h cells were fed with fresh growth medium for another 24 h and 
afterwards treated with 1 µg/ml doxycycline for 24 h and 48 h. Cells were washed with 
PBS, trypsinized and centrifuged for 8 min at 300 x g. The cell pellet was resuspended in 
500 µl binding buffer containing FITC-Annexin V in a concentration of 10 µg/ml and 
suspension was incubated for 20 min at RT in the dark. 50 µg/ml 7AAD was added and 
suspension was incubated for another 10 min at RT in the dark. Subsequently cells were 
analyzed by flow cytometry in a CyAn ADP Analyzer.  
 
2.3.4. Cell cycle analysis 
Cell cycle was analyzed by measurement of propidium iodide (PI) intercalation 
into cells. PI intercalates into the major groove of double-stranded DNA and is the most 
commonly used dye for DNA content. When excited with a wavelength of 488 nm, PI 
fluoresces red, with an emission centered on 600 nm. Since it also can bind to double-
stranded RNA it is necessary to treat cells in advance with ribonuclease A (RNaseA) for 
optimal DNA resolution. 
1 x 105 cells were seeded into 100 mm cell culture dishes and serum starved for 
synchronization. After 24 h without serum, growth medium containing FCS and 1 µg/ml 
doxycycline was added. Subsequent to 24 h or 48 h of treatment with doxycycline, cells 
were harvested and pelleted by centrifugation of 500 x g for 8 min. Cell pellet was 
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washed twice with PBS containing 1 % (w/v) BSA. Resulting pellet was resuspended in 
500 µl PBS 1 % BSA. For fixation, a single cell suspension was dropped into ice cold 70 % 
ethanol while vortexing.  After 4 h at -20 °C or 24 h at 4 °C fixed cells were centrifuged 
for 8 min at 500 x g and pellet was washed twice with PBS 1 % BSA. Cells were 
resuspended in 200 µl PI staining solution containing 2 µg/ml RNase A. Cell cycle profile 
was analyzed by flow cytometry in a CyAn FACS sorter. 
 
2.3.5. Wound healing/migration 
Wound healing assays study directional cell migration in vivo. A wound is 
introduced in a cell monolayer and pictures are taken in regular intervals documenting 
accomplishment of wound healing and quantifying migration of cells. 
Wound healing was analyzed using silicone culture inserts (ibidi) in a 12-well 
plate. A cell solution of 5 x 105 cells was prepared and 70 µl of this solution were applied 
in both wells of the insert. Cells were incubated over night until 100 % of confluence. 
The culture insert was removed and left a 500 µM gap between the two defined cell 
patches. 1 ml growth medium was added to the well. 1 µg/ml doxycycline was added for 
induction of the dnSOX2 construct. Wound healing was observed microscopically after 0 
h, 24 h, 36 h and 48 h. Pictures were taken at a Leica DMB microscope. 
 
2.3.6. Analysis of senescence associated -galactosidase (SA--gal) activity  
When diploid cells are no longer able to divide normally theses cells go to so 
called cellular replicative senescence. Senescent cells express -galactosidase detectable 
at a pH 6.0, distinct from the acidic lysosomal -galactosidase activity all cells express at 
a pH of 4.0. Using a citric acid/sodium phosphate buffer at pH 6.0, senescence can easily 
be visualized through the cleavage of X-gal, which yields in an insoluble blue color.  
Cells were seeded on a 6 cm cell culture dish and grown until 50 % of confluence. 
Cell culture medium was removed and cells were washed three times with PBS. After 
washing, cells were fixed with fixative solution for 5 min at RT. Subsequently fixative 
solution was removed and cells were washed two times with PBS. 4 ml of staining 
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solution was added to the dish and cells were incubated at 37 °C without CO2 over night. 
Cells were microscopically analyzed and photographed in a Leica DMB Microscope. 
 
2.4. Immunofluorescence  
 
Immunofluorescence is a method to detect proteins in tissue sections or seeded 
cells. Primary antibodies bind to their corresponding antigen and respective 
fluorescence-conjugated secondary antibodies build a complex with the primary 
antibodies which is detectable in fluorescence microscopy.  
Cells were grown on cover slips in a 12-well plate until 60 % of confluence. Cover 
slips were washed with PBS and cells were fixed with a mixture of equal parts methanol 
and acetone for 15 min at RT. Fixation solution was removed and cover slips were 
washed three times with PBS. For permeabilization and blocking, cells were treated with 
blocking buffer for 15 min at RT to prevent unspecific antibody binding and to 
permeabilize cells for antibodies. Primary antibodies were incubated in antibody buffer 
over night at 4 °C in a humidified chamber. The following day cover slips were washed 
three times with antibody buffer. Corresponding secondary antibodies were diluted 
1:200 in antibody buffer and incubated for 1 h in the dark in a humidified chamber. Cells 
were washed once in washing buffer. Plasma membrane was stained using 5 µg/ml 
CellMask Deep Red Plasma Membrane Stain (Invitrogen) according to manufacturer’s 
recommendations. Cover slips were mounted on a microscope slide with VECTASHIELD 
Mounting Medium (Vector Laboratories) and sealed with nail polish. For long term 
storage slides were kept at -80 °C. Cells were microscopically analyzed and 
photographed using the confocal microscope, Leica SP5.  
 
2.5. Infection with Helicobacter pylori 
 
 H. pylori strains (Tab. 2) were cultured on Wilkins–Chalgren plates supplemented 
with Dent supplement antibiotic mix (Oxoid). The bacteria were harvested, and the OD 
at 600 nm was measured.  OD600 of 1 represented 2 x 10
8 bacterial cells. Different tumor 
cells were infected with H. pylori with a MOI (multiplicity of infection) of 50:1, 3 h after 
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transfection with SOPFlash/NOPFlash (see above). Luciferase activity was analyzed 3 h, 6 
h and 24 h after infection. 
Tab.2: H. pylori strains used 
Strain Resistance Reference 
G27 wt - Baltrus et al, Journal of Bacteriology, 2009 [180] 
G27  CagA Kana Figura et al, Gastroenterology & Hepatology, 2004 
[181] 
 
2.6. Sodium-dodecyl-sulfate- Polyacrylamide Gel Electorphoresis (SDS-PAGE) 
 
In SDS polyacrylamide gel electorphoresis proteins are separated according to 
their molecular weight by migration through a gel in an electric field. The anionic 
detergent SDS denaturates proteins, disrupts hydrogen bonds, blocks hydrophobic 
interactions and unfolds protein molecules by elimination of their tertiary and structure. 
The discontinous gel [182] consists of a non-restrictive large-pore stacking gel, which 
concentrates the protein, on top of a resolving gel. In the latter, samples are separated. 
With aid of a protein marker the molecular weight of samples of interest can be 
estimated, as MW equals the logarithm of the distance the protein traveled in the gel.  
Proteins were extracted by using 250 – 400 µl SDS lysis buffer depending on 
confluence of cells. Lysates were sonicated for 10 sec with amplitude of 50 %. An equal 
volume of each sample (30 µl) was heated for 5 min at 95 °C for denaturation and 
subsequently applied on the gel. Electrophoresis was performed at 120 V for 1 h. 
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2.7. Western Blot 
 
For western blot, samples were separated by SDS-PAGE and the gel was blotted 
in a blotting chamber onto a Nitrocellulose Transfer Membrane. Assembling of the blot 
was as follows: four sponges, two sheets of whatman paper, nitrocellulose membrane, 
gel, two sheets of whatman paper and three sponges on top. All layers were soaked in 
transfer buffer and applied carefully without bubbles. The transfer was accomplished in 
transfer buffer with a voltage of 230 mA for 90 min. Proteins migrate towards the anode 
and stick to the membrane due to hydrophobic interactions. After blotting, the 
membrane was stained with ponceau red (Roth) to check if protein transfer was 
successful.  
The membrane was washed in TBS-T for 5 min, followed by 30 min of blocking in 
5 % non-fat milk powder in TBS-T, to prevent unspecific binding of antibodies. Primary 
antibodies were diluted in 1 % milk solution and incubated over night at 4 °C. Unbound 
antibody was removed by three wash steps with TBS-T for 5 min. Corresponding 
secondary antibodies, coupled to horse-radish peroxidase (HRP), were diluted 1:3000 in 
1 % non-fat milk in TBS-T and incubated for 1 h at RT, followed by three final 5 min wash 
steps in TBS-T. All steps were conducted on a shaker. Peroxidase activity of the 
secondary antibody was detected by chemiluminescence using SuperSignal West Pico 
Chemiluminescence Substrate (Thermo Scientific) according to manufacturer’s protocol. 
Signals were visualized on an X-ray film in a Curix 60 developing machine. 
 
2.8. RNA Analysis 
 
2.8.1. RNA Isolation 
RNA isolation was done by using GenElute Mammalian Total RNA Miniprep Kit. 
Cells were lysed and homogenized in 250 µl of lysis buffer containing guanidine 
thiocyanate and 2-mercaptoethanol to release RNA and inactivate RNases. Cell debris 
was removed by spin column. Total RNA was captured by binding to a high capacity silica 
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column and eluted with 50 µl nuclease free water. RNA was stored at -80 °C. 
Concentration and quality of RNA was proofed spectrophotometrically by NanoDrop at 
an absorbance of 260 nm. 
To get rid of DNA contamination, DNA was digested by using DNA-free DNase 
treatment and removal according to manufacturer’s protocol. 
 
2.8.2. Reverse transcription 
Reverse transcription is a technique to synthesize complementary DNA (cDNA) 
from RNA template. 3 µg RNA was incubated with 150 ng random primer for 5 min at 70 
°C to melt secondary structure within the template in order to allow primer to bind to 
the mRNA. To prevent secondary structure to reform, the reaction was immediately 
cooled on ice for 5 min. The mixture was spun down for 2 min at 10.000 x g and 
supernatant of each sample was divided into two separate reaction tubes. Reverse 
Transcription-Mix was added to the samples. RT-Mix without M-MLV reverse 
transcriptase was used as negative control. 
RT-Mix 
M-MLV 5x reaction buffer  5 µl 
(250 mM Tris/HCl, pH 8.5, 375 mM KCl, 15 mM MgCl2, 50 mM DTT) 
dNTP      
M-MLV or ddH2O   200 Units (1 µl) 
ddH2O     add 25 µl 
 
The entire mixture was incubated in a thermocycler as follows: 
RT (20 °C) 10 min 
55 °C  50 min 
70 °C  15 min 
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 After reverse transcription 250 µl of nuclease free water was added to each 
sample to obtain a final volume of 300 µl cDNA with a concentration of about 10 ng/µl. 
Long-term storage of cDNA took place at -20 °C. 
 
2.8.3. Quantitative real-time polymerase chain reaction (qRT-PCR) 
 qRT-PCR is a method to quantify mRNA expression levels throughout 
measurement of respective amount of cDNA via a PCR system, that allows to monitor 
the increase of DNA amount during amplification. The method is based on the fact that 
the fluorescence signal of SYBRGreen, intercalating into double-strand DNA is directly 
proportional to the amount of DNA. 
 All quantitative real-time PCR gene expression analyses were done in duplicates 
using Maxima SYBR Green/ROX qPCR MasterMix on a Light Cycler 480 real-time PCR 
system. 50 ng of RNA were mixed with 100 ng of forward and reverse primer of gene of 
interest and 12.5 µl Maxima SYBR Green/ROX qPCR MasterMix. dH2O was added to a 
final volume of 25 µl to each sample. PCR was running over 40 cycles with 15 sec of 95 °C 
for denaturation and 1 min of 60 °C annealing temperature. All results were normalized 
to an endogenous housekeeping control gene Glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH). Quantification was performed by comparison of the median 
cycle threshold (CT) value. 
Tab. 3: Human primer used for quantitative real-time PCR 
Gene Primer sequences 
C-MYC 
fwd - AGCGACTCTGAGGAGGAACA 
rev - CTCTGACCTTTTGCCAGGAG 
Cyclin B1 
(CCNB1) 
fwd - GGAAACATGAGAGCCATCCT 
rev - TTCTGCATGAACCGATCAAT 
Cyclin D1 
(CCND1) 
fwd - CCGCTGGCCATGAACTACCT 
rev - ACGAAGGTCTGCGCGTGTT 
Cyclin E 
(CCNE1) 
fwd - TATCCTCCAAAGTTGCACCAGT  
rev - CAGGGGACTTAAACGCCACTTA 
-Catenin 
(CTNND1) 
fwd - GATGCTGTCAAGTCCAATGCAG 
rev - AGTACTGGGATGCCCTTGAGC 
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DKK4 
fwd - GGAGGTGCCAGCGAGATG 
rev - GGTGCCCAGTTGTTCCTTC 
FGF10 
fwd - CACATTGTGCCTCAGCCTTCC 
rev - AGGTGATTGTAGCTCCGCACA 
GAPDH 
fwd - GAAGGTGAAGGTCGGAGT 
rev - GAAGATGGTGATGGGATTTC 
LEF1 
fwd - TCCAGCTCCTGATATCCCTACTTT 
rev - CTGACCTTGCCAGCCAAGAG 
NOTCH1 
fwd - GTCAACGCCGTAGATGACC 
rev - TTGTTAGCCCCGTTCTTCAG 
TP21 
fwd - CAAAGGCCCGCTCTACATCTT 
rev - AGGAACCTCTCATTCAACCGC 
SOX2 
fwd - CCCTGTGGTTACCTTTTCCT 
rev - AGTGCTGGGACATGTGAAGT 
SOX18 
fwd - ACGCGTCGACCATGCAGAGATCGCCG 
rev - GAAGATCTCTAGCCGGAGATGCA 
TGFb-RAP1 
fwd -  GCGGCTGTGTCCTTTCCATA 
rev - GCGTCTGCTTCTGTTGCTGAT 
TP63 TA 
fwd - GCATATCTGGGATTTTCTGGAAC  
rev - GGAGCCCCAGGTTCGTGTA 
TP63 N 
fwd - GAAAACAATGCCCAGACTCAA  
rev - TGCGCGTGGTCTGTGTT 
 
2.8.4. RNA Microarray 
The principle behind expression microarrays is that complementary nucleic acid 
sequences specifically hybridize with each other by forming non-covalent hydrogen 
bonds. Isolated mRNA is transcribed into cDNA, which is subsequently labeled and 
transferred to a micro chip harboring a large subset of probes. Non-specifically paired 
strands are removed after washing, leaving only tightly bonded specific sequences for 
analysis.  
AZ-521 dnSOX2 inducible cell clones and their parental cell line were seeded in 
triplicates in a 6-well plate. Cells were induced with doxycycline for 4 h, 8 h, 12 h, 18 h, 
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and 24 h and RNA was isolated using TRIzol® Reagent according to manufacturer’s 
protocol. Three independent biological replicates were performed and each was tested 
for integrity on an agarose gel. Pure RNA was transcribed to cDNA and hybridized to a 
Gene Chip human gene 1.0 ST array (Affymetrix) according to manufacturer’s 
recommendations. RMA-normalized data were analyzed using LIMMA [183]. Genes were 
scored as differentially expressed at a false discovery rate ≤ 0.05 and a log2-fold-change 
≥ 1. Conduction and evaluation of the RNA microarray experiment was done in 
collaboration with Dr. Stefan Krebs (Gene center, Großhadern, Munich, Germany). Raw 
data can be accessed at GEO, accession number GSE42937. 
 
2.9. In vivo studies  
 
All animal experiments were permitted and controlled by a local ethics 
committee and conducted according to the guidelines of the German law of protection 
of animal life. Mice were kept in vented cages with cellulose bedding. Autoclaved 
standard food and water was provided ad libidum. The day/night cycle was 12 h. 
 
2.9.1. Genotyping transgenic mice 
In order to define genotypes of mice, PCR amplification was used. Primers were 
designed binding to a site unique to a mutation or a transgenic element and DNA was 
detected by agarose gel electrophoresis.  
Tissues (clipped tail or ear) from mice were digested at 56 °C over night at 750 
rpm in 500 µl Laird’s Buffer containing 25 µg proteinase K. Suspension was centrifuged 
at 16.000 x g for 5 min. Supernatant was added to a new reaction tube containing 500 µl 
ice cold 2-propanol and gently mixed by inverting the tube several times until DNA 
precipitates. The DNA precipitate was transferred into a new collection tube and 
dissolved in 200 µl DNase free H2O for up to 5 h at 37 °C at 750 rpm. 
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 PCR was conducted as follows using Taq Polymerase PCR Core Kit (Qiagen): 
Amplification Mix 
Sample DNA  1.5 µl 
Q-Solution  5 µl 
Buffer   2.5 µl 
dNTP   0.5 µl 
Primers (100 ng) 1 µl each 
Taq Polymerase 0.125 µl (1 Unit) 
dH2O   ad 25 µl 
Amplification conditions 
Hot Start  95 °C  5 min 
 
Denaturation  95 °C  1 min  
Annealing  x °C  x min  x 36 cycles 
Extension   72 °C  1 min 
 
Final extension 72 °C  10 min 
End hold  4 °C 
 
Annealing temperature and duration was dependend on primers used.  
Tab. 4: Primers used for gentoyping 
Genotype Primer sequences Annealing Product length 
Apc flox fwd - TAGGCACTGGACATAAGGGC 
rev - GTAACTGTCAAGAATCAATGG 
 
55 °C – 1 min 
flox - 380 bp 
wt - 87 bp 
Cea - T fwd - AATTCTGAAGGAAAGTCCTTGG 
rev - TAATGGACCTTCTAGGTCTTGA 
 
54 °C – 45 sec 387 bp 
Flp-e fwd - CTAATGTTGTGGGAAATTGGAGC 
rev - CTCGAGGATAACTTGTTTATTGC 
 
50 °C – 1 min 600 bp 
Gp130 k.o. vs. wt GP130A - CTGAATGAACTGCAGGACGA 
GP130B - CAAGTGTTCTCAAGGTCCGAGTCCAC 
GP130C - TGAAGCCACTCGTCTTTAGC 
 
60 °C - 1 min k.o. – 700 bp 
wt – 500 bp 
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Lgr5- CreER
T2
 fwd - CACTGCATTCTAGTTGTGG 
rev - CGGTGCCCGCAGCGAG 
 
58 °C – 45 sec 
 
180 bp 
Rosa26- CreER
T2
 fwd - AATCGCCATCTTCCAGCAGG 
rev - GATCGCTGCCAGGATATACG 
 
58 °C - 45 sec 356 bp 
Rosa26-LacZ vs. wt Rosa1 - AAAGTCGCTCTGAGTTGTTAT 
Rosa2 - GCGAAGAGTTTGTCCTCAACC 
Rosa3 - GGAGCGGGAGAAATGGATATG 
52 °C – 45 sec Lac Z – 340 bp 
wt – 650 bp 
Sox2 geo rf 56 - CGTTGGCTACCCGTGATATT 
rf 24 - AGGCTGAGTCGGGTCAATTA 
 
50 °C - 45 sec 700 bp 
Sox2 deleted rf 33 - GACCTAGCCAGACCCCCTTA 
rf 24 - AGGCTGAGTCGGGTCAATTA 
 
60 °C - 45 sec 600 bp 
Sox2 flox  Neo rf 23 - CAGTCCAAGCTAGGCAGGTT 
rf 24 - AGGCTGAGTCGGGTCAATTA 
 
56 °C – 45 sec 
flox – 500 bp 
wt – 300 bp 
Sox2-RFP-CreER
T2
 
k.i. vs. wt 
fwd – TACGACGTCAGCGCCCT 
rev k.i. - GTACAGCATCTCGGTGTTGG 
rev wt- CCTCCAGATCTATACATGGTC 
56 °C – 1 min k.i. – 882 bp 
wt – 662 bp 
Sox2-RFP-CreER
T2
 
Neo 
fwd - GATCTGCTCCTCGAAGCCG 
SOXNeo - CGCAGCTGTCGTTTCGCTG 
56 °C – 1 min Neo – 468 bp 
Sox17iCre 
Neo vs. Neo 
EP420 - ATTGCATCGCATTGTCTGAGTAG 
EP401 - CTCAACTGTTCAAGTGGCAG 
EP564 - GATCTATGGTGCCAAGGATGAC 
 
60 °C – 45 sec 
 Neo – 446 bp 
Neo – 374 bp 
Sox17iCre 
Neo vs. wt 
EP400 - GTGTATAAGCCCGAGATGG 
EP401 - CTCAACTGTTCAAGTGGCAG 
EP564 - GATCTATGGTGCCAAGGATGAC 
 
60 °C – 45 sec 
 Neo – 446 bp 
wt  - 288 bp 
 
Samples were loaded onto a 1.5 % or 2 % agarose-gel and analyzed under an UV 
Transilluminator, Eagle Eye Gel Doc (see above). 
 
2.9.2. Preparation of blastocystes  
Sox2geo/wt x Sox2geo/wt mice were mated and plugs were checked every day in 
the morning and in the evening. At day 3 after positive plug check (E 3.5) pregnant 
mothers were sacrificed and ovaries, oviducts and uteri were prepared and transferred 
into a petri dish containing M2 medium. Both uteri were flushed with 0.5 µl M2 medium 
and subsequently streaked out to remove all blastocystes. Blastocystes were carefully 
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transferred to a new petri dish containing drops of fresh M2 medium covered by paraffin 
oil and washed several times in M2 medium. Subsequently they were evaluated, 
counted and photographed.  
 
2.9.3. Tamoxifen application 
 The CreERT2 is an inducible version of Cre-recombinase from bacteriophage P1 
[25]. In this system the Cre enzyme is fused to a mutated human estrogen receptor (ER) 
binding-domain and thus located in the cytoplasm where it is inactive. Upon induction 
with tamoxifen, a synthetic estrogen antagonist, Cre recombinase translocates into the 
nucleus. It specifically mediates recombination of two 13 bp long loxP recognition sites. 
The DNA fragment flanked by these lox p sites (“floxed gene”) is excised [26]. 
 20 mg tamoxifen was pestled in a 25 mm mortar for 10 to 15 min. Powder was 
transferred to a 15 ml tube and bottles and mortar were rinsed with 500 µl absolute 
EtOH to capture all remains of tamoxifen. 10 ml corn oil was added to reach a final 
concentration of 2 mg/ml. The suspension was vortexed and subsequently added to an 
ultrasonic bath for 10 min. This cycle was repeated 5 – 10 times until tamoxifen was 
completely dissolved. The solution was used immediately or aliquoted in 1.5 ml reaction 
tubes and stored for up to 3 month at -20 °C. 100 µl of tamoxifen solution (200 µg) was 
applied to adult mice orally or intraperitoneally. Analyses took place between one day 
and several weeks after the first application, depending on experimental set up. 
 
2.9.4. Histology 
2.9.4.1. Organ isolation and embedding 
Mice were killed by cervical dislocation. For paraffin embedding organs of 
interest were removed and fixed in 4 % paraformaldehyde (PFA) over night at 4 °C. 
Organs were transferred into embedding cassettes. Dehydration took place in a tissue 
processor. Organs were subsequently embedded in paraffin. Paraffin blocks were stored 
at room temperature. Before cutting blocks were cooled on ice or in a -20 °C freezer. 
Paraffin embedded tissue was cut in 4- 6 µm thick sections using a microtome. Sections 
were collected on positively charged glass slides and stored at RT or 4 °C until staining.  
 Methods 
 
 
66 
 
For cryo-embedded sections organs were fixed for 30 – 60 min in 4 % PFA and 
subsequently transferred to 15 % sucrose. After 6 – 8 h sucrose was changed to 30 %. 
Organs were incubated over night at 4 °C. The next day organs were placed in cryo-
molds and carefully covered in Tissue-Tek O.C.T. Compound without bubbles. Blocks 
were frozen on dry ice in 80 % ethanol. Frozen organs were stored at -80 °C. Frozen 
tissue was cut with a cryotome into 5 -10 µm thick sections. Sections were collected on 
positively charged glass slides, air-dried for 30 – 60 min at RT and stored at -80 °C until 
staining.  
2.9.4.2. Hematoxylin-Eosin (HE) staining 
HE staining is a commonly used histological technique to visualize tissue 
morphology. Hematoxylin has an affinity for negatively charged molecules. It is staining 
acidic tissue components, e.g. nucleic acids or acidic proteins (purple/blue). Alkaline 
tissue components such as keratin or collagens are stained by Eosin (pink/red). 
To remove paraffin, sections were put in an oven at 60 °C for 20 – 30 min and 
subsequently washed in AppliClear (3 x 10 min). Rehydration of sections was achieved by 
putting them in a graded series of EtOH dilutions – EtOH abs. (2 x 10 min) – 90 % EtOH (5 
min) – 70 % EtOH (5 min) – 50 % EtOH (5 min) followed by a 2- 3 min washing step in 
dH2O. Sections were stained by 20 % hematoxylin solution in PBS for 5 – 15 min, rinsed 
with tap water until residual staining was removed (3 – 5 min) and put into dH2O. 
Subsequently slides were incubated in 80 % EtOH containing 0.15 % HCl for 1 min, 
followed by washing in dH2O and a 5 sec incubation in 0.3 % ammonia water. After 
washing in dH2O and a 1 min step in 96 % EtOH tissue was stained with 0.5 % Eosin for 
30 – 60 sec followed by incubation in EtOH abs. (3 x 5 min) and AppliClear (3 x 5 min). 
Sections were mounted in DPX mounting medium and pictures were taken using a phase 
contrast microscope with camera.  
2.9.4.3. Immunohistochemistry 
Mouse sections were incubated in an oven for 20 – 30 min at 60 °C and 
subsequently washed with AppliClear (3 x 10 min) to remove paraffin. Slides were 
hydrated by consecutive incubation in a graded series of EtOH dilutions – EtOH abs. (2 x 
10 min) – 90 % EtOH (5 min) – 70 % EtOH (5 min) – 50 % EtOH (5 min). Sections were 
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washed for 5 min in dH2O. Unmasking of antigen was performed by boiling for 10 – 15 
min in a pressure cooker filled with 0.01 M Sodium citrate pH 6.0 or 1mM EDTA pH 8.0 
depending on specific recommendations for the antibody. After washing in dH2O slides 
were washed in PBS (2 x 5 min), ice cold acetone (10 min) and PBS (2 x 5 min). For the 
last wash step slides were transferred to shandon coverplates. After 10 min treatment 
with peroxidase solution slides were blocked with blocking buffer for 30 – 60 min at RT. 
Primary antibody was diluted according to manufacturer’s recommendations and 
incubated over night at 4 °C. The next day slides were equilibrated to room temperature 
for 15 min followed by six washing steps in PBS for 5 min each. Adequate biotinylated 
secondary antibody was diluted according to recommendations of the manufacturer and 
incubated for 30 min at RT. If ABC avidin/biotin method was used, VECTASTAIN Elite ABC 
Kit (Vector Laboratories) was prepared according to manufacturer’s instructions and 
incubated for 30 min at RT. Sections were washed five times with PBS for 5 min each. 
DAB was prepared according to supplier’s recommendations and added to slides for 5 
min followed by washing in PBS (2 x 1-3 min). Tissue was counterstained with 
hematoxylin for 30 – 60 sec and washed in tap water until residual staining was 
removed. Subsequently slides were put in dH2O and dehydrated by EtOH dilutions – 
EtOH 50 % (5 min) – EtOH 70 % (5 min) – EtOH 90 % (5 min) – EtOH abs. (2 x 10 min) 
followed by incubation with AppliClear (3 x 10 min). Coverslips were mounted in DPX 
mounting medium and pictures were taken using a phase contrast microscope with 
camera. 
Gastric tumor samples (n=31) were obtained from the paraffin-embedded tissue 
bank of the Institut für Pathologie, Klinikum Bayreuth (Bayreuth, Germany), after 
approval of the local ethics committee. 4 µm sections were incubated with anti-SOX2 or 
Ki67 antibodies after antigen retrieval in Epitope Retrieval Solution pH 6. Slides were 
then incubated with ImmPRESS (peroxidase) Polymer Detection kit (Vector Laboratories) 
for 30 minutes and developed using AEC Single Solution (Invitogen) following 
manufacturer’s instructions. Sections were counterstained with hematoxylin. For 
automated image acquisition Olympus Virtual Slide System VS120 was used. 
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2.9.5. Analysis of AZ-521 tumorgenicity in vivo 
 Female 6- 10 week old athymic NMRI nude-mice were used (n = 5 per group). AZ-
521 dnSOX2 cells were virally transduced with an eGFP-Luc construct. Cells were sorted 
for eGFP by fluorescence activated cell sorting and GFP positive cells were grown in cell 
culture as described above, being kept under antibiotic free conditions prior to injection. 
To harvest cells they were trypsinized, washed three times with PBS and diluted in ice 
cooled PBS at a concentration of 106 cells per 150 μL. 150 μL of cell suspension was 
injected subcutaneously or intravenously. Bioluminescence signal was measured 4 h and 
24 h after tumor cell injection and then every 3 to 4 days by a CCD camera in an IVIS 
Lumina system. For measurement mice were anaesthetized by inhalation of isoflurane in 
oxygen (2.5 % (v/v)) at a flow of 1 L/min. Bepanthene was put on the eyes for protection. 
Subsequently 100 μL luciferin solution (c = 60 mg/mL) was injected intraperitoneally and 
was allowed to distribute 10 - 15 min prior to bioluminescent measurement. 
Bioluminescence was measured with a medium or large binning and 1 - 5 min exposure 
time. Results were evaluated using Living Image 3.0 software. 
 
2.10. Materials 
2.10.1. Buffers and Solutions 
 
Agarose Gel electrophoresis: 
1 x TAE-Buffer 
Tris/HCl pH 8.2     40 mM 
Acetic acid      20 mM 
EDTA pH 7.6      2 mM 
In dH2O 
 
Apoptosis assay: 
Binding buffer 
HEPES/NaOH, pH 7.4     10 mM  
NaCl       140 mM 
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CaCl2       5 mM 
in dH2O 
 
β-Galactosidase staining: 
Staining Solution  
Potassium Ferricyanide Crystalline   5 mM 
Potassium hexacyanoferrate (II) Trihydrate  5 mM 
MgCl2        2 mM 
X-Gal        1 mg/ml 
in PBS 
Staining solution was prepared freshly at the day of experiment. X-Gal was 
dissolved in dimethylformamide and stored at -20 °C in the dark. 
 
Blastocyste isolation: 
 M2 medium 
 NaCl       94.66 mM 
 KCl       4.78 mM 
 CaCl2 x 2H2O      1.71 mM 
KH2PO4      1.19 mM 
 MgSO4 x 7H2O      1.19 mM 
 NaHCO3      4.15 mM 
 Hepes (pH 7.4)     20.58 mM 
 Sodium lactate     23.28 mM 
 Sodium pyruvate     0.33 mM 
 Glucose      5.56 mM 
 BSA       4 g/l 
 Penicillin G, Potassium salt    1000 IU/ml 
 Streptomycin sulfate     50 µg/ml 
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 Phenol red      0.01 g/l 
Osmolarity was measured (should be between 280 and 287 mOsmole) and 
medium was filtered for sterilization and stored at -20 °C. BSA was added freshly 
before use. 
 
Cell cycle assay: 
PI staining solution 
Sodium citrate     3.8 mM 
PI       10 µg/ml 
in PBS  
 
Competent E. coli: 
LB (Luria Broth) medium 
Tryptone      10 g 
Yeast extract      5 g 
NaCl       10 g 
dH2O        ad 1 L 
Before addition of antibiotics, LB medium was autoclaved and cooled to 50 °C. LB 
medium was stored at 4 °C.  
 
 LB agar (pH 7.4) 
NaCl       0.5 % 
 Yeast Extract      0.5 % 
 Tryptone       1 %  
 Agar       1.5 % 
 in dH2O   
LB agar was autoclaved and cooled to 50 °C before addition of antibiotics and 
transfer to plates. LB agar plates were stored at 4 °C.  
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Tfb-I Buffer 
K-acetate      30 mM 
MnCl2       50 mM 
KCl       100 mM 
CaCl2       10 mM 
Glycerol      15 % (v/v) 
in dH2O 
MnCl2 and Glycerol were added after autoclaving.  
 
Tfb-II Buffer 
HEPES pH 7      10 mM 
CaCl2       75 mM 
KCl       10 mM 
Glycerol      15 % (v/v) 
in dH2O 
 
TYM medium 
Tryptone      2 % 
Yeast extract      0.5 % 
NaCl       0.1 M 
MgSO4       10 mM 
in dH2O 
 
Histology: 
Blocking solution 
Normal goat serum     5 % 
in PBS 
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Peroxidase solution 
30 % H2O2 (pH 7.5)      200 µl 
NaN3 (10%)      15 µl 
PBS       ad 1500 µl 
 
Immunofluorescence: 
Antibody buffer 
BSA       3 % 
Saponin      1 % 
Sodium Azide      0.05 %  
in PBS 
 
Blocking solution 
BSA       3 % 
Triton X-100      0.1 % 
Saponin      1 % 
Sodium Azide      0.05 % 
in PBS 
 
Washing buffer for Immunofluorescence 
Saponin      1 % 
in PBS 
 
Senescence associated –βgalactosidase activity staining: 
Citric Acid/Phosphate Buffer, pH 6.0  
Citric Acid      0.1 M  
Sodium Phosphate Dibasic (Na2HPO4)   0.2 M 
in H2O  
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Fixative Solution  
Formaldehyde     2 % (v/v) 
Glutaraldehyde     0.2 % (w/v) 
in PBS 
 
Staining Solution  
Potassium Ferricyanide Crystalline   5 mM 
Potassium hecacaynoferrate (II) Trihydrate  5 mM 
MgCl2       2 mM 
NaCl2       150 mM 
Citric acid phosphate buffer, pH 6.0   30 mM 
X-Gal       1 mg/ml 
in dH2O 
Staining solution was prepared freshly at the day of experiment. X-Gal was 
dissolved in dimethylformamide and stored at -20 °C in the dark. 
 
SDS-PAGE and Western Blot: 
Resolving Buffer  
SDS             0.4 % (w/v) 
Tris/HCl, pH 6.8     0.5 M 
in dH2O 
 
Resolving Gel 
Resolving Buffer     6 ml     
Bis-Acrylamide (30 %)    9.56 ml   
APS (10 %)      80 µl    
TEMED (10 %)      40 µl 
dH2O       ad 23.92 ml 
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SDS Electrophoresis buffer 
Tris       0.025 M 
Glycine      0.2 M 
SDS       0.1 % (w/v) 
in dH2O 
 
SDS lysis buffer (pH 6.8) 
Tris/HCL, pH 6.8     62.5 mM 
SDS       2 %  
Glycerol      10 % 
DTT       50 mM 
Bromphenol blue     0.01 % 
in dH2O 
 
Stacking Buffer 
SDS       0.4 % (w/v) 
Tris/HCL, pH 8.8     1.5 M 
APS (10 %)      40 µl  
in dH2O 
 
Stacking Gel       
Stacking Buffer     1.96 ml   
Bis-Acrylamide (30%)     1.56 ml    
TEMED (10%)      40 µl 
dH2O       ad 7.84 ml 
 
4x SDS sample buffer (pH 6.8) 
 Tris/HCl       240 mM 
  Glycerol      40 % 
  SDS       8 % 
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 β-Mercaptoethanol     5 % 
 Bromophenol Blue     0.004 % 
 
Ponceau S staining solution 
Ponceau S      0.1 % 
 Acetic acid       5 % 
 
10 x transfer buffer 
Tris       25 mM 
Glycin       190 mM 
SDS       0.01 % (w/v) 
in dH2O 
 
1 x transfer buffer 
10 x transfer buffer     100 ml 
Methanol      200 ml 
dH2O       ad 1 L 
 
TBS (pH 7.5) 
Tris/HCl, pH7.5     50 mM 
NaCl       150 mM 
in dH2O 
 
TBS-T 
TBS 
Tween       0.1 % 
 
shRNA cloning: 
Annealing buffer  
K-Acetate      100 mM 
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HEPES pH 7.4      30 mM 
Mg-Acetate      2 mM 
in dH2O 
 
Tissue lysis: 
Laird’s Buffer 
NaCl        100 mM 
Tris, pH 8      10 mM 
EDTA       10 mM 
SDS       0.5 % 
in dH2O 
Buffer was autoclaved after preparation. 
 
2.10.2. Chemicals and Kits 
2-Propanol  67523 Roth   
30 % Acrylamid/Bis Solution  161-0158 Bio-Rad 
4-Hydroxytamoxifen  H-6278 Sigma 
Acetic acid  100063 Merck 
Aceton  9372 Roth 
Agar-Agar  5210 Roth 
Agarose  A9539-5009 Sigma-Aldrich 
Albumin Fraction V (BSA)  A1391 AppliChem 
Ammoniumpersulfat, APS  A2941 AppliChem 
Ampicillin  K029.3 Roth 
Annexin V-FITC  556419 BD Pharming 
AppliClear  A4632 AppliChem 
Aqua ad iniectabilia Diaco  2034374 Serag-Wiessner KG 
Bench Top 1kb DNA Ladder  G7541 Promega 
Bepanthene  7.158 Bayer 
Beta-Mercaptoethanol  M3148 Sigma-Aldrich 
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Blasticidin S  R210-01 Gibco 
Bovine Serum Albumin  A9416 Sigma-Aldrich 
Bromophenol Blue  8122 Merck 
Calcium chloride, CaCl2  2385 Merck   
Caspase-Glo 3/7 Assay System  G8090 Promega 
CellMask Plasma Membrane Stain  C10046 Invitrogen 
Cell Proliferation Dye eFluor 670 Cell Labeling 65-0840 eBioscience 
Cell Titer-Glo® Substrate  G755A Promega 
Citric acid  251275 Sigma-Aldrich 
Corn Oil  C-8267 Sigma-Aldrich 
DAB solution Set  S-99014-103 42 Life Science 
Dimethylformamide (DMF)  319937 Sigma-Aldrich 
Disodium hydrophosphate, Na2HPO4x2H2O 119753 Merck 
Dithiothreitol, DTT  A3668 AppliChem 
DMSO  A3672 AppliChem 
DNA-free DNase treatment and removal AM1906  Ambion  
Doxycycline  44577 Fluka 
DPX mounting medium  360294H VWR 
Dual Luciferase Reporter Assay System E1960 Promega 
Dulbecco´s modified Eeagle Medium, DMEM 41965 Gibco 
EDTA-free Protease Inhibitor tablets, Complete  4693159001 Roche 
Eosin  1024390500 Merck Millipore 
Ethanol, absolute  A3678 AppliChem 
Ethylenediaminetetraacetic acid, EDTA A2937 AppliChem 
Fetal Calf Serum  F7524-500ML Sigma-Aldrich 
FideliTaq PCR Master Mix (2X)  71182 USB 
GenElute Mammalian Total RNA Miniprep Kit  RTN70-1KT Sigma-Aldrich 
Glutaraldehyde  85191 Fluka 
Glycerin  A2926 AppliChem 
Glycine  3790.3 Sigma-Aldrich 
GoTaq Green Master Mix (2X)  M7112 Promega 
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Helicobacter pylori selective supplement SE0147 Oxoid  
Hematoxylin  1.09253 Merck 
Hepes  25245 Serva 
Hydrochloric acid, HCl  109063 Merck 
Illustra GFX PCR and Gel Band Purification Kit 28-9034-70 GE Healthcare 
Isofluran (Forene 100%)  B506 Abbott 
Kaliumacetat, KAc  1.04820 Merck 
Kaliumchloride, KCl  4936 Merck 
LB Agar  75851 USB 
LB Broth  75852 USB 
Lipofectamine 2000  11668  Invitrogen 
Loading Dye, 6X  R0611 Fermentas 
Luciferin VivoGlo, In Vivo Grade  P1041 Promega 
Maxima SYBR Green/ROX qPCR MasterMix (2X) K0221  Fermentas 
MEM-Glutamax  41090 Gibco 
Methanol  4627.4 Roth 
Milk Powder  T145.2 Roth 
Magnesium acetate  105819 Merck 
Magnesium sulfated, MgSO4  1.05886 Merck 
Manganese Chloride, MnCl2  805930 Merck  
M-MLV Reverse Transcriptase, RNase H(-) M3682 Promega 
Monopotassium phosphate, KH2PO4 104873 Merck 
Normal goat serum  S26-100ML Millipore 
Opti-MEM  51985  Gibco 
Orange G  O3756 Sigma-Aldrich 
Paraformaldehyde  PZN2652965 Fischar 
Penicillin G, Potassium salt  5161 Merck 
Penicillin/Streptomycin 100 X Solution 15140  Gibco 
Peroxidase 3 %, H2O2  - Apo. Klinikum r.d.I. 
peqGOLD Protein-Marker V  27-2210 PeqLab 
Phenole red  A7615 AppliChem 
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Phosphate Buffered Saline, 1X  14190 Gibco 
Pierce® ECL Western Blotting substrate 32106 Thermo Scientific 
Ponceau Red  5938.1 Roth 
Potassium chloride, KCl  P9541 Sigma-Aldrich 
Potassium Ferricyanide Crystalline  P8131 Sigma-Aldrich 
Potassium hecacaynoferrate (II) Trihydrate 60279 Fluka 
Propidium Iodite  P4864 Sigma-Aldrich 
Protein A-Agarose  05015979001 Roche 
Protein G-Agarose  05015952001 Roche 
Proteinase K  P2308 Sigma-Aldrich 
PureYield Plasmid Midiprep System  A2492 Promega 
Restore Western Blot Stripping Buffer 21059 Thermo Scientific 
Ribonuclease A  R6513 Sigma-Aldrich 
Roti®-Safe GelStain  3865.1 Roth 
RPMI 1640  21875-091 Gibco 
Saponine  4185.1 Roth 
SDS-Pellets  CN30.2 Roth 
SITRAN 1.0 siRNA transfection reagent TT300002 Origene 
Sodium azide, NaN3  6265 Merck 
Sodium chloride, NaCl  3957.1 Roth 
Sodium citrate  1.12005 Merck 
Sodium hydrogene carbnoate, NaHCO3 HN01.1 Roth 
Sodium hydroxide, NaOH  A4422 AppliChem 
Sodium lactate  L7022 Sigma-Aldrich 
Sodium pyruvate  S8636 Sigma-Aldrich 
Staurosporine  S-9300 LC Laboratories 
Streptomycine sulfate salt  S9137 Sigma-Aldrich 
Sucrose  S0389 Sigma-Aldrich 
SuperSignal West Pico Chemiluminescence Subs. 34080 Thermo Scientific 
SV Minipreps Wizard Plus  A1460 Promega 
T4 polynucletide kinase (PNK)   M0236L NEB 
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T4 DNA Ligase  M180  Promega 
Taq PCR Core Kit  201225 Qiagen 
Tetramethylethylenediamine, TEMED A1148 AppliChem 
Tissue-Tek O.C.T. Compound  SAK 4583 Sakura 
Tris  9090.3 Roth 
Triton X-100  A1388 AppliChem 
TRIzol® Reagent  15596-026 Ambion 
Trypan Blue 0.4 %  15250 Gibco 
Trypsin/EDTA  41010 PromoCell 
Tryptone   A1553 AppliChem 
Tween 20  A1389 AppliChem 
VECTASHIELD mounting medium   H-1000 Vector 
Laboratories 
VECTASHIELD mounting medium with DAPI H-1200 Vector 
Laboratories 
VECTASTAIN Elite ABC Kit  PK-6100 Vector 
Laboratories 
Wizard SV Gel and PCR Clean Up System A9282 Promega 
X-Gal (5-Bromo-4-Chloro-3-Indolyl b-DGalacotpyranoside) B4252 Sigma-Aldrich 
Yeast extract  212750 BD Bioscience 
Zeocin  R25001 Invitrogen 
 
2.10.3. Antibodies 
Tab. 5: Antibodies used in this study 
Primary antibodies 
Name Implemented concentration Manufacturer 
Anti--actin (mouse, monoclonal) WB 1:5000 Sigma-Aldrich 
A1978 
Anti-HA (mouse, monoclonal) WB 1:1000 
IF 1:200 
Sigma-Aldrich 
H3663 
Anti-HA (rabbit, polyclonal) WB 1:1000 
IF 1:200 
Sigma-Aldrich 
H6908 
Anti-Np63 (rabbit, polyclonal) WB 1:200 Santa Cruz 
SC-8609-R 
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Anti-SOX2 (rabbit, monoclonal) IF 1:400 
WB 1:1000 
IHC 1:100 
Cell signaling 
3579 
Anti- pSTAT3 WB 1:1000 
IF 1:100 
Cell signaling 
9131 
p21 WB 1: 1000 Cell signaling 
2947 
Secondary antibodies 
Name Implemented concentration Manufacturer 
Anti-mouse IgG (H&L) HRP 
conjugate 
WB 1:2500 Promega W402B 
Anti-rabbit IgG (H&L) HRP 
conjugate 
WB 1:2500 Promega W401B 
AlexaFlour488 goat anti-mouse 
IgG 
IF 1:200 Invitrogen A11001 
AlexaFlour594 chicken anti-rabbit 
IgG 
IF 1:200 Invitrogen A21442 
 
2.10.4. Consumables 
Blotting Paper  GB46 Hartenstein 
Cell scrapers, 30 cm  99003 TPP 
Cell culture flasks, sterile, 25 cm2  734-2311 VWR International 
Cell culture flasks, sterile, 75 cm2  734-2313 VWR International 
Cell culture flasks, sterile, 175 cm2  734-2315 VWR International 
Cellstar Centrifuge Tubes, 15 ml  188271 Greiner Bio-one 
Cellstar Centrifuge Tubes, 50 ml  227261 Greiner Bio-one 
Cloning cylinders  TR-1004 Millipore 
Cryogenic vial  LW3332 Alpha Laboratories 
Cryomolds, Intermediate (15 x 15 x 5) SAK 4566 Sakura 
Cryomolds, Standard (25 x 20 x 5)  SAK 4557 Sakura 
Culture inserts   80209 ibidi 
DNA Pick-Tips  03DNA65 Süd-Laborbedarf 
Electroporation cuvettes, 0.4 cm gap 165-2081 Bio-Rad 
Eppendorf Microcentrifuge tubes, 1.5ml T9661 Sigma-Aldrich 
Gel cassettes  NC2010 Invitrogen 
Inoculation Spreader  612-1561 VWR International 
LightCycler480 Multiwell Plate 96, white 04 729 692 001 Roche 
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Medical X-ray film (Super RX)  47410 08389 Fujifilm 
Microscope Cover Glasses, 18 mm  0101030 Marienfeld  
Microscope Slides  ISO8037/1 Thermo Scientific 
PCR tubes  6003-SF Kisker 
Plastic embedding device  07-7100 Biooptica 
Protan Nitrocellulose Transfer Membrane, 0.45 µm NC04 Whatman 
Round-Bottom Assay Plate, 96 well  3789 Costar 
Serological pipettes, 5 ml  606 180/5ml Greiner Bio-one 
Serological pipettes, 10 ml  607 180/10ml Greiner Bio-one 
Serological pipettes, 25 ml  706 180/25ml Greiner Bio-one 
Superfrost plus microscope slides  J1800AMNZ Thermo Scientific 
TipOne Graduated Filter Tips, 10 µl S1121-3810 Starlab 
TipOne Bevelled Filter Tips, 20 µl  S1121-1810 Starlab 
TipOne Graduated Filter Tips, 200 µl S1120-8810 Starlab 
TipOne Graduated Filter Tips, 1000 µl S1122 1830 Starlab 
Tips, 0.1 - 10 µl  613-3500 VWR International 
Tips, 2 - 200 µl  613-3503 VWR International 
Tips, 500 - 1000 µl  613-3508 VWR International 
Tissue culture plate, 6 well  353046 BD Bioscience 
Tissue culture plate, 12 well  353043 BD Bioscience 
Tissue culture plate, 24well  353047 BD Bioscience 
Tissue culture plate, 48 well  353078 BD Bioscience 
Tissue culture dish, 100 mm  353003 BD Bioscience 
Tissue culture dish, 150 mm  353025 BD Bioscience 
 
 
2.10.5. Instruments 
Agate morter (25 x 20 mm) with pistil neoLab 
Agarose Electrophoresis Chambers Bio-Rad 
AxioVert 40 Microscope  Zeiss 
Biofuge Pico Centrifuge  Heraeus, Thermo Scientific 
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Biofuge Primo R Centrifuge  Thermo Scientific 
Cell Culture Incubator, HeraCell, 240 Heraeus, Thermo Scientific 
Centrifuge 5415D  Eppendorf 
Centrifuge 5424  Eppendorf 
Centrifuge Micro 200R  Hettich 
Confocal Microscope, Leica SP5  Leica Microsystems 
Developing Machine Curix60  AGFA 
Electrophoresis Power Supply PowerPac300 Bio-Rad 
Embedding system TBS88  Medite 
Fluorescence Microscope, DMRB  Leica 
Freezer -20°C  Liebherr 
GenePulserXCell  Bio-Rad 
Heatable magnetic stirrer  IKAMAG RET-G 
HERAFreeze Basic -80°C Freezer  Thermo Scientific 
Hybridization Oven OV3  Biometra 
Ice Machine  Ziegra 
iCycler  Bio-Rad 
Innova 2100 Platform Shaker  New Brunswick Scientific 
IVIS Lumina System  Caliper Life Sciences 
Laboratory Precision Scale XB120A Precisa Precisa 
Laboratory Scale  Kern 
Laminar Airflow Cabinet, HeraSafe  Heraeus, Thermo Scientific 
Leica DMRB Microscope  Leica microsystems 
LightCycler480  Roche 
Mithras LB9440  Berthold 
Multifuge 3 S-R  Heraeus, Thermo Scientific 
Neubauer hemocytometer cell counting chamber Marienfeld  
Orion Microplate Luminometer  Berthold 
Olympus Virtual Slide System VS120  Olympus 
pH-Meter  WTW inoLab 
Electronic Pipet Filler, Easypet®  Eppendorf 
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Power Supply PowerPac Basic (for SDS gels) Bio-Rad 
Refrigerator 4°C  Liebherr 
Shaker, Titramax 100  Heidolph 
Shandon Coverplates  Thermo Scientific 
Single Channel Pipettor, 0.5-10 µl  Corning 
Single Channel Pipettor, 2-20 µl  Corning 
Single Channel Pipettor, 20-200 µl  Corning 
Single Channel Pipettor, 200-1000 µl Corning 
Sonoplus HD60   Bandelin 
Spectrophotometer NanoDrop 1000 Thermo Scientific 
StepOnePlusTM Real-Time PCR System Applied Biosystems 
T10 basix ULTRA-TURRAX Disperser IKA 
T3000 Thermocycler   Biometra 
Thermomixer compact   Eppendorf 
Tissue processor Shandon Excelsior ES Thermo Scientific  
UV Transilluminator, Eagle Eye Gel Doc Bio-Rad 
Vortex Genie 2  Schultheiss 
Waterbath Julabo   Julabo  
Waterbath  GFL 
XCell IITM Blot Module  Invitrogen 
XCell SureLock® Mini-Cell  Invitrogen 
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3. Results 
 
3.1. Role of SOX2 in gastric cancer  
 
3.1.1. SOX2 expression in gastric tumors and gastric cancer cell lines 
3.1.1.1. SOX2 expression in gastric cancer tissue samples 
Several GC tissue samples from intestinal and diffuse type tumors were stained 
and analyzed for SOX2 expression. About 30 % of all tumors were positive for SOX2. 80 
% of SOX2 positive tumors were classified as intestinal type, whereas 20 % were diffuse 
type tumors. Among SOX2 negative tumors 70 % were intestinal type and 30 % diffuse 
type tumors. Positive and negative type tumors did not significantly differ in histological 
grade. All SOX2 negative tumors were infected with H. pylori. Among SOX2 positive 
tumors one case was negative for H. pylori infection (Tab. 6).  
 
Tab.6: Clinico-pathological characteristics of SOX2 positive and negative human gastric tumors (n =31) 
 SOX2 positive (n=11) SOX2 negative (n=20) 
Age 65.1 ± 12.7 73.6 ± 8.6 
Sex 
M 
F 
 
51 (45.5%)2 
 6 (54.5%) 
 
11 (55.0%) 
  9 (45.0%) 
Lauren´s classification 
Intestinal 
Diffuse 
 
9 (81.8%) 
2 (18.2%) 
 
14 (70.0%) 
6 (30.0%) 
Histological grade 
Low grade (G1-G2) 
High grade (G3-G4) 
 
 5 (45.5%) 
6 (54.5%) 
 
11 (55.0%) 
9 (45.0%) 
H. pylori 
Active 
H .pylori (eradicated) 
Negative 
 
8 (72.7%) 
2 (18.2%) 
1 (9.1%) 
 
15 (75.0%) 
5 (25.0%) 
0 
1 Number of cases  2 Percentage of cases  
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Additionally, KI67 staining was performed, to determine proliferation sites in the 
tumors. Tumor cells expressing SOX2 showed also KI67 expression (Fig. 13), indicating, 
that cells positive for SOX2 are highly proliferative and thus potentially tumorigenic. 
 
Fig. 13: Immunohistochemical analysis of gastric tumor tiussue samples; SOX2 expression in several 
gastric tumors correlated with KI67 expression. 
 
3.1.1.2. Cell line screening for SOX2 expression in gastric cancer cells 
The expression of the transcription factor SOX2 was analyzed in eleven GC cell 
lines by quantitative real time PCR and by western blot. The stomach carcinoma cell line 
AZ-521 showed highest RNA levels of SOX2. Significant amounts were also detected in 
AGS, Kato III and MKN45 cells. In all other cell lines no RNA of SOX2 was detected. 
Similar results were observed at the level of protein expression. AZ-521, AGS, Kato III 
and MKN45 cells showed high protein levels. Minor expression levels were detected in 
MKN7. No SOX2 protein expression could be detected in the other cell lines. 
Furthermore, SOX2 transcriptional activity was also analyzed in the same GC cell lines. 
For this purpose a SOX2 reporter plasmid containing a 6-fold SOX2 binding site in front 
of a luciferase gene was used (see Material and Methods 2.1.2.1). The relative level of 
transcriptional activity was expressed as relative light units (RLU) of luciferase to renilla. 
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Correlating with the expression levels of SOX2, AZ-521 cells showed very high SOX2 
transcriptional activity. Interestingly, some cell lines, such as Kato III or MKN45 cells, 
exhibiting high SOX2 mRNA and protein levels, showed only moderate or low 
transcriptional activity (Fig. 14). 
. 
Fig. 14: SOX2 expression and transcriptional activity in GC cell lines; q-RT PCR was performed for analysis 
of mRNA expression of SOX2. N = 3, n = 9 (A). SOX2 protein was detected by Western Blot. N = 3 (B) SOX2 
transcriptional activity was measured by SOPFlash/NOPFlash assay. N = 3, n = 6 (C) 
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3.1.2. The functional role of SOX2 in gastric cancer cells 
3.1.2.1. SOX2 knock-down strategies 
To determine the functional role of SOX2 in GC, AZ-521, a cell line highly 
expressing SOX2, was chosen for further experiments. Two knock-down strategies to 
inhibit SOX2 were followed. The first strategy was to transiently transfect AZ-521 cells 
with shRNA of SOX2 cloned into the expression vector pLVTHM. SOX2 protein expression 
was analyzed 48 h after transfection. Western blot showed a decrease of SOX2 protein 
after transfection with shSOX2 in contrast to control shRNA, proving effectiveness of the 
SOX2 shRNA (Fig. 15 A). Moreover, SOX2 transcriptional activity was analyzed 48 h after 
transfection. SOX2 transcriptional activity was 50 % decreased by SOX2 shRNA in 
comparison to the parental cell line and cells transfected with the control shRNA (Fig. 15 
B).  
 
Fig. 15: Analysis of AZ-521 cells transiently transfected with SOX2 shRNA; western blot of AZ-521 cells 48 
h after transient transfection with shSOX2 showed a decrease in SOX2 protein compared to parental cell 
lines and cells transfected with a control shRNA (A). N = 3; In contrast to the control shRNA, expression of 
shSOX2 significantly reduced SOX2 transcriptional activity measured by reporter gene assay 48 h after 
transient transfection (B). N = 3, n = 6; 
 
In parallel, SOX2 was inhibited by blocking transcriptional activity, using a 
dominant negative construct for SOX2. Therefore, AZ-521 cells were stably transfected 
with a regulatory plasmid containing a tetracycline repressor (TR) and a responsive 
plasmid harboring a C-terminally truncated version of SOX2 under the control of a 
tetracycline responsive element (TRE). Two different truncated versions of SOX2 were 
cloned. The longer version consisted of the amino acids 1-158, the shorter version 
harbored only the amino acids 1-129. Both truncated dominant negative (dn) SOX2 
constructs were designed to bind to recognition sites on DNA, as the HMG binding 
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domain was still functional, but they lacked the activation domain abolishing signaling 
activity (Fig. 16).  
 
 
Fig. 16: Scheme of the SOX2 gene, the truncated SOX2 constructs and the Tet-On system; the nuclear 
targeting sequence lies in the HMG domain of the SOX2 gene. Both dominant negative SOX2 constructs 
were C-terminally truncated, leaving the N-terminal domain and the HMG box fully functional (A). In 
untreated cells dnSOX2 was blocked by a tetracycline repressor (TR) and SOX2 was transcribed normally. 
After adding doxycycline to the system, dnSOX2 was transcribed, blocking SOX2 binding sites, therefore 
inhibiting transcription of target genes (B). Drawings are not to scale. 
 
Both versions were tested in transient transfection experiments for their ability 
to down-regulate SOX2 transcriptional activity. Significant inhibition of SOPFlash activity 
could be achieved by both truncated versions after transient transfection (Fig. 17 A). For 
generating stable cell clones, cells positively selected for the regulatory plasmid 
containing a tetracycline repressor (TR) by 20 µg/ml blasticidin were transfected with 
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each construct version of dnSOX2 and selected by applying 400 µg/ml zeocin. 24 clones 
of each version were picked and further cultured under antibiotic selective conditions. 
Only a subset of cells was viable after one week of selection and could be extended to 
test its function. Only cells harboring the shorter version, dnSOX2 1 -129, showed a 
down-regulation of SOX2 activity after inducing with 1 µg/ml doxycycline (Fig. 17 B). 
Thus, further experiments were conducted with this shorter dominant negative SOX2 
construct in stable cell clones under the regulation of a tetracycline repressor. 
 
Fig. 17: Analysis of transcriptional activity of SOX2 after transfection with dnSOX2 constructs; SOX2 
transcriptional activity was measured after transient transfection by SOPFlash/NOPFlash assay. SOX2 over 
expression induced SOX2 activity, whereas expression of dnSOX2 1 -129 and dnSOX2 1- 158 both led to a 
significant decrease of SOX2 activity in AZ-521 cells. (A) N = 4, n = 8; Four stable clones of AZ-521 TR 
dnSOX2 1-129 (no. 3, no. 4, no. 7 and no. 8) led to a decrease of SOX2 activity after induction with 
doxycycline. In AZ-521 TR dnSOX2 1 - 158 no inducible stable cell clone, down-regulating SOX2 could be 
identified (B). N = 4, n = 8; Light units were normalized to renilla., * p < 0.05, p** < 0.01 
 
Clone no. 4 and clone no. 7 were selected for further experiments as they 
showed best effects on blocking SOX2 transcriptional activity after induction with 
doxycycline. First, cell clones were tested for the expression of the HA-tagged dnSOX2 
construct. Western blot showed dnSOX2 expression as early as 4 h after induction of 
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cells with doxycycline. Expression levels were increasing over time (Fig. 18 A). Nuclear 
expression was analyzed by immunofluorescence and staining was already visible after 8 
h. After 12 h approximately 85 % of cells were positive for dnSOX2 staining (Fig. 18 B). 
Down-regulation of SOX2 transcriptional activity was time dependent and most 
pronounced 48 h after induction (Fig. 18 C). All following data are shown for the cell 
clone no. 4. 
 
Fig. 18: dnSOX2 expression in doxycycline induced AZ-521 stable cell clones; dnSOX2 is expressed as early 
as 4 h after induction with doxycycline as shown by western blot against the HA-tag (A). N = 5; Nuclear 
expression of dnSOX2 12 h after doxycycline treatment detected by immunofluorescence; green = SOX2, 
red = deep red plasma membrane stain (B). N = 5; dnSOX2 expressing cells showed a time dependent 
decrease in SOX2 activity measured by SOPFlash/NOPFlash assay, whereas control cell line AZ-521 did not 
show any down-regulation (C). N = 5, n = 10; *p < 0.05; ** p < 0.01 
 
3.1.2.2. The role of SOX2 in cell proliferation 
SOX2 is known to play a crucial role in cell proliferation and cell differentiation in 
ES and iPS cells. Furthermore, a co-expression of SOX2 and KI67 was seen in gastric 
tumor samples (see Fig. 13), emphasizing the role of SOX2 in proliferation. Thus, the 
impact of SOX2 on cell proliferation was analyzed in vitro. AZ-521 cells were 
synchronized by serum starvation and released from cell cycle arrest by addition of 10 % 
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FCS after 24 h. Proliferation was measured by quantification of ATP after 12 h, 24 h, 48 
h, 72 h, and 6 d after transient transfection with shSOX2 or after induction of dnSOX2 in 
the stable cell clones. After 12 h (Fig. 19 A) and 24 h (Fig. 19 B) no differences in 
proliferation of stable AZ-521 dnSOX2 cell clones could be detected compared to 
parental control cells. Same results were found for cells transient transfected with SOX2 
shRNA. After 48 h a decrease of proliferation was observed in induced stable cell clones 
(Fig. 19 C) however, this effect could not be seen in cells transfected with SOX2 shRNA. 
After 72 h in both, induced stable cell clones (Fig. 19 D) as well as SOX2 shRNA 
transfected cells (Fig. 19 F) a significant decrease of proliferation was shown, however, it 
was more pronounced in the stable cell clones than in SOX2 shRNA transfected cells. 6 
days after induction with doxycycline proliferation levels in cells stably expressing 
dnSOX2 began to increase again (Fig. 19 E). 
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Fig. 19: Proliferation analysis in AZ-521 cells after inhibition of SOX2; 12 h (A) and 24 h (B) after induction 
of dnSOX2 no effect of proliferation was observed. After 48 h (C) and 72 h (D) a significant decrease in cell 
proliferation could be observed in the stable cell clone compared to the non-induced clone and the 
parental control cell line. The effect of dnSOX2 in proliferation was most pronounced after 72 h and 
started to rise again beginning after 6 days (E). N = 4, n = 12; AZ-521 cells transfected with shSOX2 RNA 
showed a significant decrease of proliferation only after 72 h (F). N = 3, n = 9; *p < 0.05 
 
In addition cell divisions were monitored by staining AZ-521 cells stably 
expressing dnSOX2 with Cell Proliferation Dye eFluor 670. After synchronization, cells 
were stained and proliferation was measured by FACS analysis 24 h and 48 h after 
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doxycycline treatment. After 24 h no differences could be seen, comparing stable AZ-521 
dnSOX2 cell clones to the parental cell line. However, 48 h (Fig. 20) of dnSOX2 induction 
resulted in less cell division in the inducible cell clone. 
 
Fig. 20: Cell division in AZ-521 dnSOX2 cells 48 h after doxycycline treatment; AZ-521 control cells do not 
show differences in proliferation whether treated with doxycycline (bold line) or not induced (A). A clear 
difference could be seen in AZ-521 dnSOX2 cells. Induced cells (bold line) proliferate slower compared to 
the not treated controls (B). The line on the left side of each diagram represents unstained cells. N = 3, n = 
6; one representative experiment shown. 
 
3.1.2.3. The role of SOX2 in apoptosis 
Dysregulation of apoptosis is an essential mechanism in the development of 
neoplasms and in cancer progression. Tumor cells are able to avoid apoptosis, leading to 
an uncontrolled cell replication. To analyze apoptosis of cells after SOX2 blocking, 
Caspase 3/7 assays were performed, as Caspase 3 is important for the initiation of 
apoptosis. Prior to experiments cells were serum starved 24 h for synchronization. Stably 
transfected AZ-521 dnSOX2 cells were analyzed for Caspase3/7 activity after 8 h, 24 h 
and 48 h of inhibition of SOX2. At 8 h (Fig. 21 A) and 24 h (Fig. 21 B) no significant 
differences could be observed compared to the non-induced cell clone or the parental 
cell line. 48 h after doxycycline treatment an increase of apoptosis was observed with 30 
% more cells being apoptotic (Fig. 21 C). In cells transfected with shSOX2, Caspase 3/7 
activity was measured 48 h after transfection. No significant differences could be 
observed in comparison to control shRNA or the parental cells (Fig. 21 D). This might be 
due to the exceptional high expression level of SOX2 which could only be marginally 
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reduced by RNA interference, as also seen in SOX2 transcriptional activity assay and 
proliferation analysis. As no differences of apoptosis in Caspase 3/7 assay was observed 
in shSOX2 transfected cells, Annexin V staining and all following experiments were 
conducted with cells expressing dnSOX2. Annexin V identifies cells at the early stage of 
apoptosis, but after induction of Caspase 3. To discriminate apoptotic cells from necrotic 
cells, they were co-stained with 7AAD. Annexin V staining was performed after 24 h, 48 
h and 72 h of induction of dnSOX2 and analyzed by FACS. Concordant with the results of 
Caspase 3/7 analysis, no differences could be observed after 24 h but an increase of 
apoptosis was detected after 48 h in the doxycycline treated AZ-521 dnSOX2 cell clone 
compared to non-treated cells. However, the differences observed were less apparent 
than seen in the Caspase 3/7 assay (Fig. 21 E). No further increase of apoptosis was seen 
after 72 h. Differences of results in Caspase 3/7 assay and Annexin V staining might be 
due to higher sensibility of the Caspase 3/7 assay and more sources of error in Annexin V 
analysis, as here many factors like cell culture conditions, quality of the binding buffer, 
time of staining and concentration of 7AAD were highly influencing the outcome of the 
experiment. 
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Fig. 21: Analysis of apoptosis via Caspase 3/7 and Annexin V staining after inhibiting SOX2 in AZ-521 
cells; Caspase 3/7 activity was analyzed in the inducible stable cell clone. After 8 h (A) and 24 h (B) no 
differences could be observed. After 48 h Caspase 3/7 activity was significantly increased in induced AZ-
521 dnSOX2 cells compared to non-treated cell clone and the control cell line (C). N = 4, n = 12; 
Transfection with shSOX2 did not result in a significant increase of apoptosis (D). N = 4; n = 12; 
Staurosporine was used as a positive control to induce Caspase 3 activity. Annexin V staining after 48 h 
showed 5.05 % of cells in the apoptotic phase. In non-treated cell clones only 3 % of cells were apoptotic 
(E). N = 4; *p < 0.05 
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3.1.2.4. The role of SOX2 in cell migration 
Migration is a key process of cancer cells to spread from the initial site of tumor 
growth into the surrounding tissue. Therefore, the analysis of migratory behavior of 
tumor cells is essential to define their metastatic potential. With the aim of evaluating 
differences in migration of AZ-521 tumor cells with or without blocking of SOX2, wound 
healing assays were performed. A 500 µM wound was introduced into a confluent cell 
monolayer and AZ-521 parental cells and the cell clone stably expressing dnSOX2 were 
subsequently treated with doxycycline. Healing of cell wound was observed 
microscopically 12 h and 24 h after inhibition of SOX2 activity. Compared to non-treated 
dnSOX2 cells, which achieved 88 % wound closure after 12 h, treated cells showed a 
wound closure of only 72 %. After 24 h, cells with high SOX2 activity showed a wound 
closure of 98 % whereas cells with inhibited SOX2 activity only showed 85 % of closure of 
the wound (Fig. 22). Results indicate that SOX2 plays an essential role in migration and 
cellular invasion of gastric tumor cells. 
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Fig. 22: Migration analysis of AZ-521 cells after inhibition of SOX2 activity; microscopic monitoring of 
wound healing in AZ-521 control cells and AZ-521 dnSOX2 cell clones after induction with doxycycline (A). 
Percentage of cell covered area over time in control cell line and the inducible stable AZ-521 dnSOX2 cell 
clone (B). N = 3, n = 6; *p < 0.05 
 
3.1.2.5. The role of SOX2 in cell cycle regulation 
Since a decrease in proliferation as well as slower migration rates were seen after 
inhibiton of SOX2, which might occure only partly due to apoptosis of the cells, analyzing 
potential differences in cell cycle was the next step to examine cells for their 
tumorigenic potential. In order to monitor cells in the different phases of the cell cycle, 
namely Gap1 (G1) phase, where cells do not replicate but synthesize new organelles, 
synthesis (S) phase, in which DNA is synthesized and Gap2/Mitosis (G2/M) phase, where 
cells are prepared for mitosis and finally separate into two daughter cells, FACS analysis 
was performed. Cell cycle profile was analyzed in synchronized cells by flow cytometry 
using propidium iodide as DNA stain. Analyses were done 24 h and 48 h after 
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doxycycline induction of the stable dnSOX2 cell clone. No differences of cell cycle profile 
could be observed after 24 h. This result was concomitant to analysis of proliferation, 
which also did not reveal any changing of proliferative activity during early time points. A 
cell cycle arrest could be detected after 48 h in cells where SOX2 activity was blocked 
through dnSOX2, while distribution of the different cell cycle phases in not induced AZ-
521 dnSOX2 stable clones was comparable to the parental cell line. In induced AZ-521 
dnSOX2 cell clones, cells accumulated in G2/M phase of the cell cycle and a concomitant 
reduction of cell numbers in the S-phase was observed (Fig. 23).  
 
 
 
 
 
 
 
 
 
Results 
 
 
100 
 
 
              
 
Fig. 23: Distribution of cells in the different cell cycle phases after down-regulating SOX2; after inhibition 
of SOX2 activity by treatment of stable cell clones with doxycycline for 48 h, fewer cells were detected in 
S-phase as cell cycle was arrested in G2/M phase. Upper pictures show one representative experiment; 
cells were stained with PI and analysed by FACS; N = 3; *p < 0.05 
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Since a cell cycle arrest was observed after induction of dnSOX2, changes in the 
expression of cell cycle regulators were further analyzed, as cyclins, could be responsible 
for these changes. First the expression of cyclin B1, cyclin D1 and cyclin D3 was analyzed 
by quantitative real time PCR. The analysis showed a significant decrease of cyclin B1 
during SOX2 inhibition (Fig. 24 A). Furthermore, cyclin D1 mRNA, was significantly up-
regulated 12 h upon induction in stable AZ-521 dnSOX2 cell clones with expression 
returning to basal levels after 48 h (Fig. 24 B), whereas expression levels of cyclin D3 did 
not show any differences (Fig. 24 C). c-myc is known to be an oncogene and an 
important factor influencing expression of cyclins, thus, c-myc was also analyzed. 
However, no significant differences in c-myc mRNA expression were observed (Fig. 24 
D). 
 
Fig. 24: mRNA expression of different cell cycle regulators; mRNA levels of cyclin B1 decreased over time 
after SOX2 activity was inhibited (A). Level of cyclin D1 mRNA was increased after 12 h but return to basal 
levels 24 h after treatment with doxycycline (B). No changes of mRNA levels could be observed in cyclin D3 
(B) or c-MYC expression (C) in the AZ-521 dnSOX2 induced cell clone. N = 4, n = 12; *p < 0.05 
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3.1.2.6. The role of SOX2 in cellular senescence 
Cellular senescence is a molecular mechanism by which cells lose their ability to 
divide after a limited number of cell divisions in vitro, however, remaining metabolic 
active for a long period of time [184]. Senescence might occur due to changes in gene 
expression as well as due to DNA damages. Furthermore, it also limits excessive or 
aberrant cellular proliferation, protecting against the development of cancer. As 
blocking of SOX2 arrested AZ-521 GC cells, it was sought to analyze if dnSOX2 was also 
inducing senescence. Senescence associated β-galactosidase (SA- βgal) activity at pH 6.0 
and was analyzed in the AZ-521 dnSOX2 stable cell clone and parental control cells after 
treatment with doxycycline. After 24 h of inhibition of SOX2 activity, approximately 30 % 
of induced AZ-521 dnSOX2 cells were in a senescent state, in contrast to the non-
induced cell clone and the parental cell line, in which the percentage of senescent 
positive cells did not exceed 5 % (Fig. 25). 
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Fig. 25: SA--gal activity in AZ-521 cells after SOX2 was blocked; AZ-521 dnSOX2 cell clones were 
analyzed for cellular senescence. The parental AZ-521 control cell line without (A) or with (B) doxycycline 
induction as well as the non-induced cell clone (C) did not show SA--gal activity, whereas doxycycline 
treated dnSOX2 cells appeared highly positive for senescence (D). One representative experiment is 
shown. Cells were analysed in an AxioVert 40 microscope and stained cells were counted per square. 
Results of seven counted squares are graphically shown as box plot (E). N = 5; **p < 0.01  
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3.1.2.7. The role of SOX2 in tumor growth and metastasis 
Having observed a functional role for SOX2 in regulation of proliferation, 
migration, apoptosis and cell cycle in vitro, tumorigenic characteristics of SOX2 
expression were subsequently analyzed in vivo, regarding tumor growth and migratory 
behavior of cells. Therefore, AZ-521 dnSOX2 cells were stably transduced with an eGFP-
Luc plasmid, allowing monitoring of cell growth via bioluminescence live imaging. NMRI 
nude mice were injected s.c. with the luciferase expressing cell clone of stable AZ-521 
dnSOX2 and tumor growth was monitored in an in vivo imaging system. Seven days after 
injection, one group of mice (n = 5) was treated with doxycycline via food uptake. The 
control group (n = 5) received regular food. Bioluminescence was measured in an in vivo 
imaging system to assess tumor burden every 2 to 4 days.  Tumor growth was monitored 
for 24 days after injection of cells. A significant difference in tumor growth could be 
observed, comparing treated to untreated mice, beginning 3 days after induction of 
dnSOX2 expression. This strongly emphasizes the fundamental role of SOX2 in tumor 
development of GC (Fig. 26). 
 
Fig. 26: In vivo analysis of AZ-521 dnSOX2 cells; subcutaneous tumor growth was monitored by 
bioluminescence (A). Growth was significantly reduced in mice treated with doxycycline (B). Arrow 
indicates the day of food change. N = 5 per group, *p < 0.01 
Tumors were dissected and embedded in paraffin to analyze protein expression 
of several genes of interest associated to GC by immunohistochemistry. As dnSOX2 
induced changes in proliferation, initially the expression of KI67, which is a marker of 
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proliferating cells, was analyzed. Interestingly no significant differences in KI67 staining 
could be observed comparing tumors from treated to non-treated mice (Fig. 27). Yet, 
fewer cells seemed necrotic in tumors from doxycycline treated mice, however, low 
number of tumor samples did restrict accurate assessment of data (Tab. 7).  
Tab. 7: Evaluation of IHC staining of AZ-521 derived s.c. tumors in NMRI nude mice 
Block number KI67 HE 
AZ-521 Contr. 1 90 % Cells pleomorphic, few necrotic  
AZ-521 Contr. 2 80 % Cells pleomorphic, 30 % necrotic 
AZ-521 Contr. 3 80 % Cells pleomorphic, few necrotic 
AZ-521 Contr. 4 90 % Cells pleomorphic, 40 % necrotic 
AZ-521 Contr. 5 80 % Cells pleomorphic, 30 % necrotic 
Mean AZ-521 Contr 84 %  
AZ-521 Dox. 1 90 % Cells pleomorphic, few necrotic 
AZ-521 Dox. 2 80 % Cells pleomorphic, 10 % necrotic 
AZ-521 Dox. 3 70 % Cells pleomorphic, 10 % necrotic 
AZ-521 Dox. 4 90 % Cells pleomorphic, 30 % necrotic 
AZ-521 Dox. 5 80 % Cells pleomorphic, few necrotic 
mean AZ-521 Dox. 82 %  
 
 A panel of genes which were known to be correlated to tumor formation was 
analyzed in AZ-521 derived tumors in order to find potential targets of SOX2. Staining 
was done for -Catenin, Vimentin, P21, P16, CDX2, SNAI2 (slug) and SNAI1 (snail). -
Catenin is an important gene in the WNT signaling pathway. It is accumulating upon 
WNT activation, leading to the transcription of WNT target genes. Mutation in -catenin 
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can cause colorectal cancer. Vimentin is aberrantly expressed in several different cancer 
tissue, including GCs, where its over expression is associated with poorer outcome and 
plays an important role in metastasis [185, 186]. P21 is known to prevent cell 
proliferation and cell growth in various tumors by mediation of the P53 tumor 
suppressor or by inhibiting the activity of cyclin dependent kinases (CDK) [187]. P16 is, 
like p21, a tumor suppressor gene inhibiting CDKs [188]. Thus both proteins are 
adequate markers of neoplastic transformation. CDX2 is a tumor suppressor, which can 
induce p21 expression and is often down-regulated in colorectal cancer. In intestinal 
metaplasia expression patterns of CDX2 and SOX2 are inversely related [173]. Aberrant 
expression of SNAI1 and SNAI2 in human cancers has been correlated with invasive 
growth potential [189]. IHC staining did not reveal any significant differences in 
expression of any of those proteins, when comparing tumors from treated to non-
treated mice. Nontheless, protein expression was evaluated in both AZ-521 derived 
subcutaneous tumors. As the tumorigenicity of the cell line is highly dependent on SOX2, 
a high SOX2 expression was seen in IHC. Furthermore, nuclear -Catenin expression was 
observed as well as the expression of vimentin. p21 was only marginally expressed in 
tumors and seemed to be higher expressed in treated tumors however, differences were 
not significant. CDX2, P16 as well as SNAI1 and SNAI2 expression was not observed.  
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Fig. 27: IHC of AZ-521 derived tumors in NMRI- nude mice; no differences in amount of proliferating cells 
(KI 67) could be observed when comparing tumors derived from treated to non-treated mice. Nuclear 
SOX2, β-Catenin and vimentin expression was seen in both tumors. A minor expression of p21 could be 
observed. No expression of CDX2, P16, slug and snail was seen. N = 2 
 
 An assay for experimental pulmonary metastasis in vivo was performed in which 
NMRI nude mice (N = 5) were intravenously injected with 1 x 106 AZ-521 cells to monitor 
metastatic characteristic of the cell line. Cell spreading and tumor growth was 
monitored after 4 h and 24 h and subsequently twice weekly for one month. A weak 
signal in the lungs of four mice was observed 4 h after injection, indicating trapping of 
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the tumor cells in the lung capillaries (Fig. 28 A). The next day no signals could be 
measured, hence presumably most cells did not survive. One week after injection of cells 
three mice showed weak signals in the abdomen, but still no signals were observed in 
the lungs. At day 25 mouse no. 1 and no. 4 showed signals in the lower body part. 
Mouse no. 3 showed a signal in the snout. No. 2 and no. 5 showed no or background 
signals (Fig. 28 B). Weight of mice was not changing significantly over time (Fig. 28 C). 
These data indicate, in agreement with previous observations, that AZ-521 cells are 
hardly metastatic when injected i.v. 
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Fig. 28: Monitoring of metastasis of AZ-521 cells in vivo after i.v. injection; 4 h after injection cells could 
be found in the lungs in 4 of 5 mice (A). After 25 days no lung tumors had grown. Mouse no. 1 and no. 4 
showed signals in the abdomen, whereas mouse no. 3 showed tumor cells in the snout region. No signals 
could be found in mouse no. 2 and no. 5 (B). Weight of mice was not significantly changing over time 
comparing injected mice and control mouse (C). N = 5 
 
3.1.3. Identification of SOX2 target genes 
To identify potential target genes and signaling pathways regulated by SOX2 in 
GC, the gene expression profile in stable dnSOX2 cell clone was analyzed through RNA 
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microarray analysis and compared to AZ-521 parental cells in collaboration with Dr. 
Stefan Krebs at the gene center, Munich.  
Three independent experiments were performed, in which cells were induced for 
8 h, 12 h, 18 h, and 24 h, and RNA expression profile was analyzed together with the 
corresponding non-induced controls. Since there were no genes differentially expressed 
(with significance levels set at fdr < 0.05) at the early time points (8 hours and 12 hours) 
the further analyses were done with the values obtained at later time points. 
Quality control of RNA did not show any outliers in their expression data when 
normalized with robust multi-array average (RMA) algorithm. Hierarchical clustering of 
the array data showed that induction with dnSOX2 is strongly influencing the expression 
profile of the cells, but there are only small differences between the two different time 
points of induction (Fig. 29).  
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Fig. 29: Quality control of RNA; expression data are shown as box plot before (A) and after normalization 
with robust multi-array average algorithm (B). The dotted line shows the range of signal intensity. 50 % of 
data are within the frame marked with an asterisk. The bold line indicates the median. Expression profiles 
were also compared through hierarchic clustering in a heat map (C). Colors of squares correspond to the 
rank of similarity of expression patterns. They range from dark red (highest similarity) to dark blue (highest 
differences). The tree structure represents the relation between the expression profiles. Length of 
branches indicates the grade of difference between the comprised groups. Figures were kindly provided 
by Dr. Stefan Krebs. 
 
Results were analyzed with LIMMA [190]. Setting the false discovery rate (fdr)-
adjusted p-value to 5 %, 578 differentially expressed genes (DEG) could be identified 24 
h after induction with doxycycline. However, only a few genes had a fold change of more 
than two. Cluster analyses were done for the 578 DEGs using the SOTA algorithm as 
A B 
C 
* 
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implemented in the program MeV4.5 (www.tm4.org/mev), which assigned the genes 
correlating to the progression of their expression at the different time points. The time 
points of 8 h and 12 h after induction were included in this analysis as it was assumed 
that genes regulated at later time points are already regulated during these earlier time 
points. DEGs were grouped into 6 different clusters of up- and down-regulated genes. 
Cluster 1 showed DEGs which increased their expression continuously during expression 
of dnSOX2, whereas Cluster 4, 5 and 6 showed all DEGs which decreased during 
induction with doxycycline. Cluster 2 includes DEGs with a peak at 18 h. DEGs in Cluster 
3 also show a peak at 18 h but almost no regulation after 24 h (Fig. 30). A list of all DEGs 
is included in the appendix. 
 
Fig. 30: Cluster analysis of genes; relative alterations of every gene and every sample in comparison to 
untreated control; Cluster 1 and Cluster 6 show DEG with continuously increasing (Cluster 1) or decreasing 
(Cluster 6) expression over time. Genes in Cluster 4 and Cluster 5 are also decreasing over time. Genes in 
Cluster 2 and Cluster 3 show a peak of expression at 18 h with decreasing (Cluster 2) or almost no (Cluster 
3) expression of DEG after 24 h. Figure was kindly provided by Dr. Stefan Krebs. 
 
Interestingly, SOX2 could be found in the list of down-regulated DEGs. It was 
assumed to find SOX2 in the list of up-regulated genes, as doxycycline is increasing 
expression of dnSOX2 which would give a positive signal in mRNA expression analysis. 
However, probe level plots of SOX2 after different time points showed a constant 
reduction of SOX2 over time, leading to the assumption that the expression of 
endogenous SOX2 mRNA was decreased by dnSOX2 expression. This might be due to 
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disruption of the SOX2 positive feedback loop. Nevertheless in 3’ region of dnSOX2 the 
signal of one oligo nucleotide (oligo 7) was continuously increasing. 5’-3’ degradation of 
dnSOX2 might take place, leaving a residue in 3’ region which is accumulating over time. 
Accumulation of dnSOX2 might therefore lead to degradation of its own mRNA (negative 
feedback loop) (Fig. 31).    
Fig. 31: Probe level plots of SOX2 after different time points of induction; probe level plots showed 
measured values for every single oligo in the SOX2 transcript. Blue lines represent not induced cells, red 
and orange lines correspond to values after induction of dnSOX2. The left diagram shows analysis after 8 h 
and 12 h, the right diagram shows the later time points of 18 h and 24 h. Signals of the SOX2 transcript 
were continuously decreasing, except one oligo (indicated by arrow). Accumulation of oligo 7 as well as 
the repression of every other oligo was more pronounced in the later time points. Figure was kindly 
provided by Dr. Stefan Krebs. 
 
DEGs were analyzed by CoPub [191]. This web-based tool detects keywords 
which are functionally linked to a set of regulated genes using co-occurrence statistics of 
genes and keywords in the Medline library. Hints for proceeding differentiation of cells 
(Cluster 2) and, among others, reduced cell proliferation, cell growth, migration and cell 
cycle activity (Cluster 6) could be found (Tab. 8). The other clusters did not reveal 
significant DEGs, functionally linked to any keywords. 
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Tab. 8: CoPub analysis of DEGs. Biological processes and pathways in Cluster 2 and Cluster 6 which can be 
linked to the expression of several DEGs; detailed information which gene corresponds to which category 
can be found in the appendix. 
Cluster 2 (up-regulated genes) 
Keyword Category p-value Number of genes 
Cell differentiation 
biological 
process 4.09E-03 25 
Cluster 6 (down-regulated genes) 
Keyword Category p-value Number of genes 
cell growth and-or maintenance, cell 
growth 
biological 
process 1.15E-03 39 
apoptosis 
biological 
process 1.27E-03 49 
cell adhesion 
biological 
process 2.01E-03 27 
growth 
biological 
process 2.80E-03 61 
cell proliferation 
biological 
process 4.38E-03 41 
tissue regeneration 
biological 
process 4.38E-03 5 
migration 
biological 
process 5.74E-03 23 
phosphorylation 
biological 
process 6.87E-03 50 
metaplasia 
liver 
pathology 7.76E-03 8 
WNT signaling pathway pathways 2.39E-07 5 
motility 
biological 
process 1.1E-07 11 
wound healing 
biological 
process 8.45E-03 12 
 
Further analyses focused on DEGs in the LIMMA table with a significance of p < 
0.01 and with a fold change of 2 or more. 33 genes showed a 2-fold or more change, 
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among those, 19 genes were down-regulated after inhibition of SOX2 and 14 genes were 
found to be up-regulated (Tab. 9). 
Tab. 9: DEG with significance of p < 0.01 and a fold change of 2 or more after induction of dnSOX2 
Down-regulated genes Up-regulated genes 
 BIRC3   baculoviral IAP repeat-
containing 3  
 ZNF114   zinc finger protein 114  
 XRCC4   X-ray repair complementing 
defective repair in Chinese 
hamster cells 4  
 APOE   apolipoprotein E  
 PCDH18   protocadherin 18   NELF   nasal embryonic LHRH factor  
 FGF10   fibroblast growth factor 10   SNAPC1   small nuclear RNA activating 
complex, polypeptide 1, 43kDa  
 P2RY5   purinergic receptor P2Y, G-
protein coupled, 5  
 C18orf19   chromosome 18 open reading 
frame 19  
 COQ3   coenzyme Q3 homolog, 
methyltransferase (S. 
cerevisiae)  
 SFN   stratifin  
 MMP10   matrix metallopeptidase 10 
(stromelysin 2)  
 CD68   CD68 molecule  
 TFDP2   transcription factor Dp-2 (E2F 
dimerization partner 2)  
 GDF15   growth differentiation factor 15  
 EGR1   early growth response 1   LEF1   lymphoid enhancer-binding 
factor 1  
 GOLPH3L   golgi phosphoprotein 3-like   IFI30   interferon, gamma-inducible 
protein 30  
 
ARHGAP24  
 Rho GTPase activating protein 
24  
 ELAVL3   ELAV (embryonic lethal, 
abnormal vision, Drosophila)-
like 3  
 CYB5R1   cytochrome b5 reductase 1   DKK4   dickkopf homolog 4 (Xenopus 
laevis)  
 COL3A1   collagen, type III, alpha 1   IFITM1   interferon induced 
transmembrane protein 1 (9-27)  
 MAMDC2   MAM domain containing 2   CRABP2   cellular retinoic acid binding 
protein 2  
Results 
 
 
116 
 
 COL5A2   collagen, type V, alpha 2      
 RBMS3   RNA binding motif, single 
stranded interacting protein  
    
 CHRDL1   chordin-like 1      
 PCOTH   prostate collagen triple helix      
 FRMD5   FERM domain containing 5      
 
Real time qRT-PCR was performed for the most significantly differentially 
expressed genes listed in table 8, to verify their differential mRNA expression. However, 
the expression of only very few DEGs could be confirmed by qRT-PCR. 
 Initially the decrease of SOX2 expression itself was confirmed by real time mRNA 
expression analysis (Fig. 32).  
 
Fig. 32: mRNA levels of SOX2 after inhibition of SOX2 transcriptional activity; AZ-521 parental cell line, an 
AZ-521 TR control cell clone, only harboring the rtTA plasmid and AZ-521 dnSOX2 inducible cells were 
analyzed for mRNA expression of SOX2 via qRT-PCR. When dnSOX2 was expressed and SOX2 
transcriptional activity was inhibited, mRNA levels of SOX2 decreased over time. N = 4, n = 12; *p < 0.05 
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RNA array and real time PCR also showed a significant increase of LEF1 (lymphoid 
enhancer-binding factor 1) expression when SOX2 was inhibited in AZ-521 cells (Fig. 33 
A). LEF1 is a well known downstream effector of the canonical WNT signaling pathway. 
WNT signaling leads to activation of LEF1/TCF-mediated transcription and SOX2 is known 
to antagonize WNT signaling. To support these results, TOPFlash assays in AZ-521 
dnSOX2 cells treated with doxycycline were performed, to detect TCF4 transcriptional 
activity. A significant up-regulation of TCF4 transcriptional activity was seen, when SOX2 
was down-regulated (Fig. 33 B). Another gene found to be up-regulated in the array, 
DKK4 was confirmed to be up-regulated in by qRT-PCR. The DKK4 protein is also known 
to be a TCF/LEF target gene (Fig. 33 C). Another interesting candidate of genes was 
FGF10, since it is also involved in WNT signaling. However, during development of 
stomach and in several other tissues FGF10 is known to antagonize SOX2 and down-
regulate its expression. Nonetheless, a down-regulation of FGF10 expression was 
verified after inhibition of SOX2 in AZ-521 cells in qRT-PCR analysis (Fig. 33 D).  
Fig. 33: Analysis of mRNA of WNT target genes and TCF4 transcriptional activity in cells with decreased 
SOX2 transcriptional activity; mRNA levels of LEF1 (A) and DKK4 (C) were increasing over time, as found in 
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the array. Concordant to this data, TCF4 transcriptional activity was increasing over time when SOX2 was 
inhibited in AZ-521 dnSOX2 cell clones (B). FGF10 could be proven to be down-regulated (D); N = 5, n = 15; 
*p < 0.05; ** p < 0.01 
 
Furthermore, some genes which did not show a fold change of 2 or more were 
also analyzed as they were assumed to be important in SOX2 regulatory pathways. From 
the genes that were shown to be down-regulated by SOX2, TGF receptor associated 
protein 1 (TGFb RAP1), TP63, and CTNND1 (-Catenin) were analyzed. TGF RAP1 binds 
to the TGFß receptor and plays a role in TGF signaling. -Catenin over expression was 
recently associated with tumor invasion in small-cell lung cancer and glioma [192, 193].  
TGFb RAP1 (Fig. 34 A) and CTNND1 (Fig. 34 B) did not show significantly down-regulation 
of mRNA, but down-regulation of the N variant of P63 (Fig. 34 C) was confirmed. P63 
down-regulation after repression of SOX2 activity could also be observed by western 
blot (Fig. 34 D). Tumor protein P63 belongs to the P53 gene family and encodes for two 
main isoforms, namely TAP63 and NP63. The latter is known to be involved in adult 
stem cell and progenitor regulation. A differential expression of the TAP63 isoform was 
not observed in qRT-PCR.  
Fig. 34: mRNA expression of genes down-regulated after of SOX2 inhibition; TGFb RAP1 (A) as well as 
CTNND1 (-Catenin) (B) did not show any significant changes in mRNA. The transcription variant NP63 of 
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P63 was significantly down-regulated, as seen in qRT-PCR (C) and Western blot analysis (D). N = 3, n = 9; 
*p < 0.05 
 
From the genes up-regulated after SOX2 inhibition, SOX18, NOTCH1 and cyclin 
dependent kinase inhibitor 1 (p21, CIP1) were tested in qRT-PCR. SOX18 is, like SOX2, a 
transcription factor, involved in the regulation of embryonic development, especially in 
vascular epithelium formation and the generation of hair follicles [194]. NOTCH1 is a 
transmembrane receptor which functions as a tumor suppressor in skin through 
suppression of the WNT pathway [195] and is also known to have growth suppressive 
function in hematopoetic cells, pancreatic epithelium and hepatocytes [196]. SOX18 (Fig. 
35 A) as well as NOTCH1 (Fig. 35 B) did not show significant differential expression of 
mRNA. Nevertheless, a significant up-regulation of p21 (CIP1) was observed by qRT-PCR 
(Fig. 35 C) as well as western blot (Fig. 35 D). p21 is commonly regulated by P53 but can 
also be expressed without being induced by P53, as a regulation of P53 tumor 
suppressor gene was not observed. p21 prevents cell proliferation and reduction of cell 
growth promoted by p21 expression can lead to cell differentiation.  
Fig. 35: mRNA expression of up-regulated genes after down-regulation of SOX2; SOX18 (A) and NOTCH1 
(B) did not show up-regulation of mRNA in qRT-PCR; p21 (CIP1) mRNA was up-regulated 24 h after 
doxycycline induction of the AZ-521 dnSOX2 cell clone (C). N = 3, n = 9; an up-regulation of P21 protein 
was also observed by western blot (D). N = 3; *p < 0.05 
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3.1.4. Regulation of SOX2 in gastric cancer 
Moreover, it was not only important to identify target genes of SOX2 but also to 
elucidate how SOX2 expression can be modulated in GC.  
3.1.4.1. The regulation of SOX2 by STAT3 
During neuronal development SOX2 has been described to be regulated by STAT3 
[141]. Since STAT3 is also a key gene in promoting oncogenesis, specifically in gastric 
neoplasia, and is involved in all aspects of carcinogenesis, including cell proliferation, 
apoptosis, angiogenesis, invasion, migration, and disruption of immune surveillance it 
was interesting to determine if STAT3 regulated SOX2. 
 The expression of SOX2 and STAT3 in gastric tumors of Gp130 mutant 
mice 
First, possible co-expression of SOX2 and STAT3 was analyzed in a Gp130 mutant 
mouse model, developing spontaneous gastric tumors at 4 weeks of age due to STAT3 
hyper activation as a consequence of a knock-in mutation in the GP130 receptor subunit. 
Gp130 heterozygous mice were sacrificed at the age of 80 days and expression of SOX2, 
p-STAT3 and KI67 was detected in paraffin embedded stomachs by IHC. High levels of 
SOX2 were observed in the tumors that correlated with p-STAT3 expression and 
proliferation sites (Fig. 36).  
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Fig. 36: Tumor sections of Gp130 mutant mice; HE staining (A) and expression of Ki67 (B), SOX2 (C) and p-
STAT3 (D) in gastric tumors from Gp130 mutant mice. Co-expression of SOX2 and p-STAT3 was observed, 
which also correlated with proliferation sites (Ki67). 
 
 Co-expression and co-localization of SOX2 and STAT3 in GC cells 
SOX2 and p-STAT3 protein levels were detected by western blot in GC cell lines 
(Fig. 37). SOX2 and p-STAT3 expression correlated in all cell lines, except in AZ-521 cells, 
which presented high SOX2 levels but not activated STAT3. 
  
Fig. 37: p-STAT3, STAT3 (79-86 kDa) and SOX2 (35 kDa) protein expression in GC cell lines; -actin (45 
kDa) was used as a loading control. N = 3 
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As AGS and MKN45 cell lines showed highest expression levels of SOX2 and p-
STAT3 they were used for further experiments. First, co-localization analysis of both 
proteins was performed by immunofluorescence. In both cell lines SOX2 and p-STAT3 co-
localized (Fig. 38). 
 
Fig. 38: Co-localization of SOX2 and STAT3 in AGS and MKN45 GC cells; AGS and MKN45 cells expressed 
high levels of SOX2 and STAT3. Expression of both transcription factors was observed in the nucleus of the 
cells. Nuclei were stained with DAPI. Co-localization was seen in overlay as yellow colour. N = 3 
 
 Regulation of SOX2 by STAT3 in vitro 
To determine whether STAT3 can modulate the transcriptional activity of SOX2, 
AGS and MKN45 cells were co-transfected with 100 ng of SOX2 reporter (SOPFlash) and 
different concentrations of three different STAT3 constructs: STAT3 wild type, STAT3 
constitutively active (cSTAT3) and the dominant negative splice variant STAT3A 
significant increase in SOX2 transcriptional activity was observed in both cell lines 
transfected with 250 ng and 500 ng STAT3 wild type, and was enhanced when 
transfecting the cells with the constitutively active STAT3 plasmid. In AGS cells even 100 
ng of cSTAT3 led to a significant increase of SOX2 transcriptional activity. In contrast, 
transfection with STAT3 did not induce significant changes (Fig. 39).  
 
Results 
 
 
123 
 
Fig. 39: SOX2 levels after STAT3 transfection; STAT3 induced SOX2 transcriptional activity in AGS (A) and 
MKN45 (B) cells in a dose dependent manner. This effect was higher when using the constitutive active 
STAT3 construct. No significant changes were observed after transfection with STAT3. N = 3, n = 6; * p < 
0.05, ** p < 0.01. 
 
To analyze if the IL-6/STAT3 pathway regulates SOX2 expression in vitro, GC cells 
were treated with IL-6 to activate the STAT3 pathway. Subsequently SOX2 mRNA levels 
were analyzed. After treating the cells with 5 ng/ml IL-6 for 24 h an increase in SOX2 
mRNA was observed in AGS, NUGC-4, MKN7 and N87 cells (Fig. 40). 
 
Fig. 40: SOX2 mRNA amounts after IL-6 treatment of GC cells; AGS, NUGC-4, MKN-7 and N87 cells were 
treated for 24 h with 25 ng/ml IL-6. All cell lines showed a significant increase of SOX2 mRNA. Results from 
one representative experiment are shown. 
 
These results show that there is a co-expression of SOX2 and STAT3 in vivo and in 
vitro and that STAT3 can regulate the expression of SOX2 via IL-6 in GC cells. However, 
further investigation should be done to elucidate the mechanisms by which STAT3 
regulates SOX2 in GC. 
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3.1.4.2. The influence of H. pylori infection on SOX2 expression in GC cells 
Since another possible mechanism regulating SOX2 in GC is the inflammatory 
response associated to H. pylori, the direct effect of H. pylori infection on SOX2 
expression was analyzed in GC cells. AZ-521 cells, presenting high SOX2 activity, AGS 
cells, showing intermediate activity and St2957 and St3051 cells with no SOX2 activity 
were co-incubated with the H. pylori strain G27 or its isogenic CagA deficient mutant at a 
MOI 50. 24 h after infection, SOX2 transcriptional activity was measured by 
SOPFlash/NOPFlash assay. AZ-521 cancer cells showed a decrease of SOX2 activity when 
treated with H. pylori. However, this decrease was independent from CagA. AGS cells 
showed a significant down-regulation of SOX2 activity after H. pylori wt infection, 
whereas no changes were induced with the CagA deficient strain. In St2957 and St3051 
H. pylori infection did not have any effect on SOX2 transcriptional activity as both cell 
lines do not present basal SOX2 expression. To induce SOX2 transcriptional activity, 
these cells were stimulated with IL-4. A strong increase of SOX2 activity was observed 
after IL-4 treatment, which was blocked by H. pylori infection. In the absence of CagA, 
the inhibition of SOX2 transcriptional activity after IL-4 stimulation was significantly 
lower, suggesting that CagA might be an important factor in the regulation of SOX2 in 
gastric tumor cells (Fig. 41).  
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Fig. 41: The influence of H. pylori on SOX2 transcriptional activity in GC cell; AZ-521 cells showed a 
significant decrease in SOX2 transcriptional activity when infected with H. pylori. However, this effect was 
independent of CagA (A). H. pylori down-regulated SOX2 transcriptional activity in AGS cells, and this 
effect was dependent on CagA expression (B). St3051 (C) and St2957 (D), which did not show basal SOX2 
transcriptional activity, were stimulated with IL-4. IL-4 significantly up-regulated SOX2 activity and this 
effect was reversed by H. pylori.  SOX2 activity was measured as SOP/NOP ratio. N = 3, n = 6; *p < 0.05; ** 
p < 0.01 
 
Since reporter assays showed less SOX2 activity after infection with H. pylori, 
changes in SOX2 protein expression levels were analyzed. As SOX2 was seen to be 
regulated by STAT3, additionally STAT3 activation was also analyzed in parallel. AGS cells 
showed a reduction of SOX2 expression, correlating with SOPFlash assay results. 
Concomitant to SOX2 decrease, a decrease in p-STAT3 protein levels was observed, 
beginning 6 h after H. pylori infection and being most pronounced after 24 h (Fig. 42 A). 
Similar results were found in MKN45 cells 24 h and 48 h after treatment with H. pylori 
(Fig. 42 B). 
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Fig. 42: Protein levels of SOX2 and p-STAT3 after H. pylori infection; AGS cells showed a decrease of SOX2 
levels concomitant to pSTAT3 expression (A). Same results were observed in MKN45 cells after 24 h and 
48 h (B). N = 3 
 
As reporter assays indicated an involvement of CagA in the regulation of SOX2 
activity, AGS cells were additionally screened for SOX2 protein expression levels after H. 
pylori infection with the wild type strain and the CagA deficient mutant. 6 h after 
infection with MOI 10 and 50 of the wild type strain a decrease of SOX2 protein levels 
could be observed, but no decrease of SOX2 protein did occur after infection with the 
CagA deficient mutant. The effect was even more pronounced 24 h after infection (Fig. 
43). Those results correlated with the findings on SOX2 transcriptional activity. 
 
Fig.43: Expression levels of SOX2 after infection of AGS cells with H. pylori in dependency of CagA; SOX2 
protein levels were significantly decreased after infection with H. pylori G27 wt, whereas the knock out 
mutant H. pylori G27 CagA could not down-regulate SOX2 expression. N = 3 
 
 These results indicate that H.pylori infection influences SOX2 expression in a 
subset of GC cells and that these effects are correlating with expression of p-STAT3. 
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Furthermore, reduction of SOX2 expression might be dependent on the presence of 
CagA. 
 
3.2. The role of SOX2 in stomach development  
 
SOX2 is known to be highly expressed in endoderm derived tissue of vertebrates. 
As it is an important factor for pluripotency of stem cells, it may thus play a crucial role 
in stomach development and maintenance of adult gastric stem cells. Therefore, Sox2 
knock out during development and in the adult stomach could give fundamental 
information about the role of Sox2 and possible involved pathways.  
Initially the expression of SOX2 in various embryonic stages, from E 10.5 to E 
18.5, was assessed in order to find out when SOX2 is expressed in the stomach, and is 
shown representatively for embryonic stage E 14.5 (Fig. 44). Examining expression 
pattern was also important for the planning of temporal knock-out experiments using 
inducible CreERT2, as well as to foresee possible off target effects due to deletion of Sox2 
in other tissues. High SOX2 expression could be observed as early as E 10.5 in the central 
nervous system (CNS), in the retina of the eye, in hair follicles, as well as in stomach, 
esophagus and lungs. 
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Fig. 44: Expression of Sox2 in a mouse embryo at E 14.5 analysed by IHC; Sox2 is highly expressed in 
several tissues and in the central nervous system (CNS) at day E 14.5 (A). Expression could be observed in 
the retina (B), in hair follicles (C) and in anterior endoderm of the stomach and in the esophagus (D). (st = 
stomach, l = lungs) 
 
A mouse model was employed in which the one exon gene Sox2 was flanked by 
two lox p sites (“floxed” = fl). Crossing these Sox2fl mice into Cre-mice holding the 
ubiquitous Rosa26-CreERT2 [197] and activating the Cre-system by injection of 
tamoxifen, the floxed Sox2 allele was excised, leading to a conditional Sox2 knock out. As 
excision is strongly dependent on the dose of tamoxifen reaching the cells, this knock 
out is usually not 100 % complete, leaving some cells still with remaining Sox2 
expression. Therefore, an additional mouse line was used, in which the Sox2 allele was 
replaced by a β-galactosidase gene (“β-geo” knock in) resulting in a complete Sox2 knock 
out in one allele [127]. This reduces the bias in results which might occur due to 
application variations of tamoxifen. 
3.2.1. Sox2 in embryonic development 
For embryonic analysis Sox2fl/fl x Rosa26-CreERT2 mice were mated with Sox2fl/fl or 
Sox2fl/wt mice and pregnant mothers were s.c. injected with 200 µg tamoxifen at 
embryonic day 7.5 (E 7.5) and E 18.5. Embryos were dissected at E 19.5. Sox2fl/fl Cre-
positive tamoxifen induced pups (Sox2 deleted) showed striking differences in 
phenotype. Ears and eyes were degenerated when compared to control embryos. 
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Embryos also were smaller. The stomach was smaller in size and showed less lumen 
when analyzed microscopically (Fig. 45 A and B). Additionally, stomach crypts showed an 
abnormal branched like structure (Fig. 45 C). The phenotype of the Sox2 deleted 
embryos was highly depending on dose and time point of tamoxifen injected as it was 
observed in a further experiment with more induction time points. Here, four 
subsequent induction time points during pregnancy at E 7.5, E 9.5, E 14.5 and E 18.5 
seemed to result in stagnancy of embryonic development in the last third of pregnancy. 
At E 19.5 a lower number of embryos was found in the uterus than usual, with about 1/2 
to 1/4 of them being much smaller and not properly developed (Fig. 45 D). Genotyping 
revealed all fully developed intact embryos being either heterozygous for Sox2fl or 
negative for CreERT2 or both, compared to degenerated embryos, which all showed Sox2 
deletion. Furthermore, a more severe phenotype was observed when pregnant mothers 
were positive for Sox2fl/fl and Rosa26-CreERT2compared to mothers who did not harbor 
homozygosity for Sox2fl and a Rosa26-CreERT2. Similar results could be achieved with 
Sox2fl/geo x Rosa26-CreERT2 breedings.  
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Fig. 45: Embryonic analysis of Sox2 deletion in mice; Sox2 deleted mice showed significant differences in 
Results 
 
 
131 
 
phenotype. They developed degenerated eyes and aplastic ears as well as a much smaller stomach (A). 
Furthermore, the stomach lumen appeared smaller (B) and stomach crypts had an abnormal branched like 
structure (C). More induction time points during pregnancy of a Rosa26CreER
T2
 positive mother led to a 
more severe phenotype with embryos holding a homozygous Sox2 deletion being absorbed or 
development being stagnated in the last third of pregnancy. Arrows indicating Sox2
fl/fl 
x CreER
T2
 (deleted) 
embryos (D). N = 4 (pregnant mothers), n = 26 (embryos) 
 
As Sox2 is a crucial factor in early embryonic development, influencing 
gastrulation, homozygous Sox2β-geo mice, having a complete Sox2 knock out are not 
viable. Analyses of blastulation at E 3.5 showed no significant differences of numbers of 
blastocystes, late morulae or unfertilized oocytes in comparison to wt-mice (Tab. 10), 
however, at day E 7.5 about 1/3 to 1/4 of the embryos of a Sox2β-geo/wt inmate breeding 
were degraded and genotyping revealed that the remaining intact embryos were 
heterozygous for the β-geo allele. These results lead to the assumption that Sox2β-geo 
homozygous embryos fail to complete gastrulation due to the lack of Sox2.       
Tab. 10: Analysis of E 3.5 in a Sox2
β-geo/wt 
x Sox2
β-geo/wt
 mating 
 Wild type (wt)  
Total wt 
Sox2
β-geo/wt 
x Sox2
β-geo/wt
 (k.i.)  
Total k.i. 
Mating no. No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 
Blastocyste 11 10 14 35 12 10 12 34 
Late morula 0 3 1 4 1 2 2 5 
Unfertilized 
oozyte 
2 1 0 3 1 0 1 2 
 
          
Fig. 46: Blastocyste (E 3.5) in Sox2
β-geo
 homozygous embryo; pregnancies for each condition: N = 3  
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 A limitation for the experimental set up was that the Rosa26-CreERT2 is a 
ubiquitous Cre and geo k.i also influences the whole mouse organism and not only the 
stomach. Thus, to have a look at the influence of Sox2 solely on the stomach, it was 
planned to work with another mouse model holding a different Cre-system. 
Unfortunately, a stomach specific Cre-line has not been developed until now. Therefore, 
a Sox17iCre mouse line was used, which was kindly provided by Dr. Heiko Lickert, 
Institute of Stem Cell Research, Helmholtz center, Neuherberg. A constitutive active iCre 
is here under the control of the Sox17 promoter. Sox17 is expressed in the definitive 
endoderm which gives rise to lung, liver pancreas, stomach and the gastrointestinal 
tract. Sox17 expression initiates around E 6.0 in the extraembryonic visceral endoderm 
[198]. Since Sox2 is also expressed in early endoderm, presumably at Sox17 positive 
sites, it was expected to see a stronger effect on the phenotype of the mice. In 10 
breeding experiments, viable Sox17iCre x Sox2fl/fl pubs or embryos could not be obtained 
(Tab. 11) leading to the assumption that Sox2 expression in the definitive endoderm is 
pivotal for the development and viability of embryos. 
Tab. 11: Expected and observed genotypes in ten [Sox17iCre x Sox2
fl/wt 
] x [Sox2
fl/fl
] breedings (n = 45 
pubs) 
Breeding [Sox17iCre x SOX2fl/wt ] x [Sox2fl/fl] 
Expected Sox2fl/fl Sox2fl/wt 
Sox17iCre + 25 % 25 % 
Sox17iCre - 25 % 25 % 
  
Observed Sox2fl/fl Sox2fl/wt 
Sox17iCre + 0 % 11 % 
Sox17iCre - 57 % 32 % 
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Therefore, selective deletion of Sox2 in the stomach to further analyze the 
observed phenotype is not yet possible due to the lack of stomach specific Cre-lines.  
3.2.2. The influence of Sox2 on postnatal development 
To investigate how Sox2 knock down could interfere in early postnatal 
development of pups, nursing mothers were induced with tamoxifen 2 times a week 
after birth. Since tamoxifen is highly lipophilic, pups receive tamoxifen via the maternal 
breast milk. Sox2fl/fl x Rosa26-CreERT2 pups seemed retarded in development, concerning 
weight (Tab. 12), size and overall fitness compared to their control siblings.  
Tab. 12: Comparison of body weight of wt vs. k.o. pups; data of one representative experiment are 
shown. 
 Body weight (g) at age (d) genotype  
sex 
number 10 12 14 Sox2 Rosa-Cre 
1 5.9 6.7 7.3 fl/fl neg m 
2 6.2 6.7 7.3 fl/fl neg m 
3 6.2 6.8 7.4 fl/fl neg m 
4 5.8 6.5 7.0 fl/fl neg m 
5 5.9 6.4 6.9 fl/fl neg w 
6 5.9 6.5 6.9 fl/fl +/- m 
7 6.1 6.5 6.8 fl/fl +/- m 
8 5.6 6.2 6.8 fl/fl +/- w 
9 5.7 5.9 6.5 fl/fl +/- w 
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Fig.47: Body weight of wt pups vs. Sox2 k.o. pups; in comparison to wt pups, k.o. pups showed significant 
lower body weight, when receiving tamoxifen via breast milk. *p < 0.05 
 
Furthermore, mice with Sox2 deletion did not grow proper fur (Fig. 48). The 
stomach phenotype of Sox2 deleted pups resembled the one in Sox2 deleted embryos, 
yet the phenotype was not as pronounced. Knock-out pups died at an age of about two 
to three weeks. It is important to mention, that tamoxifen treated mothers in this 
experiment were never positive for both genotypes (Sox2fl/fl and Rosa26-CreERT2), as in 
80 % of all cases pups of these mice died one day after birth with no milk in the stomach. 
It was assumed that Sox2 knock-out might influence breast milk production in mothers. 
However, no further investigations were done to strengthen this hypothesis. 
 
Fig. 48: Two week old pups after treatment with tamoxifen via breast milk; less fur growth is observed in 
Sox2 deleted pups compared to control siblings without Sox2 deletion. 
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These results demonstrate that Sox2 contributes to various stages of 
development and is specifically important in stomach formation. Moreover, the 
embryonic phenotype highly depends on dosage and time point of the knock-out, 
implying that Sox2 expression needs to be accurately balanced during stomach 
formation. 
 
3.2.3. Sox2 in the adult murine stomach 
Adult Sox2fl/fl x Rosa26-CreERT2 mice were injected s.c. with tamoxifen for 3 
weeks every other day. Stomach was analyzed by IHC for SOX2 expression. In wt mice, 
SOX2 expression was adjacent to proliferating cells, marked by Ki67 expression (Fig. 49 
A). After Sox2 knock out the proliferation zone was reduced as assessed by BRDU 
staining (Fig. 49 B). Same results were obtained with Sox2fl/βgeo x Rosa26-CreERT2 mice. 
Fig.49: Sox2 expression and proliferation in adult murine stomach; in adult gastric murine glands SOX2 
expression was adjacent to the proliferation zone (A). Sox2 knock down in adult mouse stomach led to a 
decrease of proliferating cells (B). N = 5 
 
These results indicate that in adult mouse stomach Sox2 is essential to sustain 
proliferation in gastric crypts, suggesting Sox2 to be a potential factor of maintenance of 
adult gastric stem cells.  
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4. Discussion 
4.1. Role of SOX2 on gastric carcinogenesis 
 
Gastric cancer (GC) is currently the fourth most common cancer in the world and 
still one of the leading causes of cancer-related death worldwide [41]. Although H. pylori 
infections, one of the most important risk factors for GC, are declining and preventive 
measures are becoming more commonplace, prognosis of advanced GC and hence 
survival rate still remains poor [49]. Few specific treatments are available to date, 
making it important to develop novel therapeutic approaches. Thus, identifying essential 
genes involved in gastric carcinogenesis is mandatory to develop specific therapies. 
Numerous different molecular alterations involving various pathways have been 
implicated in the development of GC. For example the WNT signaling pathway 
contributes to gastric carcinogenesis by stimulating the migration and invasion of GC 
cells [199]. Moreover, CTNNB1 (β-catenin) is known to be frequently mutated in 
stomach cancer [200]. In several types of GC a full epithelial-mesenchymal transition 
(EMT) characterized by SNAI1 (Snail) induction and CDH1 (E-cadherin) reorganization is 
induced [201]. Furthermore, over-expression of the proto-oncogene MET was found in a 
subset of GC [50].  
The transcription factor SOX2 plays a major role in self-renewal and 
differentiation of cells [122, 130] and has been shown to be overexpressed in GC as well. 
It is well known that SOX2 is highly expressed in diffuse-type GC [172]. In contrast to 
those studies, in the present work SOX2 was also found to be over expressed in 
intestinal and mixed-type gastric tumors. In some in vitro settings [168], as well as in 
differentiation of adult stem cells [202] and osteoblast differentiation [203], SOX2 was 
reported to antagonize TCF/Catenin activity and therefore repress the WNT pathway 
by promoting the transcription of its negative regulators. However, contrary to these 
findings, in retinal development of Xenopus, it was described that inhibition of WNT 
signaling is accompanied by a decrease of SOX2 expression [204]. Moreover, Neumann 
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et al. recently discovered that SOX2 was expressed in colorectal cancer (CRC) and was 
associated with poorer outcome [167]. They showed that high expression levels of SOX2 
or nuclear -Catenin were associated with metastasis in these tumors. Nearly all CRCs 
exhibit a chronic activation of the WNT/Catenin signaling pathway [205], implying 
that the up-regulation of SOX2, which was shown in CRCs, might be involved in the 
regulation of this pathway or at least is not inhibiting WNT signaling. Thus, intestinal 
type GC, showing high structural and biochemical similarities to CRC, might also be 
dependent on dysregulation of the canonical WNT pathway and is, for that reason, likely 
to be influenced by SOX2 expression. These facts can explain the findings of this study: 
that SOX2 is expressed also in some intestinal and mixed-type GC. Investigations also 
revealed that cells positive for SOX2 showed strong expression of KI67, a marker for 
proliferation. Since increased cell proliferation is a key aspect in development of 
neoplasms, driving cells towards uncontrolled growth and hence accumulation in the 
tissue, these data suggest that SOX2 expression in GC cells is an important factor for 
tumorigenesis.  
To investigate the role of SOX2 in gastric tumors, several different GC cell lines 
were screened for SOX2. A heterogeneous expression of SOX2 mRNA and protein was 
found in the different cell lines, with some cells highly expressing SOX2 and others 
lacking SOX2 expression. Those results also reflected the heterogeneous SOX2 
expression patterns which were found in gastric tumor tissue samples. Unexpectedly, in 
some of the cell lines, expression levels of SOX2 did not correlate with its transcriptional 
activity. SOX2 can undergo different post translational modifications, such as 
sumoylation [206], phosphorylation [207] and acetylation [208]. The latter is involved in 
nuclear translocation, which could explain the lack of correlation between protein levels 
and transcriptional activity, since all such modifications affect SOX2 binding to DNA. 
Moreover, some cell lines seem to be independent from SOX2 expression. This indicates 
that the development of GC does not occur due to one specific event but arises from 
different combinations of factors and is therefore not necessarily dependent on 
dysregulation of the same gene or pathway [55, 56]. Furthermore, it also explains the 
heterogeneous levels of SOX2 expression in the gastric tumor samples.  
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To further pinpoint the role of SOX2 in GC cells, SOX2 was knocked down via RNA 
interference and via a dominant negative SOX2 construct. The advantage of a dominant 
negative approach was, that in contrast to RNA interference, the mutated transcription 
factor directly blocks the wild-type transcription factor from binding to the DNA binding 
site in a competitive manner, leading to a reduced level of gene activation and therefore 
more effectively inhibing SOX2 signaling. Although a significant down-regulation of SOX2 
protein expression and transcriptional activity was also achieved by shRNA, concomitant 
with down-regulation of cell proliferation, it was not possible to obtain sufficient 
inhibition of SOX2 to conduct more extensive experiments. It was assumed that the 
extraordinarily high SOX2 levels in AZ-521 cells could not be overcome with this 
approach. Another reason for the strategy of inhibiting SOX2 transcriptional activity lay 
in the post-transcriptional modifications explained above, since the capacity of SOX2 to 
bind DNA, and not merely its expression, is essential to regulate target genes that might, 
in turn, be involved in gastric tumorigenesis. For that reason further experiments were 
performed with the dnSOX2 approach. An additional advantage was that using a 
tetracycline repressor provided the opportunity to control the onset of expression of 
dnSOX2, making it easy to conduct time dependent experiments. The system was 
validated by expression analysis of the HA-tagged dnSOX2 protein by western blot and 
confirmation of nuclear localization of the truncated protein by immunofluorescence. 
Furthermore, decrease of SOX2 transcriptional activity was observed to occur in a time 
dependent manner. However, a time shift was noted between protein expression and 
effects on transcriptional activity. This time shift between protein expression and actual 
activity of protein can be explained by the fact that the expressed protein needs to first 
accumulate and then localize to the SOX2 binding sites of target genes.  
The function of SOX2 in GC was further analyzed by investigating its role in 
different aspects related to tumorigenesis. Cancer cells are characterized by a high 
proliferative activity, leading to accumulation of cells at the tumor site and uncontrolled 
growth. Since SOX2 expression was observed at the proliferation sites within the tumor 
tissue, the influence of SOX2 in proliferation of GC cells on SOX2 was subsequently 
verified in vitro. It was proven that the proliferative activity of cells decreased after 
inhibiting SOX2 in a time dependent manner. As this effect was reversible after some 
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days, it was supposed that this was a true effect on proliferation and was not due to cell 
death. As soon as dnSOX2 was degraded and the cells could regain their normal activity, 
the proliferation rate rose almost to basal levels. This led to the conclusion that the 
proliferation of AZ-521 GC cells is controlled by SOX2 activity. These results resemble 
findings in glioma cells as well as in breast cancer cells in which SOX2 was shown to be 
necessary for continuous proliferation [158, 159].  
To explore whether the inhibition in cell proliferation observed was also related 
to an induction of apoptosis, Caspase 3/7 assays were performed. Dysregulation of 
apoptotic pathways can lead to uncontrolled cell growth, since bypassing apoptosis 
promotes cancer progression. An up-regulation of Caspase 3/7 activity was observed 
after blocking SOX2. However, this effect could not be assigned to a particular apoptotic 
pathway influenced by SOX2. These findings are consistent with recent studies showing 
that down-regulation of SOX2 inhibits proliferation and induces apoptosis in human lung 
cancer cells in vitro as well as in vivo [160, 162].  
Recently, SOX2 has been described to correlate with lymph-node metastases and 
distant spread in right-sided colon cancer [167]. To determine if SOX2 could also be 
involved in GC cell migration, wound healing assays were performed. The significant 
slower wound healing after blocking SOX2 indicated that SOX2 is contributing to the 
migration of cancer cells. A role for SOX2 in migration and invasion has also been shown 
in malignant gliomas [209, 210], strengthening the findings that SOX2 is essential for 
migration in GC cells. Certainly there is a strong correlation between proliferation rate 
and migration in vitro as proliferation of cells strongly influences migration. However, it 
is assumed that in the present setting a valid effect of SOX2 down-regulation on 
migration was observed, independent from a decreased rate of proliferation, since the 
effect on migration occurred earlier after SOX2 inhibition than the time point at which a 
decrease of proliferation was evident. Hence, observations of proliferation, apoptosis 
and migration imply that SOX2 expression is a major effector involved in different 
aspects related to the tumorigenic potential of AZ-521 stomach cancer cells. 
Furthermore, interruption of SOX2 activity leads to a less tumorigenic phenotype of 
cells.  
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To depict if decrease of proliferation was related to senescence, SA--gal activity 
was examined. Analysis of AZ-521 cells revealed that almost 30 % of cells undergo 
senescence after inhibition of SOX2 activity. In the senescent phase, cells are no longer 
dividing, nor are they dying, but in a state of inactivity. Senescence is a condition of 
irreversible cell growth arrest, protecting cells against aberrant proliferation, restricting 
tumor progression and can be assumed to be a plausible tumor suppressor mechanism 
[211]. Previous studies suggested that activation of senescence in tumors might 
contribute to the success of chemotherapy [212, 213]. In this study inhibition of SOX2 
led to an increase of senescent cells, hence it might contribute to the protection against 
tumor formation. Studies done by Yoon et al. suggested that replicative senescence in 
mesenchymal stem cells may be dominantly regulated by SOX2 [214, 215], supporting 
the observation in the present work. Moreover, the onset of senescence in human 
neural stem cells was also associated with decreased expression of SOX2 [215].  
Furthermore, the inhibition of cell growth was found to be due to changes in the 
cell cycle, since inhibition of SOX2 led to cell cycle arrest in G2/M phase, and translated 
into a lower cell migration rate. A recent study by Lin et al. showed that SOX2 is known 
to regulate cell cycle proteins in prostate cancer, and that inhibition of SOX2 induces cell 
cycle arrest [216]. Moreover, attenuated S-phase entry was observed in human glioma 
cells upon inhibition of SOX2 [209]. These data support findings presented here 
indicating that SOX2 is a major factor driving GC cells towards tumorigenesis. 
Subsequently it was analyzed if SOX2 influences the expression of certain cell cycle 
regulatory proteins. C-MYC is an oncogene, altered in human cancers and known to be 
deregulated in about 50 % of all tumors. Among other properties it influences the cell 
cycle by up-regulation of cyclins [217]. However, an altered expression of C-MYC after 
inhibition of SOX2 could not be observed. Nevertheless, lower CCNB1 (Cyclin B1) levels 
were detected in cells with abolished SOX2 activity. It has recently been shown for 
colorectal cancer cells that down-regulation of Cyclin B1 induces G2/M cell cycle arrest 
and consequently inhibits proliferation of cells [218]. Moreover, Xu et al. reported that 
during autophagy mRNA expression of Cyclin B is decreasing concomitant with a 
decrease of OCT4, SOX2 and NANOG [219]. In contrast to findings of the present work, 
SOX2 was shown to inhibit the transition from G1 to S phase in prostate cancer cell lines 
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by targeting Cyclin E (CCNE1) and P27 [216]. This could be due to the different cellular 
context, or a differential dependency of the cell lines employed on cell cycle regulators. 
On the other hand, the data repoted here are in contrast to the observations by Otsubo 
et al. [171], describing inhibition of proliferation and apoptosis upon over expression of 
SOX2 in GC cell lines. The use of different cell lines with distinct tumor origin could 
explain these discrepancies. Several of the cell lines employed in the work by Otsubo are 
known to depend on WNT signaling. The results presented here and the work of other 
groups [168, 202, 203] indicate that SOX2 negatively regulates the WNT pathway by 
inhibiting TCF4 transcriptional regulation. The fact that Otsubo et al. observed a SOX2-
mediated decrease of Cyclin D1 (CCND1) and an increase of P27 (KIP1) levels, both of 
which are regulated by TCF4, clearly indicates a loss of TCF4 activity upon SOX2 over 
expression.  
In vitro results indicated an essential role of SOX2 in gastric tumorigenesis, which 
were validated in a xenograft mouse model in vivo, where blocking of SOX2 resulted in 
reduced subcutaneous tumor growth in mice. Dissected tumors where stained for KI67 
in order to evaluate proliferation rate of cells. However, no significant differences in 
proliferating cells were found, when comparing tumors of treated mice with blocked 
SOX2 to non-treated mice. Nevertheless, a tendency of non-treated tumors to exhibit 
more necrotic cells was detected. Since tumors are growing faster in those mice, there 
might be a higher tendency of tissue to undergo necrosis. However, this has to be 
investigated in more detail with a larger group of mice to assign data more accurately. 
Furthermore, tumors were stained for several genes known to be involved in gastric 
tumorigenesis. However, no significant differences in protein expression were seen. 
Both groups of tumors were negative for P16, CDX2, slug and snail and showed low 
expression of P21. Moreover, both exhibited high expression of -Catenin and vimentin. 
-Catenin is involved in the WNT signaling pathway and is highly expressed in most types 
of colorectal cancer. A co-expression of SOX2 and nuclear -Catenin was seen in one 
third of all SOX2 positive CRCs and was associated with nodal status and distant 
metastasis [167]. Interestingly, SOX2 was found to be inhibiting WNT signaling in AZ-521 
cells in vitro. It was therefore speculated that inhibition of WNT signaling might occur 
through blocking of -Catenin by SOX2. It has been shown by Mansukhani et al. that 
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SOX2 binds to nuclear -Catenin, thus preventing its binding to TCF/LEF during 
osteoblast differentiation [203]. The same mechanism might be true for GC but has to be 
further investigated. Over expression of Vimentin in GC was correlated to higher 
metastasis [185, 186]. Since high expression of Vimentin was seen in both tumor groups, 
as well as nuclear -Catenin the metastasis rate of AZ-521 cells was investigated by 
injecting cells i.v. into athymic nude mice. However, AZ-521 cells were not metastatic 
and were cleared from the lungs one day after i.v. injection of cells. AZ-521 cells have 
been previously shown to have very low metastatic potential [220]. It can be assumed 
that missing discrepancies in tumor sections occur due to the exceptional high level of 
SOX2 in AZ-521 cells which is, however blocked by dnSOX2 and therefore regulated on a 
sub-cellular level, are still not low enough to detect differences by IHC.  
To date not many SOX2 target genes in tumors have been found. To identify 
potential SOX2 targets, comparative RNA gene expression microarrays were performed 
at different time points after inhibition of SOX2 and differentially expressed genes were 
analyzed. A report by Tani et al. identified Pepsinogen A (PGA5) as potential target gene 
of SOX2 in a subset of GC cell lines [221], yet, in this study, differential expression of 
PGA5 in AZ-521 cancer cells was not seen after blocking SOX2. This might be due to a 
different cellular background. However, regulations of several other genes could be 
verfied. Up-regulation of CDKN1A (p21) mRNA as well as protein was seen after down-
regulating SOX2. A deregulation of p21 is known from several human cancers [187]. In 
GC tissue samples it has been shown that negative expression of p21 is correlated with 
poor survival and advanced stage and lymph node metastasis [222]. Similar results were 
found for laryngeal and oral carcinomas [223]. Furthermore, p21 knock-out mice 
developed spontaneous tumors [224]. Thus, it is suggested that the tumor suppressive 
role for p21 in GC might be a direct link to SOX2 regulating the expression of p21. 
Moreover, a down-regulation of NP63, a splice variant of P63, was observed. In 
squamous cell carcinomas of the GI tract and of the lung SOX2 is co-expressed with P63 
[225, 226]. Yet, the role of P63 and its different isoforms, TAP63 and NP63 in 
tumorigenesis is still not clearly understood. A work by Barbieri et al. suggested, that the 
alpha splice variant of NP63 has an anti-apoptotic effect [227]. Tissue culture 
experiments as well as tumor sample analysis revealed NP63 to be over expressed in 
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several cancers and to contribute to proliferative characteristics, tumor growth and the 
inhibition of senescence [228-230]. Furthermore, p63 knock-out mice showed reduced 
proliferative capacity in keratinocytes which might be due to an increase of p21 since it 
is directly transcriptionally repressed by Np63 [231]. Present results suggest that SOX2 
might be inducing the expression of ∆NP63, which in turn represses p21 expression, 
contributing this way to proliferation and apoptosis of GC cells. These data for the first 
time show a potential correlation between SOX2, p21 and NP63 in GC.  
A further interesting observation concerning differentially expressed genes was 
the regulation of several WNT pathway related genes. Numerous in vitro experiments 
[168] as well as observations of differentiation of adult stem cells [202] and osteoblast 
differentiation [203] report SOX2 to antagonize TCF/Catenin activity and therefore to 
repress the WNT pathway by promoting the transcription of its negative regulators. An 
up-regulation of LEF1 mRNA was confirmed in AZ-521 cells after blocking SOX2. LEF1 is a 
WNT effector gene activated upon WNT signaling. Concomitant to this up-regulation an 
increase in TCF/LEF transcriptional activity was observed. Moreover, an up-regulation of 
DKK4, a direct target gene and upstream antagonist of the WNT pathway was detected. 
DKK4 acts as a WNT inhibitor, though. Its over expression in hepatocellular carcinoma 
cells was found to inhibit cell proliferation, reduce colony formation and delay cell 
migration [232]. As a WNT target gene it is up-regulated upon WNT signaling acting as a 
negative feed back regulator to attenuate WNT signaling after its activation. An 
induction of DKK4 by the canonical WNT pathway has also been reported by Bazzi et al. 
[233]. In the present setting DKK4 up-regulation may follow SOX2-mediated WNT 
activation in order to regulate aberrant WNT signaling. Additionally, a down-regulation 
of FGF10 was verified, which is also known to be a WNT target gene. It has been shown 
earlier that WNT signaling suppresses the activity of FGF10 in branching morphogenesis 
of lung and the lacrimal glands and leads to a decrease in proliferation [234]. 
Furthermore, during osteogenesis, FGF10 signals counteract WNT signaling [235]. In 
human breast cancer and GC over expression of FGFR2, the binding receptor for FGF10, 
is linked to tumorigenesis and leads to more malignant phenotypes [236, 237]. To date 
there is no link known between SOX2, the interaction of FGF10 and the canonical WNT 
signaling. However, FGF10 is claimed to antagonize SOX2 expression during mouse 
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development [148, 238]. One might argue that in GC progression SOX2 inhibition is 
followed by subsequent suppression of FGF10. Yet further experiments would be 
necessary to clarify if FGF10 down-regulation is an indirect effect of WNT up-regulation 
upon loss of SOX2 or if SOX2 can directly influence FGF10 expression in GC cells.  
In summary, these results demonstrate that SOX2 is involved in several aspects of 
gastric carcinogenesis in vitro and in vivo by regulating the expression of genes 
implicated in cell proliferation, apoptosis and cell cycle regulation. Importantly, present 
data support a model of gastric carcinogenesis that involves the gastric stem cell and 
differentiation marker SOX2, indicating a novel pathway apart from activating mutations 
in the WNT signaling pathway or E-cadherin. The fact that SOX2 was specifically 
observed in over 40 % of intestinal tumors challenges the current doctrine that loss of 
SOX2 is implicated in development of intestinal metaplasia and intestinal type GC. 
Rather, these data support the hypothesis that tissue specific stem cells in the stomach 
are SOX2 proficient and involved in the carcinogenic process in the stomach, and that 
intestinal metaplasia – devoid of SOX2 expression – is not a direct precursor lesion of 
intestinal type GC. 
 
4.2. The regulation of SOX2 in gastric cancer 
To understand the influence of SOX2 on GC it is not only important to analyze 
potential target genes of SOX2 but also to understand how SOX2 is regulated in the 
stomach. Since it is known that STAT3 is regulating SOX2 expression during neuronal 
development [141] it was sought to investigate if it was also regulating SOX2 in GC. Co-
localization of phosphorylated STAT3 (p-STAT3), Ki67 and SOX2 was obsereved in tumors 
derived from Gp130 mutant mice with hyperactivated STAT3 signaling. These data are in 
line with the observations Foshay et al. made in neuronal development. They could 
detect co-localization of SOX2 and STAT3 in vivo and in vitro [141]. In a subset of GC cell 
lines analyzed a nuclear co-localization of both transcription factors could also be 
verified. These results again strengthen the assumption that STAT3 is regulating SOX2 in 
GC. Moreover, a correlation of p-STAT3 and SOX2 protein expression was observed in all 
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GC cell lines investigated, except AZ-521 cells. It has been shown before that STAT3 is 
not phosphorylated in AZ-521 cells. Okamoto et al. suggested that the lack of 
phosphorylation occurs due to a concomitant lack of expression of the proto-oncogene 
c-met [239]. It is therefore speculated that SOX2 as well might be indirectly regulated by 
c-met in GC. However, AZ-521 cells might use a different pathway modulating SOX2 
expression. Additionally, SOX2 reporter assays in a subset of GC cell lines revealed an up-
regulation of SOX2 transcriptional activity after transfection with STAT3. These results 
again indicate that there might be a direct link between SOX2 and STAT3 in GC cell lines.  
IL-6 leads to the phosphorylation of STAT3 by binding to gp130 receptor 
activating JAK [240]. An up-regulation of the transcriptional activity of SOX2 upon IL-6 
stimulation was observed in GC cell lines, suggesting an involvement of the IL-6/STAT3 
pathway during regulation of SOX2 in gastric tumorigenesis. It has been shown recently 
that a suppression of SOX2 in ES cells as a result of sodium arsenite exposure is even 
further augmented due to simultaneous inhibition of IL-6/STAT3 dependent pathways 
[241]. However, the present data are the first hint of a regulation of SOX2 via the IL-
6/STAT3 pathway in GC.  
GC often is preceded by inflammation, usually triggered by H. pylori infection. It 
was observed that the infection of H. pylori had different effects on SOX2 transcriptional 
activity in several GC cell lines. In AGS cells it has been shown before that infection with 
H. pylori results in a decrease of SOX2 expression [242]. These results were confirmed 
and furthermore it could be observed that the decrease was dependent on the presence 
of the virulence factor CagA. This CagA dependent decrease was also verified at the 
protein level. Moreover, AGS cells showed a concomitant decrease of p-STAT3 protein 
expression after infection, strengthening the assumption that SOX2 is regulated by 
STAT3 in GC. A simultaneous decrease of SOX2 and p-STAT3 protein after H. pylori 
infection was also found in MKN45 cells. A decrease of SOX2 transcriptional activity was 
observed in AZ-521 cells, but interestingly was not dependent on the expression of 
CagA, leading to the conclusion that different cell lines have different susceptibility to H. 
pylori virulence factors, wherein the involvement of CagA is not fully understood so far. 
In addition, it has been shown before in MKN45 and MKN28 cells, that H. pylori down-
regulates SOX2 expression independently from CagA expression [243]. St 3051 and St 
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2957 are both not expressing SOX2 endogenously. Stimulation of those cells with IL-4 
resulted in an up-regulation of SOX2, as reported by Asonuma et al. [170]. Subsequent 
infection with H. pylori could significantly down-regulate SOX2 transcriptional activity, 
while infection with the CagA deficient mutant strain resulted in a less intense effect 
than infection with the wild type strain as seen in AGS cells. Thus, in these and in the 
previous cell lines, H. pylori is likely to influence cells via activation of one of the various 
pathways CagA can be involved in, like the RAS-mitogen activated protein kinase (MAPK) 
pathway [78, 79], the E-Cadherin/-Catenin pathway [80] or activation of NF- [82]. In 
summary, it was observed that SOX2 is regulated by p-STAT3 in several GC cell lines and 
moreover infection with H. pylori is able to down-regulate SOX2 expression most likely 
via a down-regulation of p-STAT3, but the detailed involvement of this pathway still 
needs to be further elucidated. 
 
4.3. The role of SOX2 during murine development 
SOX2 is not only an important factor for pluripotency of embryonic stem cells but 
also known to be highly expressed in endoderm derived tissues of vertebrates, thus 
likely to contribute to stomach development and upholding of adult gastric stem cells. 
SOX2 expression during mouse embryonic development was confirmed in the central 
nervous system including the retina as reported by Stevanovic and Collignon [244, 245], 
in the hair follicles [246], in the lungs [247] as well as in stomach and esophagus [147, 
148].  
Deletion of Sox2 using a conditional knock out mouse resulted in different 
phenotypes depending on dose and time point of injection of tamoxifen. Early Sox2 
depletion at day E 7.5 resulted in deformed embryos at day E 19.5 showing especially 
degeneration of the stomach. It was assumed that deletion of Sox2 leads to an 
intestinalization of the stomach due to a shift in pathway regulation. Sox2, together with 
Cdx2, plays a crucial role during early gut development. It is important for regionalization 
of the primitive streak influencing anterior and posterior gut formation. Later on these 
compartments become subdivided into foregut, midgut and hindgut and then 
differentiate into stomach and esophagus where SOX2 is expressed, or duodenum, 
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jejunum, ileum caecum and colon which express CDX2 but not SOX2 [248]. In correlation 
to these data it has been shown recently that expression of Sox2 in the prospective 
intestinal part redirects intestinal epithelium towards a premature gastric phenotype 
during gut development [249]. These data strengthen the findings of the present work 
that loss of Sox2 in the gastric part of the gut on the other hand might induce an 
intestinal phenotype. A more severe macroscopic phenotype was observed with 
increasing dosage of tamoxifen injections. Injecting four times during pregnancy led to 
stagnation of development of knock-out embryos. This severe phenotype might occur 
due to several reasons. As mentioned above Sox2 is not only important in development 
of the stomach but also contributing to formation of several other tissues. Therefore, 
degeneration of embryos could not further be curtailed to a specific reason and has to 
be investigated in more detail. Thus, to have a more specific view on Sox2 deletion in 
embryonic stomach development and to avoid too many off-targets effects due to the 
expression of Sox2 in other tissue we additionally worked with a Sox17iCre mouse. Sox17 
is expressed in the definite endoderm, which gives rise to lung, heart, liver, pancreas, 
stomach and GI tract. Since breeding generated no Sox17iCre x Sox2fl/fl offspring it is 
assumed that expression of Sox2 in the definite endoderm is crucial for the viability of 
embryos. Sox17iCre is expressed as early as day E 6.0 in the extraembryonic visceral 
endoderm [198]. An expression of Sox2 in the same part of the embryo was reported by 
Avilion et al. at day E 6.5 [127]. Hence the role of Sox2 during this stage of embryonic 
development is pivotal, so that deletion leads to complete malformation and therefore 
resorption of k.o. embryos. Generation of a stomach specific Cre-mouse-line would be 
fundamental for further investigations of the role of Sox2 during stomach development.  
Furthermore, data of Avilion et al. could be confirmed by analyzing Sox2geo mice. 
As reported earlier [144] no differences in number of blastocytes, late morulae or 
unfertilized eggs could be found, obtained from Sox2geo/wt inbred compared to Sox2wt/wt 
inbred embryos, however, at E 7.5 about 1/4 of embryos of Sox2geo/wt inbred mice 
where degenerated. These results confirm the essential role of Sox2 during early mouse 
development since it is already expressed in the inner cell mass (ICM) of blastocytes, 
although only at the stage of implantation a disruption of Sox2 leads to lethality. In the 
growing oocyte there is much maternal SOX2 protein left which might rescue the k.o. 
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blastocytes. This protein is diluted during rapid growth of the embryo and hence is not 
able to further rescue k.o. embryos after implantation. 
During early postnatal development of mice, k.o. of Sox2 by induction of CreERT2 
via breast feeding led to retardation in development which was measurable after one 
week to 10 days. K.o. pups showed significantly lower weight compared to their wt 
littermates (Fig. 46), did not develop proper fur (Fig. 47) and died within two to three 
weeks of age. Since Sox2 is an important factor in development of dermal papillae [246] 
this explains the improper growth of fur. However, further experiments should be 
conducted to investigate how Sox2 regulates generation of fur. Furthermore, Sox2 is 
important in stomach development of mice [148] and loss of Sox2 leads to a growth 
defect and moreover might also influence hormonal regulation in the stomach [147]. 
Negative effects of Sox2 k.o. in pups get more severe over time, since the daily uptake of 
breast milk increases the tamoxifen dosage, thus increasing the k.o. of Sox2, and 
resulted in weight loss and eventually in their death. Combined with the findings that 
SOX2 is co-expressed at proliferation sites in the assumed stem cell zones of the adult 
mouse stomach and Sox2 k.o. in adult mice leads to less proliferating cells (Fig. 49) it is 
suggesed that Sox2 k.o. in pups influences the growth of the stomach by suppression of 
proliferating cells, hence leading to malformations. Additionally, a hormonal 
dysregulation is also likely to influence weight loss in k.o. pups.  
A recent publication by Arnold et al. showed that Sox2 positive cells are indeed 
potential markers for adult stem cells in the stomach [37]. They could also observe that 
adult Sox2 k.o. resulted in death of mice, which they explained by the development of 
gastric ulcer. However, in this study adult mice did not die after Sox2 k.o. This might be 
due to the different k.o. systems. Excision of Sox2 in the system applied in the present 
study is strongly dependent on the dosage of tamoxifen reaching the cells, thus this k.o. 
occurs generally only partially and leaves the cells alive. The ganciclovir/delta thmyidine 
kinase (DTK) system applied by Arnold at al. is not only more sensitive but also kills every 
cell expressing DTK, thus every Sox2 positive cell, after ganciclovir induction. Hence, a 
more severe phenotype is expected. Nevertheless, findings of this study confirm the 
results of Arnold et. al. that Sox2 is influencing proliferation of cells in the adult mouse 
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stomach. Besides, these data are consistent with earlier findings shown in this work that 
Sox2 is also expressed at proliferation sites in gastric tumor samples, again accrediting 
Sox2 an essential role in controlling proliferation.  
The observed phenomenon that Sox2fl/fl x Rosa-CreERT2 mothers induced with 
tamoxifen were not able to do proper lactation might be due to the fact that SOX2, 
among other stem cell factors, was recently found to be expressed in breast milk cells 
which were derived from the breast epithelium during lactation [250]. Hence Sox2 might 
be essential to initiate proper lactation of mothers.  
In summary it can be concluded that Sox2 is essential for proper murine 
development as early as gastrulation. Embryonic k.o. after E 7.5 led to malformations of 
the stomach and was becoming more severe in a dose-dependent manner influencing 
the whole embryo. During early post-natal mouse development, depletion of Sox2 
resulted in death of pups which may be due to problems in nutrient uptake and 
hormonal regulations in the stomach. Sox2 was also seen to be essential to sustain 
proliferation in gastric crypts of adult mice, suggesting that it indeed might be a 
potential factor for the maintenance of adult gastric stem cells.  
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5. Summary 
This work for verified a tumorigenic role for SOX2 in gastric cancer. It was 
observed that SOX2 is a major factor contributing to cell proliferation in GC cells and this 
was strengthened by observation of co-expression of SOX2 and KI67 in gastric tumor 
tissue. Moreover, a role for SOX2 in migration was found and it was seen that blocking 
SOX2 induced apoptosis and senescence in GC cells. Analysis of the cell cycle revealed 
that inhibition of SOX2 led to cell cycle arrest. Moreover, it was verified in a xenograft 
model that SOX2 also influenced tumor growth in vivo. These results indicate a crucial 
role of SOX2 during gastric tumorigenesis. 
Additionally, for the first time target genes of SOX2 in gastric tumors could be 
assigned. The regulation of several genes related to the canonical WNT pathway was 
observed. An up-regulation of LEF1 and DKK4 was seen as well as a down-regulation of 
FGF10 after blocking SOX2 activity. These data indicate that SOX2 contributes to cancer 
development through regulation of WNT pathway genes. Moreover, SOX2 was found to 
influence the expression of p21 in gastric tumors. An up-regulation of p21 after blocking 
SOX2 was observed with a concomitant down-regulation of NP63. These results 
suggest that SOX2 might induce the expression of ∆NP63, which in turn represses p21 
expression, contributing in this way to proliferation and apoptosis of GC cells. These are 
the first data for SOX2 target genes in GC.  
Two different mechanisms of SOX2 regulation were also observed. A co-
expression of SOX2 and STAT3 was observed in gastric tumors and in GC cell lines. 
Furthermore, it was shown that STAT3 expression directly influenced SOX2 
transcriptional activity as well as SOX2 protein expression in several GC cells, and that 
this effect might be regulated through IL-6. Additionally, a link between H. pylori 
infection and SOX2 expression was found in gastric tumor cells. A down-regulation of 
SOX2 upon infection with H. pylori was observed and, in a subset of cell lines, the 
virulence factor CagA was identified as a key player in this regulation. Furthermore, an 
additional decrease of p-STAT3 protein expression levels following H. pylori infection 
was found. 
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Finally, SOX2 was identified to be a major factor influencing mouse development. 
Depletion of Sox2 in murine embryos resulted in malformations of several organs. A 
severe stomach phenotype was observed and therefore it is suggested that loss of Sox2 
leads to intestinalization of the stomach due to a shift in pathway regulations. 
Moreover, it was assumed that Sox2 is important for a proper hormone regulation in 
early post-natal development of mice. It was also seen that Sox2 expression in mothers 
influenced lactation. Furthermore, SOX2 protein was observed at the presumptive 
gastric stem cell zone and it was shown that inhibition of Sox2 influenced proliferation in 
the adult mouse stomach, suggesting that Sox2 might be a potential adult stem cell 
marker in the stomach.  
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Appendix 
 
1. List of differentially expressed genes (limmatable p 0.01) 
ID 
gene 
assignment     gene name 
 
Down-regulated 
  7943413 NM_001165  BIRC3  baculoviral IAP repeat-containing 3  
8106730 NM_022550   XRCC4   X-ray repair complementing defective repair in Chinese hamster cells 4  
8175252 --- 
  8102792 NM_019035  PCDH18  protocadherin 18  
8111993 NM_004465   FGF10   fibroblast growth factor 10  
7971565 NM_005767   P2RY5   purinergic receptor P2Y, G-protein coupled, 5  
8128383 NM_017421   COQ3   coenzyme Q3 homolog, methyltransferase (S. cerevisiae)  
7951259 NM_002425   MMP10   matrix metallopeptidase 10 (stromelysin 2)  
8175250 --- 
  8091103 NM_006286  TFDP2  transcription factor Dp-2 (E2F dimerization partner 2)  
8108370 NM_001964   EGR1   early growth response 1  
7919780 NM_018178   GOLPH3L   golgi phosphoprotein 3-like  
8096160 NM_001025616  
 
ARHGAP24   Rho GTPase activating protein 24  
7923516 NM_016243   CYB5R1   cytochrome b5 reductase 1  
8046922 NM_000090   COL3A1   collagen, type III, alpha 1  
8155754 NM_153267   MAMDC2   MAM domain containing 2  
8057620 NM_000393   COL5A2   collagen, type V, alpha 2  
8078330 NM_001003793   RBMS3   RNA binding motif, single stranded interacting protein  
8174513 NM_145234   CHRDL1   chordin-like 1  
7968029 NM_001014442   PCOTH   prostate collagen triple helix  
7988260 NM_032892   FRMD5   FERM domain containing 5  
8169272 NM_052936   ATG4A   ATG4 autophagy related 4 homolog A (S. cerevisiae)  
8135915 NM_013332   HIG2   hypoxia-inducible protein 2  
8095728 NM_001432   EREG   epiregulin  
8082075 NM_138287   DTX3L   deltex 3-like (Drosophila)  
7965335 NM_001946   DUSP6   dual specificity phosphatase 6  
8117219 NM_018473   THEM2   thioesterase superfamily member 2  
7916727 NM_014288   ITGB3BP   integrin beta 3 binding protein (beta3-endonexin)  
8160431 BC021861  
 
LOC554202   hypothetical LOC554202  
8144742 NM_181723   EFHA2   EF-hand domain family, member A2  
8120602 NM_024576   OGFRL1   opioid growth factor receptor-like 1  
7980403 BC015054   C14orf133   chromosome 14 open reading frame 133  
8057689 NM_022353   OSGEPL1   O-sialoglycoprotein endopeptidase-like 1  
7935660 NM_015221   DNMBP   dynamin binding protein  
7918034 NM_001077394   DPH5   DPH5 homolog (S. cerevisiae)  
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7938563 NM_001178   ARNTL   aryl hydrocarbon receptor nuclear translocator-like  
7984686 NM_033028   BBS4   Bardet-Biedl syndrome 4  
8085608 NM_012260   HACL1   2-hydroxyacyl-CoA lyase 1  
7985119 NM_018200   HMG20A   high-mobility group 20A  
8134091 NM_012129   CLDN12   claudin 12  
8150014 NM_018250   INTS9   integrator complex subunit 9  
8135576 NM_015641   TES   testis derived transcript (3 LIM domains)  
8069744 NM_016940   RWDD2B   RWD domain containing 2B  
7982597 NM_003246   THBS1   thrombospondin 1  
8085984 NM_017784   OSBPL10   oxysterol binding protein-like 10  
8122265 NM_006290   TNFAIP3   tumor necrosis factor, alpha-induced protein 3  
8094301 NM_004787   SLIT2   slit homolog 2 (Drosophila)  
8149877 NM_007257   PNMA2   paraneoplastic antigen MA2  
8129497 NM_001431   EPB41L2   erythrocyte membrane protein band 4.1-like 2  
7959025 NM_001109903   RNFT2   ring finger protein, transmembrane 2  
8089701 NM_015642   ZBTB20   zinc finger and BTB domain containing 20  
7928671 BC022252   C10orf57   chromosome 10 open reading frame 57  
7975268 NM_001172   ARG2   arginase, type II  
8113726 NM_000943   PPIC   peptidylprolyl isomerase C (cyclophilin C)  
8019954 BC137437   FLJ35776   hypothetical LOC649446  
7966026 NM_014840   NUAK1   NUAK family, SNF1-like kinase, 1  
7901363 NM_001262   CDKN2C   cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)  
7913883 NM_000437   PAFAH2   platelet-activating factor acetylhydrolase 2, 40kDa  
8002941 NM_199355  
 
ADAMTS18   ADAM metallopeptidase with thrombospondin type 1 motif, 18  
7991485 NM_001040655   TTC23   tetratricopeptide repeat domain 23  
7964834 NM_001874   CPM   carboxypeptidase M  
8136341 NM_001724   BPGM   2,3-bisphosphoglycerate mutase  
8068200 BC007928   C21orf119   chromosome 21 open reading frame 119  
8096314 NM_000297   PKD2   polycystic kidney disease 2 (autosomal dominant)  
8120860 NM_183050   BCKDHB   branched chain keto acid dehydrogenase E1, beta polypeptide  
8081241 BC006512   C3orf26   chromosome 3 open reading frame 26  
7965403 NM_002345   LUM   lumican  
8113800 NM_001999   FBN2   fibrillin 2  
8124510 NM_003519   HIST1H2BL   histone cluster 1, H2bl  
8116921 NM_001955   EDN1   endothelin 1  
8106776 NM_001867   COX7C   cytochrome c oxidase subunit VIIc  
8041553 NM_024775   GEMIN6   gem (nuclear organelle) associated protein 6  
8150364 NM_031940   TM2D2   TM2 domain containing 2  
8002904 NM_012091   ADAT1   adenosine deaminase, tRNA-specific 1  
8088065 NM_001005159   SFMBT1   Scm-like with four mbt domains 1  
7979813 NM_004926   ZFP36L1   zinc finger protein 36, C3H type-like 1  
8003922 NM_001001683   MED11   mediator complex subunit 11  
8103853 BC033172  
 
MGC45800   hypothetical protein LOC90768  
8126360 NM_004275   MED20   mediator complex subunit 20  
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7967230 NM_019887   DIABLO   diablo homolog (Drosophila)  
8113761 NM_020747   ZNF608   zinc finger protein 608  
8132515 NM_000712   BLVRA   biliverdin reductase A  
8044133 NM_003581   NCK2   NCK adaptor protein 2  
8120411 NM_000947   PRIM2   primase, DNA, polypeptide 2 (58kDa)  
7904907 NM_004326   BCL9   B-cell CLL 
7952339 NR_001453   LOC85389   RNA, small nucleolar  
7954036 NM_016355   DDX47   DEAD (Asp-Glu-Ala-Asp) box polypeptide 47  
8083272 NM_004130   GYG1   glycogenin 1  
8111101 NM_054027   ANKH   ankylosis, progressive homolog (mouse)  
8160036 AK292632   C9orf123   chromosome 9 open reading frame 123  
8099570 BC050697   C4orf30   chromosome 4 open reading frame 30  
7997332 NM_001105663   NUDT7   nudix (nucleoside diphosphate linked moiety X)-type motif 7  
8064978 NM_000214   JAG1   jagged 1 (Alagille syndrome)  
8078834 NM_020839   WDR48   WD repeat domain 48  
8107814 NM_016048   ISOC1   isochorismatase domain containing 1  
8173531 NM_018486   HDAC8   histone deacetylase 8  
8068375 NM_058182   FAM165B   family with sequence similarity 165, member B  
7940079 NM_001085458   CTNND1   catenin (cadherin-associated protein), delta 1  
8023312 --- 
  8111153 NM_012334  MYO10  myosin X  
    Up-regulated 
  8059712 NR_004398  SNORD82  small nucleolar RNA, C 
8110022 NM_003945   ATP6V0E1   ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1  
8067798 NM_018419   SOX18   SRY (sex determining region Y)-box 18  
8115831 NM_004417   DUSP1   dual specificity phosphatase 1  
7992402 NM_004548   NDUFB10   NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22kDa  
8024170 NM_012292   HMHA1   histocompatibility (minor) HA-1  
7977933 NM_012244   SLC7A8   solute carrier family 7 (cationic amino acid transporter, y+ system)  
8165508 NM_001004354   NRARP   Notch-regulated ankyrin repeat protein  
8024120 NM_019112   ABCA7   ATP-binding cassette, sub-family A (ABC1), member 7  
8007471 NM_031858   NBR1   neighbor of BRCA1 gene 1  
7988212 NM_025165   ELL3   elongation factor RNA polymerase II-like 3  
7899821 NM_020888   KIAA1522   KIAA1522  
8016463 NM_018952   HOXB6   homeobox B6  
8138045 NM_014413   EIF2AK1   eukaryotic translation initiation factor 2-alpha kinase 1  
8025368 NM_003083   SNAPC2   small nuclear RNA activating complex, polypeptide 2, 45kDa  
8081838 NM_020754   CDGAP   Cdc42 GTPase-activating protein  
8025053 NM_003811   TNFSF9   tumor necrosis factor (ligand) superfamily, member 9  
8165217 NM_017617   NOTCH1   Notch homolog 1, translocation-associated (Drosophila)  
7980338 NM_024496   C14orf4   chromosome 14 open reading frame 4  
8068866 NM_004571   PKNOX1   PBX 
8145942 NM_144652   LETM2   leucine zipper-EF-hand containing transmembrane protein 2  
7948741 NM_012200   B3GAT3   beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)  
8008922 NM_003620   PPM1D   protein phosphatase 1D magnesium-dependent, delta isoform  
 Appendix 
 
 
168 
 
7998063 NM_006086   TUBB3   tubulin, beta 3  
8072160 NM_032173   ZNRF3   zinc and ring finger 3  
7905918 NM_004952   EFNA3   ephrin-A3  
8030220 NM_003660   PPFIA3   protein tyrosine phosphatase 
7920707 NM_006589   C1orf2   chromosome 1 open reading frame 2  
7945371 NM_021034   IFITM3   interferon induced transmembrane protein 3 (1-8U)  
8007620 NM_002087   GRN   granulin  
8016457 NM_002147   HOXB5   homeobox B5  
8108080 NM_015288   PHF15   PHD finger protein 15  
8032839 NM_032108   SEMA6B   sema domain, transmembrane domain (TM)  
8067140 NM_000782   CYP24A1   cytochrome P450, family 24, subfamily A, polypeptide 1  
8119088 NM_078467   CDKN1A   cyclin-dependent kinase inhibitor 1A (p21, Cip1)  
8104107 NM_173553   TRIML2   tripartite motif family-like 2  
8010737 NM_005052   RAC3   ras-related C3 botulinum toxin substrate 3  
8007008 NM_003250   THRA   thyroid hormone receptor, alpha  
7963061 NM_001008223   C1QL4   complement component 1, q subcomponent-like 4  
7949021 NM_173587   RCOR2   REST corepressor 2  
7918694 NM_001010922   BCL2L15   BCL2-like 15  
8034130 NM_015493   KANK2   KN motif and ankyrin repeat domains 2  
7937330 NM_006435   IFITM2   interferon induced transmembrane protein 2 (1-8D)  
7915472 NM_006516   SLC2A1   solute carrier family 2 (facilitated glucose transporter), member 1  
8165538 NM_001033113   ENTPD8   ectonucleoside triphosphate diphosphohydrolase 8  
8032392 NM_199054   MKNK2   MAP kinase interacting serine 
7995783 NM_005953   MT2A   metallothionein 2A  
8038367 NM_020309   SLC17A7   solute carrier family 17  
8147351 NM_017697   RBM35A   RNA binding motif protein 35A  
8158771 NM_031426   C9orf58   chromosome 9 open reading frame 58  
8166469 NM_002970   SAT1   spermidine 
7938295 NM_000990   RPL27A   ribosomal protein L27a  
8016523 NM_004123   GIP   gastric inhibitory polypeptide  
8038126 NM_001217   CA11   carbonic anhydrase XI  
7981514 NM_138420   AHNAK2   AHNAK nucleoprotein 2  
7945680 NR_002196   H19   H19, imprinted maternally expressed transcript  
8016745 NM_003971   SPAG9   sperm associated antigen 9  
8030002 NM_153608   ZNF114   zinc finger protein 114  
8029530 NM_000041   APOE   apolipoprotein E  
8165552 NM_015537   NELF   nasal embryonic LHRH factor  
7974870 NM_003082   SNAPC1   small nuclear RNA activating complex, polypeptide 1, 43kDa  
8022404 NM_001098801   C18orf19   chromosome 18 open reading frame 19  
7899265 NM_006142   SFN   stratifin  
8004510 NM_001251   CD68   CD68 molecule  
8027002 NM_004864   GDF15   growth differentiation factor 15  
8102232 NM_016269   LEF1   lymphoid enhancer-binding factor 1  
8026971 NM_006332   IFI30   interferon, gamma-inducible protein 30  
8034263 NM_001420   ELAVL3   ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3  
8150529 NM_014420   DKK4   dickkopf homolog 4 (Xenopus laevis)  
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7937335 NM_003641   IFITM1   interferon induced transmembrane protein 1 (9-27)  
7921099 NM_001878   CRABP2   cellular retinoic acid binding protein 2  
 
2. List of DEGs assigned in Cluster 
Cluster 1 
  ID Symbol Name EntrezID 
7921099 CRABP2  cellular retinoic acid binding protein 2  1382 
8034263 ELAVL3 
 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu 
antigen C)  1995 
8150529 DKK4  dickkopf homolog 4 (Xenopus laevis)  27121 
8038126 CA11  carbonic anhydrase XI  770 
8072160 ZNRF3  zinc and ring finger 3  84133 
8032392 MKNK2  MAP kinase interacting serine 2872 
7998063 TUBB3  tubulin, beta 3  10381 
8034130 KANK2  KN motif and ankyrin repeat domains 2  25959 
8026971 IFI30  interferon, gamma-inducible protein 30  10437 
8102232 LEF1  lymphoid enhancer-binding factor 1  51176 
8030220 PPFIA3 
 protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 3  8541 
8029530 APOE  apolipoprotein E  348 
8025053 TNFSF9  tumor necrosis factor (ligand) superfamily, member 9  8744 
8165508 NRARP  Notch-regulated ankyrin repeat protein  441478 
7963061 C1QL4  complement component 1, q subcomponent-like 4  338761 
8063078 CTSA  cathepsin A  5476 
7937485 PNPLA2  patatin-like phospholipase domain containing 2  57104 
8101376 SEC31A  SEC31 homolog A (S. cerevisiae)  22872 
7949021 RCOR2  REST corepressor 2  283248 
8064808 SLC23A2  solute carrier family 23 (nucleobase transporters), member 2  9962 
8038367 SLC17A7 
 solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 7  57030 
8133459 CLIP2  CAP-GLY domain containing linker protein 2  7461 
7899265 SFN  stratifin  2810 
7937330 IFITM2  interferon induced transmembrane protein 2 (1-8D)  10581 
8158771 C9orf58  chromosome 9 open reading frame 58  83543 
8138045 EIF2AK1  eukaryotic translation initiation factor 2-alpha kinase 1  27102 
7937335 IFITM1  interferon induced transmembrane protein 1 (9-27)  8519 
8133721 HSPB1  heat shock 27kDa protein 1  3315 
7956524 PIP4K2C  phosphatidylinositol-5-phosphate 4-kinase, type II, gamma  79837 
7967544 SCARB1  scavenger receptor class B, member 1  949 
8032839 SEMA6B 
 sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6B  10501 
8010737 RAC3 
 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP 
binding protein Rac3)  5881 
7906085 LMNA  lamin A 4000 
7997427 CMIP  c-Maf-inducing protein  80790 
8104107 TRIML2  tripartite motif family-like 2  205860 
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8092002 ARPM1  actin related protein M1  84517 
8016457 HOXB5  homeobox B5  3215 
7955858 HOXC10  homeobox C10  3226 
8145942 LETM2  leucine zipper-EF-hand containing transmembrane protein 2  137994 
7999102 TFAP4  transcription factor AP-4 (activating enhancer binding protein 4)  7023 
7945680 H19 
 H19, imprinted maternally expressed transcript (non-protein 
coding)  283120 
7920707 C1orf2  chromosome 1 open reading frame 2  10712 
8030002 ZNF114  zinc finger protein 114  163071 
7959312 NA 
  8119088 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1)  1026 
8003903 ARRB2  arrestin, beta 2  409 
8007008 THRA 
 thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-
erb-a) oncogene homolog, avian)  7067 
7940924 PLCB3  phospholipase C, beta 3 (phosphatidylinositol-specific)  5331 
7956242 COQ10A  coenzyme Q10 homolog A (S. cerevisiae)  93058 
8008922 PPM1D  protein phosphatase 1D magnesium-dependent, delta isoform  8493 
8000890 SEPHS2  selenophosphate synthetase 2  22928 
7898957 RCAN3  RCAN family member 3  11123 
8009568 TTYH2  tweety homolog 2 (Drosophila)  94015 
7899821 KIAA1522  KIAA1522  57648 
8016523 GIP  gastric inhibitory polypeptide  2695 
7926983 CREM  cAMP responsive element modulator  1390 
7994518 SPNS1  spinster homolog 1 (Drosophila)  83985 
8022404 C18orf19  chromosome 18 open reading frame 19  125228 
8002121 CTRL  chymotrypsin-like  1506 
8076331 TOB2  transducer of ERBB2, 2  10766 
7938295 RPL27A  ribosomal protein L27a  6157 
7980338 C14orf4  chromosome 14 open reading frame 4  64207 
7973067 NP  nucleoside phosphorylase  4860 
7999079 ADCY9  adenylate cyclase 9  115 
7945371 IFITM3  interferon induced transmembrane protein 3 (1-8U)  10410 
8016745 SPAG9  sperm associated antigen 9  9043 
8007620 GRN  granulin  2896 
8032410 MOBKL2A  MOB1, Mps One Binder kinase activator-like 2A (yeast)  126308 
7996772 SLC7A6 
 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 6  9057 
7909285 PFKFB2  6-phosphofructo-2-kinase 5208 
8159554 UAP1L1  UDP-N-acteylglucosamine pyrophosphorylase 1-like 1  91373 
8165217 NOTCH1  Notch homolog 1, translocation-associated (Drosophila)  4851 
8058091 SATB2  SATB homeobox 2  23314 
8026991 PGPEP1  pyroglutamyl-peptidase I  54858 
7937135 C10orf93  chromosome 10 open reading frame 93  255352 
7992518 RAB26  RAB26, member RAS oncogene family  25837 
7948399 PATL1  protein associated with topoisomerase II homolog 1 (yeast)  219988 
7934393 PPP3CB  protein phosphatase 3 (formerly 2B), catalytic subunit, beta 5532 
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isoform  
7952116 BCL9L  B-cell CLL 283149 
8040742 MAPRE3  microtubule-associated protein, RP 22924 
7981514 AHNAK2  AHNAK nucleoprotein 2  113146 
7960933 M6PR  mannose-6-phosphate receptor (cation dependent)  4074 
8037537 ERCC2 
 excision repair cross-complementing rodent repair deficiency, 
complementation group 2  2068 
8034521 HOOK2  hook homolog 2 (Drosophila)  29911 
8037525 CKM  creatine kinase, muscle  1158 
7983228 MAP1A  microtubule-associated protein 1A  4130 
8172088 BCOR  BCL6 co-repressor  54880 
8166469 SAT1  spermidine 6303 
7949264 EHD1  EH-domain containing 1  10938 
7992744 FLYWCH1  FLYWCH-type zinc finger 1  84256 
8131339 FSCN1 
 fascin homolog 1, actin-bundling protein (Strongylocentrotus 
purpuratus)  6624 
8169598 ZCCHC12  zinc finger, CCHC domain containing 12  170261 
8035318 UNC13A  unc-13 homolog A (C. elegans)  23025 
7992402 NDUFB10 
 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 
22kDa  4716 
7986383 IGF1R  insulin-like growth factor 1 receptor  3480 
7905918 EFNA3  ephrin-A3  1944 
8017421 CCDC47  coiled-coil domain containing 47  57003 
8029856 GRLF1  glucocorticoid receptor DNA binding factor 1  2909 
8080714 FLNB  filamin B, beta (actin binding protein 278)  2317 
8039362 C19orf51  chromosome 19 open reading frame 51  352909 
7990253 NPTN  neuroplastin  27020 
8024120 ABCA7  ATP-binding cassette, sub-family A (ABC1), member 7  10347 
8118682 PHF1  PHD finger protein 1  5252 
8093852 MSX1  msh homeobox 1  4487 
8151816 GEM  GTP binding protein overexpressed in skeletal muscle  2669 
8066214 TGM2 
 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase)  7052 
8170921 PLXNA3  plexin A3  55558 
8003116 HSDL1  hydroxysteroid dehydrogenase like 1  83693 
7991234 MFGE8  milk fat globule-EGF factor 8 protein  4240 
8011093 SLC43A2  solute carrier family 43, member 2  124935 
8138728 HOXA4  homeobox A4  3201 
8026687 OCEL1  occludin 79629 
7940191 STX3  syntaxin 3  6809 
8086330 AXUD1  AXIN1 up-regulated 1  64651 
8034783 LPHN1  latrophilin 1  22859 
8095870 CCNG2  cyclin G2  901 
7948995 ATL3  atlastin 3  25923 
7953442 GPR162  G protein-coupled receptor 162  27239 
8028084 APLP1  amyloid beta (A4) precursor-like protein 1  333 
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8164343 FAM102A  family with sequence similarity 102, member A  399665 
8086961 PFKFB4  6-phosphofructo-2-kinase 5210 
7941260 FRMD8  FERM domain containing 8  83786 
7918694 BCL2L15  BCL2-like 15  440603 
7949067 BAD  BCL2-associated agonist of cell death  572 
8165538 ENTPD8  ectonucleoside triphosphate diphosphohydrolase 8  377841 
7962185 AMN1  antagonist of mitotic exit network 1 homolog (S. cerevisiae)  196394 
8095341 NA 
  
7937341 
B4GALNT
4  beta-1,4-N-acetyl-galactosaminyl transferase 4  338707 
8046276 SP5  Sp5 transcription factor  389058 
7963590 CSAD  cysteine sulfinic acid decarboxylase  51380 
8174610 LRCH2 
 leucine-rich repeats and calponin homology (CH) domain 
containing 2  57631 
7959330 WDR66  WD repeat domain 66  144406 
7974870 SNAPC1  small nuclear RNA activating complex, polypeptide 1, 43kDa  6617 
8164293 AK1  adenylate kinase 1  203 
7966851 TAOK3  TAO kinase 3  51347 
8001531 MT1G  metallothionein 1G  4495 
8147351 RBM35A  RNA binding motif protein 35A  54845 
7949412 LTBP3  latent transforming growth factor beta binding protein 3  4054 
7945536 CEND1  cell cycle exit and neuronal differentiation 1  51286 
8015769 BRCA1  breast cancer 1, early onset  672 
7943803 DIXDC1  DIX domain containing 1  85458 
8116780 DSP  desmoplakin  1832 
8084219 KLHL24  kelch-like 24 (Drosophila)  54800 
8077804 TATDN2  TatD DNase domain containing 2  9797 
8036865 NA 
  8175871 L1CAM L1 cell adhesion molecule  3897 
8048171 
DKFZp434
H1419  hypothetical protein DKFZp434H1419  150967 
8038117 DBP  D site of albumin promoter (albumin D-box) binding protein  1628 
8126402 TRERF1  transcriptional regulating factor 1  55809 
7953409 PTMS  parathymosin  5763 
8024170 HMHA1  histocompatibility (minor) HA-1  23526 
7977933 SLC7A8 
 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 8  23428 
8036473 PPP1R14A  protein phosphatase 1, regulatory (inhibitor) subunit 14A  94274 
8073548 Sep-03  septin 3  55964 
7959016 FLJ42957  FLJ42957 protein  400077 
8029219 TMEM145  transmembrane protein 145  284339 
8126428 TRERF1  transcriptional regulating factor 1  55809 
8093494 CRIPAK  cysteine-rich PAK1 inhibitor  285464 
7939559 TSPAN18  tetraspanin 18  90139 
7937314 ATHL1  ATH1, acid trehalase-like 1 (yeast)  80162 
8001946 LOC65331  hypothetical protein LOC653319  653319 
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 Cluster 2 
  ID Symbol Name EntrezID 
7915472  SLC2A1   solute carrier family 2 (facilitated glucose transporter), member 1  6513 
8004510  CD68   CD68 molecule  968 
8165552  NELF   nasal embryonic LHRH factor  26012 
8037594  RTN2   reticulon 2  6253 
8025368  SNAPC2   small nuclear RNA activating complex, polypeptide 2, 45kDa  6618 
8010804  NARF   nuclear prelamin A recognition factor  26502 
8037079  ATP1A3   ATPase, Na+ 478 
8100532  C4orf14   chromosome 4 open reading frame 14  84273 
8067140  CYP24A1   cytochrome P450, family 24, subfamily A, polypeptide 1  1591 
8068866  PKNOX1   PBX 5316 
7994769  CORO1A   coronin, actin binding protein, 1A  11151 
8108080  PHF15   PHD finger protein 15  23338 
7996137  KATNB1   katanin p80 (WD repeat containing) subunit B 1  10300 
8008664  AKAP1   A kinase (PRKA) anchor protein 1  8165 
8018305  HN1   hematological and neurological expressed 1  51155 
8017718  AXIN2   axin 2  8313 
8131387  USP42   ubiquitin specific peptidase 42  84132 
8110022 
 
ATP6V0E1   ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1  8992 
8000884  XTP3TPA   XTP3-transactivated protein A  79077 
8056784  DLX2   distal-less homeobox 2  1746 
8172471  PIM2   pim-2 oncogene  11040 
8029688  CD3EAP   CD3e molecule, epsilon associated protein  10849 
8012054  DLG4   discs, large homolog 4 (Drosophila)  1742 
8023995  FSTL3   follistatin-like 3 (secreted glycoprotein)  10272 
7948741  B3GAT3   beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)  26229 
8155707  TJP2   tight junction protein 2 (zona occludens 2)  9414 
7920642  MUC1   mucin 1, cell surface associated  4582 
7912994 
 RP1-
93P18.1   hypothetical protein LOC126917  126917 
8016463  HOXB6   homeobox B6  3216 
7977397  CRIP2   cysteine-rich protein 2  1397 
7953564  C12orf57   chromosome 12 open reading frame 57  113246 
8014825  FBXL20   F-box and leucine-rich repeat protein 20  84961 
7930194  CNNM2   cyclin M2  54805 
8108447  CXXC5   CXXC finger 5  51523 
8034202  RAB3D   RAB3D, member RAS oncogene family  9545 
8039340  TNNT1   troponin T type 1 (skeletal, slow)  7138 
7998055  MC1R  
 melanocortin 1 receptor (alpha melanocyte stimulating hormone 
receptor)  4157 
7905329  MLLT11   myeloid 10962 
8014956  NR1D1   nuclear receptor subfamily 1, group D, member 1  9572 
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8007745  HEXIM1   hexamethylene bis-acetamide inducible 1  10614 
8149330  CTSB   cathepsin B  1508 
8073890  GRAMD4   GRAM domain containing 4  23151 
8035249  NR2F6   nuclear receptor subfamily 2, group F, member 6  2063 
7913644  E2F2   E2F transcription factor 2  1870 
8070269  DSCR3   Down syndrome critical region gene 3  10311 
8027002  GDF15   growth differentiation factor 15  9518 
8115831  DUSP1   dual specificity phosphatase 1  1843 
7967202  RHOF   ras homolog gene family, member F (in filopodia)  54509 
7948839  NXF1   nuclear RNA export factor 1  10482 
8067798  SOX18   SRY (sex determining region Y)-box 18  54345 
7930106 
 
TMEM180   transmembrane protein 180  79847 
7997533  OSGIN1   oxidative stress induced growth inhibitor 1  29948 
8037579  ERCC1  
 excision repair cross-complementing rodent repair deficiency, 
complementation group 1 (includes overlapping antisense 
sequence)  2067 
7995783  MT2A   metallothionein 2A  4502 
7914094  WASF2   WAS protein family, member 2  10163 
7906061  SYT11   synaptotagmin XI  23208 
7955873  HOXC6   homeobox C6  3223 
8066117  SAMHD1   SAM domain and HD domain 1  25939 
8065889  UQCC   ubiquinol-cytochrome c reductase complex chaperone  55245 
8037408  KCNN4   potassium intermediate 3783 
8093130  RNF168   ring finger protein 168  165918 
8081838  CDGAP   Cdc42 GTPase-activating protein  57514 
8016438  HOXB2   homeobox B2  3212 
7936041  ARL3   ADP-ribosylation factor-like 3  403 
7956009  METTL7B   methyltransferase like 7B  196410 
7988212  ELL3   elongation factor RNA polymerase II-like 3  80237 
8007471  NBR1   neighbor of BRCA1 gene 1  4077 
8131091  MAFK  
 v-maf musculoaponeurotic fibrosarcoma oncogene homolog K 
(avian)  7975 
8133728  ZP3   zona pellucida glycoprotein 3 (sperm receptor)  7784 
8076547  TTLL1   tubulin tyrosine ligase-like family, member 1  25809 
7993713  IQCK   IQ motif containing K  124152 
8155268  POLR1E   polymerase (RNA) I polypeptide E, 53kDa  64425 
8101411  LIN54   lin-54 homolog (C. elegans)  132660 
7915160  RRAGC   Ras-related GTP binding C  64121 
8102482  SEC24D   SEC24 related gene family, member D (S. cerevisiae)  9871 
8141728  RABL5   RAB, member RAS oncogene family-like 5  64792 
8016452  HOXB4   homeobox B4  3214 
7999553  FLJ11151   hypothetical protein FLJ11151  55313 
8114526  DNAJC18   DnaJ (Hsp40) homolog, subfamily C, member 18  202052 
7930454  PDCD4   programmed cell death 4 (neoplastic transformation inhibitor)  27250 
8040103  ID2  
 inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein  3398 
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8074364  DGCR14   DiGeorge syndrome critical region gene 14  8220 
8021653  SERPINB8   serpin peptidase inhibitor, clade B (ovalbumin), member 8  5271 
8058388 
   8055952 NR4A2  nuclear receptor subfamily 4, group A, member 2  4929 
8034390  ZNF799   zinc finger protein 799  90576 
  Cluster 3 
 ID Symbol 
8029347 ZNF230 
7990429 C15orf17 
8125818 C6orf1 
8084880 HES1 
7953695 NA 
7920875 SCARNA4 
8063345 SNORD12C 
7928821 NA 
8055965 NA 
    Cluster 4 
   ID Symbol Name EntrezID 
8155754  MAMDC2   MAM domain containing 2  256691 
8135576  TES   testis derived transcript (3 LIM domains)  26136 
8085608  HACL1   2-hydroxyacyl-CoA lyase 1  26061 
8116921  EDN1   endothelin 1  1906 
8117219  THEM2   thioesterase superfamily member 2  55856 
8078544  MLH1   mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)  4292 
8096635  NFKB1  
 nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 1  4790 
8150014  INTS9   integrator complex subunit 9  55756 
8120411  PRIM2   primase, DNA, polypeptide 2 (58kDa)  5558 
8132515  BLVRA   biliverdin reductase A  644 
7988687  GABPB1   GA binding protein transcription factor, beta subunit 2  2553 
8129497  EPB41L2   erythrocyte membrane protein band 4.1-like 2  2037 
7928107  H2AFY2   H2A histone family, member Y2  55506 
7936734  FGFR2   fibroblast growth factor receptor 2  2263 
8068200  C21orf119   chromosome 21 open reading frame 119  84996 
8106709  ATG10   ATG10 autophagy related 10 homolog (S. cerevisiae)  83734 
8068375  FAM165B   family with sequence similarity 165, member B  54065 
8164587  TOR1A   torsin family 1, member A (torsin A)  1861 
8175250 
   7928671 C10orf57  chromosome 10 open reading frame 57  80195 
7924388  BPNT1   3'(2'), 5'-bisphosphate nucleotidase 1  10380 
7977841  C14orf94   chromosome 14 open reading frame 94  54930 
7971184  MRPS31   mitochondrial ribosomal protein S31  10240 
8053496  POLR1A   polymerase (RNA) I polypeptide A, 194kDa  25885 
8157843  RABEPK   Rab9 effector protein with kelch motifs  10244 
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8069676  ADAMTS1  
 ADAM metallopeptidase with thrombospondin type 1 
motif, 1  9510 
8150276 
 
PPAPDC1B  
 phosphatidic acid phosphatase type 2 domain containing 
1B  84513 
8124416  HIST1H3D   histone cluster 1, H3d  8351 
7943919  TTC12   tetratricopeptide repeat domain 12  54970 
8050060  TSSC1   tumor suppressing subtransferable candidate 1  7260 
7921970  ALDH9A1   aldehyde dehydrogenase 9 family, member A1  223 
8173531  HDAC8   histone deacetylase 8  55869 
7913858  PAQR7   progestin and adipoQ receptor family member VII  164091 
8148955  C8orf33   chromosome 8 open reading frame 33  65265 
7991216  DET1   de-etiolated homolog 1 (Arabidopsis)  55070 
7991209  MRPL46   mitochondrial ribosomal protein L46  26589 
7930148  SFXN2   sideroflexin 2  118980 
7904695  SEC22B   SEC22 vesicle trafficking protein homolog B (S. cerevisiae)  9554 
7926661  MSRB2   methionine sulfoxide reductase B2  22921 
7967287  ZCCHC8   zinc finger, CCHC domain containing 8  55596 
8149877  PNMA2   paraneoplastic antigen MA2  10687 
7925480  FH   fumarate hydratase  2271 
8115210  TNIP1   TNFAIP3 interacting protein 1  10318 
8169240  PRPS1   phosphoribosyl pyrophosphate synthetase 1  5631 
7938528  PARVA   parvin, alpha  55742 
8169028  NGFRAP1  
 nerve growth factor receptor (TNFRSF16) associated 
protein 1  27018 
8126058  PPIL1   peptidylprolyl isomerase (cyclophilin)-like 1  51645 
8103188  PET112L   PET112-like (yeast)  5188 
7952339  LOC85389   RNA, small nucleolar  85389 
7905088 
 
HIST2H2A
C   histone cluster 2, H2ac  8338 
8122242  PEX7   peroxisomal biogenesis factor 7  5191 
8021727  CNDP2   CNDP dipeptidase 2 (metallopeptidase M20 family)  55748 
8054377  FHL2   four and a half LIM domains 2  2274 
8002266  CTF8  
 chromosome transmission fidelity factor 8 homolog (S. 
cerevisiae)  54921 
8054077  ACTR1B  
 ARP1 actin-related protein 1 homolog B, centractin beta 
(yeast)  10120 
8118319 
   8059249 OBSL1  obscurin-like 1  23363 
8160036  C9orf123   chromosome 9 open reading frame 123  90871 
8108370  EGR1   early growth response 1  1958 
8169272  ATG4A   ATG4 autophagy related 4 homolog A (S. cerevisiae)  115201 
7921526  PIGM   phosphatidylinositol glycan anchor biosynthesis, class M  93183 
7944869  SPA17   sperm autoantigenic protein 17  53340 
8150364  TM2D2   TM2 domain containing 2  83877 
7902290  CTH   cystathionase (cystathionine gamma-lyase)  1491 
8043848  MRPL30   mitochondrial ribosomal protein L30  51263 
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7935058  FER1L3   fer-1-like 3, myoferlin (C. elegans)  26509 
8124423 
 
HIST1H2B
G   histone cluster 1, H2bg  8339 
8049532  LRRFIP1   leucine rich repeat (in FLII) interacting protein 1  9208 
7978644  NFKBIA  
 nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, alpha  4792 
8156295  SECISBP2   SECIS binding protein 2  79048 
7953594  EMG1   EMG1 nucleolar protein homolog (S. cerevisiae)  10436 
8044133  NCK2   NCK adaptor protein 2  8440 
8081241  C3orf26   chromosome 3 open reading frame 26  84319 
7985757  MRPS11   mitochondrial ribosomal protein S11  64963 
8062312  MYL9   myosin, light chain 9, regulatory  10398 
8138602  DFNA5   deafness, autosomal dominant 5  1687 
7933186  ZNF32   zinc finger protein 32  7580 
7899436  SESN2   sestrin 2  83667 
8117426 
 
HIST1H2B
H   histone cluster 1, H2bh  8345 
7942315  LRRC51   leucine rich repeat containing 51  220074 
7909561  C1orf97   chromosome 1 open reading frame 97  84791 
7932209 
   8123678 C6orf145  chromosome 6 open reading frame 145  221749 
7965403  LUM   lumican  4060 
8008933  BCAS3   breast carcinoma amplified sequence 3  54828 
8160431 
 
LOC55420
2   hypothetical LOC554202  554202 
7903203  SNX7   sorting nexin 7  51375 
7925033  C1orf131   chromosome 1 open reading frame 131  128061 
8055668 
   
7964248 
 
SNORD59A   small nucleolar RNA, C 26789 
8115164 
   
8005951 
 
SNORD42B   small nucleolar RNA, C 26808 
8114468  SNORD63   small nucleolar RNA, C 26785 
8001748  SNORA50   small nucleolar RNA, H 677830 
7922412  SNORD77   small nucleolar RNA, C 692197 
8059712  SNORD82   small nucleolar RNA, C 25826 
8062890  PABPC1L   poly(A) binding protein, cytoplasmic 1-like  80336 
7899392  SCARNA1   small Cajal body-specific RNA 1  677774 
8174507 
 
SNORD96B   small nucleolar RNA, C 692226 
    Cluster 5 
   ID Symbol Name EntrezID 
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7985119  HMG20A   high-mobility group 20A  10363 
8085984  OSBPL10   oxysterol binding protein-like 10  114884 
7979813  ZFP36L1   zinc finger protein 36, C3H type-like 1  677 
8113761  ZNF608   zinc finger protein 608  57507 
7967230  DIABLO   diablo homolog (Drosophila)  56616 
8103853 
 
MGC4580
0   hypothetical protein LOC90768  90768 
8046922  COL3A1   collagen, type III, alpha 1  1281 
8102214  PAPSS1   3'-phosphoadenosine 5'-phosphosulfate synthase 1  9061 
8107814  ISOC1   isochorismatase domain containing 1  51015 
7918034  DPH5   DPH5 homolog (S. cerevisiae)  51611 
8128383  COQ3   coenzyme Q3 homolog, methyltransferase (S. cerevisiae)  51805 
8136341  BPGM   2,3-bisphosphoglycerate mutase  669 
8069744  RWDD2B   RWD domain containing 2B  10069 
8099570  C4orf30   chromosome 4 open reading frame 30  54876 
7975268  ARG2   arginase, type II  384 
8003922  MED11   mediator complex subunit 11  400569 
8111101  ANKH   ankylosis, progressive homolog (mouse)  56172 
7935660  DNMBP   dynamin binding protein  23268 
7959025  RNFT2   ring finger protein, transmembrane 2  84900 
8123961  TBC1D7   TBC1 domain family, member 7  51256 
7938301  C11orf17   chromosome 11 open reading frame 17  56672 
8078834  WDR48   WD repeat domain 48  57599 
7903803  AHCYL1   S-adenosylhomocysteine hydrolase-like 1  10768 
8106776  COX7C   cytochrome c oxidase subunit VIIc  1350 
8082816  SRPRB   signal recognition particle receptor, B subunit  58477 
8057689  OSGEPL1   O-sialoglycoprotein endopeptidase-like 1  64172 
7968029  PCOTH   prostate collagen triple helix  542767 
7951781  C11orf71   chromosome 11 open reading frame 71  54494 
7923516  CYB5R1   cytochrome b5 reductase 1  51706 
8131583  BZW2   basic leucine zipper and W2 domains 2  28969 
8124510 
 
HIST1H2BL   histone cluster 1, H2bl  8340 
8177232  JARID1D   jumonji, AT rich interactive domain 1D  8284 
7964834  CPM   carboxypeptidase M  1368 
8143188  CREB3L2   cAMP responsive element binding protein 3-like 2  64764 
8084092  NDUFB5  
 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 
16kDa  4711 
8025414  RAB11B   RAB11B, member RAS oncogene family  9230 
8041179  CLIP4  
 CAP-GLY domain containing linker protein family, member 
4  79745 
8023261  ACAA2   acetyl-Coenzyme A acyltransferase 2  10449 
8045349  MGAT5  
 mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase  4249 
8059319  FARSB   phenylalanyl-tRNA synthetase, beta subunit  10056 
8144802  PDGFRL   platelet-derived growth factor receptor-like  5157 
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7952069  C11orf60   chromosome 11 open reading frame 60  56912 
7943413  BIRC3   baculoviral IAP repeat-containing 3  330 
7934178  PCBD1   pterin-4 alpha-carbinolamine dehydratase 5092 
8117408 
 
HIST1H2A
E   histone cluster 1, H2ae  3012 
8081358 
 
LOC10000
9676   Putative uncharacterized protein LOC100009676  100009676 
8154100  VLDLR   very low density lipoprotein receptor  7436 
8117580  HIST1H2AI   histone cluster 1, H2ai  8329 
7906662  UFC1   ubiquitin-fold modifier conjugating enzyme 1  51506 
7939411  C11orf74   chromosome 11 open reading frame 74  119710 
8126360  MED20   mediator complex subunit 20  9477 
7900167  CDCA8   cell division cycle associated 8  55143 
8123695  PECI   peroxisomal D3,D2-enoyl-CoA isomerase  10455 
7903786  CSF1   colony stimulating factor 1 (macrophage)  1435 
8089993  WDR5B   WD repeat domain 5B  54554 
8145470  DPYSL2   dihydropyrimidinase-like 2  1808 
8043187  MAT2A   methionine adenosyltransferase II, alpha  4144 
8149942  CCDC25   coiled-coil domain containing 25  55246 
8123802  TXNDC5   thioredoxin domain containing 5  81567 
8114425  CDC25C   cell division cycle 25 homolog C (S. pombe)  995 
8124385  HIST1H4B   histone cluster 1, H4b  8366 
7918925  TRIM45   tripartite motif-containing 45  80263 
7961483  HIST4H4   histone cluster 4, H4  121504 
8173261  KIAA1166   KIAA1166  55906 
7982723  IVD   isovaleryl Coenzyme A dehydrogenase  3712 
8113773  ALDH7A1   aldehyde dehydrogenase 7 family, member A1  501 
8011407  TAX1BP3   Tax1 (human T-cell leukemia virus type I) binding protein 3  30851 
8001537  NIP30   NEFA-interacting nuclear protein NIP30  80011 
8124537  HIST1H3J   histone cluster 1, H3j  8356 
    Cluster 6 
   ID Symbol Name EntrezID 
7965335  DUSP6   dual specificity phosphatase 6  1848 
8174513  CHRDL1   chordin-like 1  91851 
7988260  FRMD5   FERM domain containing 5  84978 
7966026  NUAK1   NUAK family, SNF1-like kinase, 1  9891 
7984686  BBS4   Bardet-Biedl syndrome 4  585 
7982597  THBS1   thrombospondin 1  7057 
7919780  GOLPH3L   golgi phosphoprotein 3-like  55204 
7954036  DDX47   DEAD (Asp-Glu-Ala-Asp) box polypeptide 47  51202 
8096160 
 
ARHGAP24   Rho GTPase activating protein 24  83478 
8103859  DCTD   dCMP deaminase  1635 
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8096314  PKD2   polycystic kidney disease 2 (autosomal dominant)  5311 
8088065  SFMBT1   Scm-like with four mbt domains 1  51460 
8120602  OGFRL1   opioid growth factor receptor-like 1  79627 
7971565  P2RY5   purinergic receptor P2Y, G-protein coupled, 5  10161 
8106730  XRCC4  
 X-ray repair complementing defective repair in Chinese 
hamster cells 4  7518 
7951259  MMP10   matrix metallopeptidase 10 (stromelysin 2)  4319 
8002904  ADAT1   adenosine deaminase, tRNA-specific 1  23536 
7913883  PAFAH2   platelet-activating factor acetylhydrolase 2, 40kDa  5051 
8102792  PCDH18   protocadherin 18  54510 
8019842  TYMS   thymidylate synthetase  7298 
8144742  EFHA2   EF-hand domain family, member A2  286097 
8019954  FLJ35776   hypothetical LOC649446  649446 
8094301  SLIT2   slit homolog 2 (Drosophila)  9353 
8160602  APTX   aprataxin  54840 
7972217  SPRY2   sprouty homolog 2 (Drosophila)  10253 
8083272  GYG1   glycogenin 1  2992 
8091103  TFDP2   transcription factor Dp-2 (E2F dimerization partner 2)  7029 
7901363  CDKN2C   cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)  1031 
8117120  ID4  
 inhibitor of DNA binding 4, dominant negative helix-loop-
helix protein  3400 
7932616  ABI1   abl-interactor 1  10006 
8045860  PKP4   plakophilin 4  8502 
8134091  CLDN12   claudin 12  9069 
8058373  WDR12   WD repeat domain 12  55759 
8113726  PPIC   peptidylprolyl isomerase C (cyclophilin C)  5480 
8078330  RBMS3   RNA binding motif, single stranded interacting protein  27303 
7980403  C14orf133   chromosome 14 open reading frame 133  63894 
8057620  COL5A2   collagen, type V, alpha 2  1290 
7918323  SORT1   sortilin 1  6272 
8122265  TNFAIP3   tumor necrosis factor, alpha-induced protein 3  7128 
8120860  BCKDHB  
 branched chain keto acid dehydrogenase E1, beta 
polypeptide  594 
8116983  CD83   CD83 molecule  9308 
8041553  GEMIN6   gem (nuclear organelle) associated protein 6  79833 
8075673  RBM9   RNA binding motif protein 9  23543 
7925904  AKR1CL2   aldo-keto reductase family 1, member C-like 2  83592 
8092328  MCCC1   methylcrotonoyl-Coenzyme A carboxylase 1 (alpha)  56922 
8058258  ALS2CR4  
 amyotrophic lateral sclerosis 2 (juvenile) chromosome 
region, candidate 4  65062 
8147573  OSR2   odd-skipped related 2 (Drosophila)  116039 
7940079  CTNND1   catenin (cadherin-associated protein), delta 1  1500 
7979551  PPP2R5E  
 protein phosphatase 2, regulatory subunit B', epsilon 
isoform  5529 
7938563  ARNTL   aryl hydrocarbon receptor nuclear translocator-like  406 
7964271  PRIM1   primase, DNA, polypeptide 1 (49kDa)  5557 
8175252 
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8097867  KIAA0922   KIAA0922  23240 
8084766  TP63   tumor protein p63  8626 
8121685  DCBLD1   discoidin, CUB and LCCL domain containing 1  285761 
8111153  MYO10   myosin X  4651 
8123274  MAP3K4   mitogen-activated protein kinase kinase kinase 4  4216 
8156199  DAPK1   death-associated protein kinase 1  1612 
7997332  NUDT7  
 nudix (nucleoside diphosphate linked moiety X)-type motif 
7  283927 
8111430  AMACR   alpha-methylacyl-CoA racemase  23600 
7916727  ITGB3BP   integrin beta 3 binding protein (beta3-endonexin)  23421 
7951614  PPP2R1B  
 protein phosphatase 2 (formerly 2A), regulatory subunit A, 
beta isoform  5519 
8084165  SOX2   SRY (sex determining region Y)-box 2  6657 
8171205  NLGN4X   neuroligin 4, X-linked  57502 
8138474  SP8   Sp8 transcription factor  221833 
8042259  MDH1   malate dehydrogenase 1, NAD (soluble)  4190 
8109732  MAT2B   methionine adenosyltransferase II, beta  27430 
8135392  HBP1   HMG-box transcription factor 1  26959 
8114320  HNRNPA0   heterogeneous nuclear ribonucleoprotein A0  10949 
7991485  TTC23   tetratricopeptide repeat domain 23  64927 
7912166  RERE   arginine-glutamic acid dipeptide (RE) repeats  473 
8081953  GTF2E1   general transcription factor IIE, polypeptide 1, alpha 56kDa  2960 
8095834 
 
SHROOM3   shroom family member 3  57619 
7935403 
 
ARHGAP19   Rho GTPase activating protein 19  84986 
8015039  SMARCE1   SWI 6605 
8122409  PEX3   peroxisomal biogenesis factor 3  8504 
8082229  UMPS   uridine monophosphate synthetase  7372 
8042495  RY1   putative nucleic acid binding protein RY-1  11017 
8145736  NRG1   neuregulin 1  3084 
8022902  INO80C   INO80 complex subunit C  125476 
8103911  IRF2   interferon regulatory factor 2  3660 
8095728  EREG   epiregulin  2069 
7922646  IFRG15   interferon responsive gene 15  64163 
7932433  NSUN6   NOL1 221078 
8088151  ACTR8   ARP8 actin-related protein 8 homolog (yeast)  93973 
8097692  EDNRA   endothelin receptor type A  1909 
7922268  KIFAP3   kinesin-associated protein 3  22920 
7985349  MESDC1   mesoderm development candidate 1  59274 
8113800  FBN2   fibrillin 2  2201 
7904018 
 
CTTNBP2N
L   CTTNBP2 N-terminal like  55917 
8175248 
   8111993 FGF10  fibroblast growth factor 10  2255 
8015969  UBTF   upstream binding transcription factor, RNA polymerase I  7343 
 Appendix 
 
 
182 
 
7975238  PLEKHH1  
 pleckstrin homology domain containing, family H (with 
MyTH4 domain) member 1  57475 
8082075  DTX3L   deltex 3-like (Drosophila)  151636 
8078147  BTD   biotinidase  686 
8105040  OSMR   oncostatin M receptor  9180 
8113413  NUDT12  
 nudix (nucleoside diphosphate linked moiety X)-type motif 
12  83594 
8088803  EIF4E3   eukaryotic translation initiation factor 4E family member 3  317649 
8099235 
 
MRFAP1L1   Morf4 family associated protein 1-like 1  114932 
8069880  TIAM1   T-cell lymphoma invasion and metastasis 1  7074 
8054364  TGFBRAP1  
 transforming growth factor, beta receptor associated 
protein 1  9392 
8108683  PCDHB2   protocadherin beta 2  56133 
7901592  C1orf83   chromosome 1 open reading frame 83  127428 
8117537  HIST1H4I   histone cluster 1, H4i  8294 
8121749  GJA1   gap junction protein, alpha 1, 43kDa  2697 
8097307  INTU   inturned planar cell polarity effector homolog (Drosophila)  27152 
7929032  FAS   Fas (TNF receptor superfamily, member 6)  355 
8089701  ZBTB20   zinc finger and BTB domain containing 20  26137 
8064978  JAG1   jagged 1 (Alagille syndrome)  182 
8128284  EPHA7   EPH receptor A7  2045 
8112709  C5orf37   chromosome 5 open reading frame 37  134359 
8135915  HIG2   hypoxia-inducible protein 2  29923 
8134201  GATAD1   GATA zinc finger domain containing 1  57798 
8046792  DUSP19   dual specificity phosphatase 19  142679 
8158725  ABL1   c-abl oncogene 1, receptor tyrosine kinase  25 
8069532  HSPA13   heat shock protein 70kDa family, member 13  6782 
8102311  CASP6   caspase 6, apoptosis-related cysteine peptidase  839 
8060977  C20orf94   chromosome 20 open reading frame 94  128710 
8021565  PHLPP   PH domain and leucine rich repeat protein phosphatase  23239 
8102468  PRSS12   protease, serine, 12 (neurotrypsin, motopsin)  8492 
7959002  SDSL   serine dehydratase-like  113675 
7913864  C1orf215   chromosome 1 open reading frame 215  149421 
8147439  PLEKHF2  
 pleckstrin homology domain containing, family F (with 
FYVE domain) member 2  79666 
8143327  PARP12   poly (ADP-ribose) polymerase family, member 12  64761 
8002941 
 
ADAMTS1
8  
 ADAM metallopeptidase with thrombospondin type 1 
motif, 18  170692 
7969533  SLAIN1   SLAIN motif family, member 1  122060 
7995552  CYLD   cylindromatosis (turban tumor syndrome)  1540 
7904907  BCL9   B-cell CLL 283149 
8100085  GNPDA2   glucosamine-6-phosphate deaminase 2  132789 
8087201  IHPK2   inositol hexaphosphate kinase 2  51447 
7956826  TBC1D30   TBC1 domain family, member 30  23329 
7938390  ADM   adrenomedullin  133 
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8030391 
   8146198 POLB  polymerase (DNA directed), beta  5423 
8155824  TMC1   transmembrane channel-like 1  117531 
8174086  ARMCX6   armadillo repeat containing, X-linked 6  54470 
8107044  ERAP2   endoplasmic reticulum aminopeptidase 2  64167 
 
3. CoPub gene list 
cell differentiation -  25 genes 
  name symbol abstract count 
cysteine rich protein 2 CRIP2 6 
SRY box 18 SOX18 4 
coronin,actin binding protein,1A CORO1A 4 
inhibitor of DNA binding 2 ID2A 3 
v maf musculoaponeurotic fibrosarcoma oncogene homolog K MAFK 12 
hexamethylene bis acetamide inducible 1 HEXIM1 3 
follistatin like 3 FSTL3 3 
homeobox B2 HOXB2 8 
RAB3D,member RAS oncogene family RAB3D 4 
homeobox C6 HOXC6 4 
homeobox B4 HOXB4 9 
nuclear receptor subfamily 4,group A,member 2 NR4A2 12 
homeobox B6 HOXB6 4 
E2F transcription factor 2 E2F2 4 
cytochrome P450,family 24,subfamily A,polypeptide 1 CYP24A1 7 
mucin 1,cell surface associated MUC1 45 
potassium intermediate/small conductance calcium activated 
channel KCNN4 5 
dual specificity phosphatase 1 DUSP1 8 
solute carrier family 2,member 1 SLC2A1 29 
growth differentiation factor 15 GDF15 4 
CD68 molecule CD68 40 
cathepsin B CTSB 22 
zona pellucida glycoprotein 3 ZP3 3 
discs,large homolog 4 DLG4 5 
 
Cell growth – 39 genes 
  
name symbol 
abstract 
count 
interferon regulatory factor 2 IRF2 40 
transforming growth factor,beta receptor associated protein 1 
TGFBRAP
1 3 
PH domain and leucine rich repeat protein phosphatase PHLPP 4 
oncostatin M receptor OSMR 5 
transcription factor Dp 2 TFDP2 4 
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epiregulin EREG 11 
cyclin dependent kinase inhibitor 2C CDKN2C 27 
neuregulin 1 NRG1 74 
upstream binding transcription factor,RNA polymerase I UBTF 16 
T cell lymphoma invasion and metastasis 1 TIAM1 11 
dual specificity phosphatase 6 DUSP6 11 
thymidylate synthetase TYMS 163 
tumor necrosis factor,alpha induced protein 3 TNFAIP3 4 
HMG box transcription factor 1 HBP1 3 
jagged 1 JAG1 24 
v abl Abelson murine leukemia viral oncogene homolog 1 ABL1 249 
gap junction protein,alpha 1,43kDa GJA1 107 
thrombospondin 1 THBS1 77 
RNA binding motif protein 9 RBM9 4 
sprouty homolog 2 SPRY2 3 
dCMP deaminase DCTD 6 
cylindromatosis CYLD 4 
catenin,delta 1 CTNND1 15 
Fas APT1 409 
polycystic kidney disease 2 PKD2 12 
tumor protein p73 like TP73L 26 
death associated protein kinase 1 DAPK1 6 
shroom family member 3 
SHROOM
3 4 
abl interactor 1 ABI1 4 
adrenomedullin ADM 38 
caspase 6,apoptosis related cysteine peptidase CASP6 10 
polymerase,beta POLB 25 
endothelin receptor type A EDNRA 34 
SRY box 2 SOX2 15 
fibroblast growth factor 10 FGF10 6 
uridine monophosphate synthetase UMPS 4 
aryl hydrocarbon receptor nuclear translocator like ARNTL 4 
matrix metallopeptidase 10 MMP10 6 
CD83 molecule CD83 9 
 
apoptosis– 49 genes 
  name symbol abstract count 
Fas APT1 11734 
caspase 6,apoptosis related cysteine peptidase CASP6 332 
inositol hexaphosphate kinase 2 IHPK2 7 
death associated protein kinase 1 DAPK1 80 
tumor protein p73 like TP73L 231 
tumor necrosis factor,alpha induced protein 3 TNFAIP3 24 
transcription factor Dp 2 TFDP2 10 
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transforming growth factor,beta receptor associated protein 1 TGFBRAP1 4 
mitogen activated protein kinase kinase kinase 4 MAP3K4 11 
Rho GTPase activating protein 24 ARHGAP24 3 
hypoxia inducible protein 2 HIG2 3 
cyclin dependent kinase inhibitor 2C CDKN2C 52 
v abl Abelson murine leukemia viral oncogene homolog 1 ABL1 889 
dual specificity phosphatase 6 DUSP6 28 
interferon regulatory factor 2 IRF2 30 
oncostatin M receptor OSMR 5 
methionine adenosyltransferase II,beta MAT2B 4 
thrombospondin 1 THBS1 168 
cylindromatosis CYLD 12 
PH domain and leucine rich repeat protein phosphatase PHLPP 3 
CD83 molecule CD83 87 
jagged 1 JAG1 38 
X ray repair complementing defective repair in Chinese hamster cells 
4 XRCC4 19 
T cell lymphoma invasion and metastasis 1 TIAM1 13 
HMG box transcription factor 1 HBP1 4 
sprouty homolog 2 SPRY2 6 
polycystic kidney disease 2 PKD2 25 
matrix metallopeptidase 10 MMP10 36 
neuregulin 1 NRG1 66 
fibroblast growth factor 10 FGF10 28 
sortilin 1 SORT1 3 
gap junction protein,alpha 1,43kDa GJA1 137 
upstream binding transcription factor,RNA polymerase I UBTF 10 
thymidylate synthetase TYMS 143 
EPH receptor A7 EPHA7 3 
adrenomedullin ADM 73 
aprataxin APTX 5 
epiregulin EREG 5 
RNA binding motif protein 9 RBM9 4 
catenin,delta 1 CTNND1 16 
peptidylprolyl isomerase C PPIC 3 
polymerase,beta POLB 50 
slit homolog 2 SLIT2 3 
Sp8 transcription factor SP8 3 
alpha methylacyl CoA racemase AMACR 5 
fibrillin 2 FBN2 3 
SRY box 2 SOX2 21 
aryl hydrocarbon receptor nuclear translocator like ARNTL 9 
abl interactor 1 ABI1 3 
   cell adhesion – 27 genes 
  name symbol abstract count 
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catenin,delta 1 CTNND1 178 
neuroligin 4,X linked NLGN4X 8 
plakophilin 4 PKP4 6 
myosin X MYO10 6 
T cell lymphoma invasion and metastasis 1 TIAM1 16 
thrombospondin 1 THBS1 143 
shroom family member 3 SHROOM3 13 
tumor necrosis factor,alpha induced protein 3 TNFAIP3 3 
EPH receptor A7 EPHA7 3 
fibrillin 2 FBN2 4 
epiregulin EREG 4 
gap junction protein,alpha 1,43kDa GJA1 67 
abl interactor 1 ABI1 5 
death associated protein kinase 1 DAPK1 6 
polycystic kidney disease 2 PKD2 8 
dual specificity phosphatase 6 DUSP6 4 
SRY box 2 SOX2 15 
jagged 1 JAG1 9 
tumor protein p73 like TP73L 16 
v abl Abelson murine leukemia viral oncogene homolog 1 ABL1 89 
matrix metallopeptidase 10 MMP10 10 
Fas APT1 166 
interferon regulatory factor 2 IRF2 3 
fibroblast growth factor 10 FGF10 5 
CD83 molecule CD83 13 
caspase 6,apoptosis related cysteine peptidase CASP6 4 
neuregulin 1 NRG1 11 
 
growth – 61 genes 
  
name symbol 
abstract 
count 
transforming growth factor,beta receptor associated protein 1 
TGFBRAP
1 19 
fibroblast growth factor 10 FGF10 390 
epiregulin EREG 127 
neuregulin 1 NRG1 837 
sprouty homolog 2 SPRY2 61 
nudix type motif 7 NUDT7 3 
thrombospondin 1 THBS1 827 
protein phosphatase 2,regulatory subunit A,beta isoform PPP2R1B 6 
transcription factor Dp 2 TFDP2 14 
dual specificity phosphatase 6 DUSP6 73 
slit homolog 2 SLIT2 35 
oncostatin M receptor OSMR 14 
cyclin dependent kinase inhibitor 2C CDKN2C 103 
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interferon regulatory factor 2 IRF2 71 
jagged 1 JAG1 162 
T cell lymphoma invasion and metastasis 1 TIAM1 50 
abl interactor 1 ABI1 57 
B cell CLL/lymphoma 9 like BCL9L 4 
chordin like 1 CHRDL1 7 
WD repeat domain 12 WDR12 3 
inositol hexaphosphate kinase 2 IHPK2 4 
mitogen activated protein kinase kinase kinase 4 MAP3K4 12 
hypoxia inducible protein 2 HIG2 3 
upstream binding transcription factor,RNA polymerase I UBTF 54 
thymidylate synthetase TYMS 701 
v abl Abelson murine leukemia viral oncogene homolog 1 ABL1 1431 
PH domain and leucine rich repeat protein phosphatase PHLPP 7 
fibrillin 2 FBN2 26 
purinergic receptor P2Y,G protein coupled,5 P2RY5 3 
EPH receptor A7 EPHA7 16 
HMG box transcription factor 1 HBP1 12 
gap junction protein,alpha 1,43kDa GJA1 545 
SRY box 2 SOX2 156 
NUAK family,SNF1 like kinase,1 NUAK1 3 
tumor protein p73 like TP73L 161 
catenin,delta 1 CTNND1 82 
matrix metallopeptidase 10 MMP10 135 
plakophilin 4 PKP4 5 
uridine monophosphate synthetase UMPS 47 
Fas APT1 2598 
methionine adenosyltransferase II,beta MAT2B 6 
adrenomedullin ADM 288 
primase,polypeptide 1,49kDa PRIM1 3 
Sp8 transcription factor SP8 15 
death associated protein kinase 1 DAPK1 32 
cylindromatosis CYLD 18 
shroom family member 3 
SHROOM
3 24 
methylcrotonoyl Coenzyme A carboxylase 1 MCCC1 4 
myosin X MYO10 7 
collagen,type V,alpha 2 COL5A2 6 
caspase 6,apoptosis related cysteine peptidase CASP6 50 
RNA binding motif protein 9 RBM9 13 
sortilin 1 SORT1 6 
peptidylprolyl isomerase C PPIC 11 
polycystic kidney disease 2 PKD2 48 
peroxisomal biogenesis factor 3 PEX3 5 
glycogenin 1 GYG1 8 
tumor necrosis factor,alpha induced protein 3 TNFAIP3 7 
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endothelin receptor type A EDNRA 219 
dCMP deaminase DCTD 18 
protease,serine,12 PRSS12 4 
 
cell proliferation  - 41 genes 
  name symbol abstract count 
WD repeat domain 12 WDR12 5 
sprouty homolog 2 SPRY2 16 
transcription factor Dp 2 TFDP2 9 
fibroblast growth factor 10 FGF10 71 
cyclin dependent kinase inhibitor 2C CDKN2C 46 
CD83 molecule CD83 193 
epiregulin EREG 18 
primase,polypeptide 1,49kDa PRIM1 3 
oncostatin M receptor OSMR 5 
dual specificity phosphatase 6 DUSP6 21 
polycystic kidney disease 2 PKD2 31 
neuregulin 1 NRG1 111 
thrombospondin 1 THBS1 138 
HMG box transcription factor 1 HBP1 5 
PH domain and leucine rich repeat protein phosphatase PHLPP 3 
jagged 1 JAG1 33 
tumor protein p73 like TP73L 56 
upstream binding transcription factor,RNA polymerase I UBTF 15 
tumor necrosis factor,alpha induced protein 3 TNFAIP3 5 
catenin,delta 1 CTNND1 25 
gap junction protein,alpha 1,43kDa GJA1 139 
abl interactor 1 ABI1 7 
Fas APT1 709 
v abl Abelson murine leukemia viral oncogene homolog 1 ABL1 281 
T cell lymphoma invasion and metastasis 1 TIAM1 7 
cylindromatosis CYLD 5 
SRY box 2 SOX2 36 
caspase 6,apoptosis related cysteine peptidase CASP6 17 
interferon regulatory factor 2 IRF2 10 
adrenomedullin ADM 66 
endothelin receptor type A EDNRA 74 
aryl hydrocarbon receptor nuclear translocator like ARNTL 12 
thymidylate synthetase TYMS 88 
Sp8 transcription factor SP8 3 
dCMP deaminase DCTD 4 
death associated protein kinase 1 DAPK1 4 
polymerase,beta POLB 23 
matrix metallopeptidase 10 MMP10 10 
X ray repair complementing defective repair in Chinese hamster cells XRCC4 3 
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4 
uridine monophosphate synthetase UMPS 4 
biotinidase BTD 4 
 
tissue regeneration – 5 genes 
  name symbol abstract count 
SRY box 2 SOX2 7 
fibroblast growth factor 10 FGF10 3 
jagged 1 JAG1 3 
thrombospondin 1 THBS1 3 
gap junction protein,alpha 1,43kDa GJA1 4 
  
cell migration – 23 genes 
  name symbol abstract count 
slit homolog 2 SLIT2 18 
T cell lymphoma invasion and metastasis 1 TIAM1 30 
shroom family member 3 SHROOM3 13 
sprouty homolog 2 SPRY2 7 
myosin X MYO10 3 
catenin,delta 1 CTNND1 27 
abl interactor 1 ABI1 9 
thrombospondin 1 THBS1 81 
sortilin 1 SORT1 3 
EPH receptor A7 EPHA7 3 
matrix metallopeptidase 10 MMP10 13 
neuregulin 1 NRG1 28 
jagged 1 JAG1 7 
cyclin dependent kinase inhibitor 2C CDKN2C 3 
gap junction protein,alpha 1,43kDa GJA1 30 
v abl Abelson murine leukemia viral oncogene homolog 1 ABL1 44 
fibroblast growth factor 10 FGF10 3 
tumor protein p73 like TP73L 5 
adrenomedullin ADM 10 
CD83 molecule CD83 6 
Fas APT1 54 
SRY box 2 SOX2 3 
endothelin receptor type A EDNRA 6 
 
Phosphorylation – 50 genes 
  name symbol abstract count 
NUAK family,SNF1 like kinase,1 NUAK1 7 
B cell CLL/lymphoma 9 like BCL9L 5 
oncostatin M receptor OSMR 11 
dual specificity phosphatase 6 DUSP6 50 
 Appendix 
 
 
190 
 
PH domain and leucine rich repeat protein phosphatase PHLPP 9 
sprouty homolog 2 SPRY2 23 
catenin,delta 1 CTNND1 102 
mitogen activated protein kinase kinase kinase 4 MAP3K4 11 
epiregulin EREG 25 
T cell lymphoma invasion and metastasis 1 TIAM1 32 
cyclin dependent kinase inhibitor 2C CDKN2C 61 
neuregulin 1 NRG1 210 
v abl Abelson murine leukemia viral oncogene homolog 1 ABL1 914 
gap junction protein,alpha 1,43kDa GJA1 397 
upstream binding transcription factor,RNA polymerase I UBTF 36 
chordin like 1 CHRDL1 4 
transcription factor Dp 2 TFDP2 6 
abl interactor 1 ABI1 28 
X ray repair complementing defective repair in Chinese hamster cells 
4 XRCC4 31 
shroom family member 3 SHROOM3 20 
EPH receptor A7 EPHA7 6 
death associated protein kinase 1 DAPK1 24 
glycogenin 1 GYG1 8 
Sp8 transcription factor SP8 10 
methionine adenosyltransferase II,beta MAT2B 3 
sortilin 1 SORT1 4 
peptidylprolyl isomerase C PPIC 8 
interferon regulatory factor 2 IRF2 16 
HMG box transcription factor 1 HBP1 4 
RNA binding motif protein 9 RBM9 7 
dCMP deaminase DCTD 13 
caspase 6,apoptosis related cysteine peptidase CASP6 28 
uridine monophosphate synthetase UMPS 16 
fibroblast growth factor 10 FGF10 25 
aryl hydrocarbon receptor nuclear translocator like ARNTL 21 
Fas APT1 738 
aprataxin APTX 6 
thrombospondin 1 THBS1 79 
polycystic kidney disease 2 PKD2 18 
CD83 molecule CD83 41 
tumor protein p73 like TP73L 31 
jagged 1 JAG1 18 
matrix metallopeptidase 10 MMP10 21 
slit homolog 2 SLIT2 3 
adrenomedullin ADM 44 
thymidylate synthetase TYMS 87 
endothelin receptor type A EDNRA 58 
polymerase,beta POLB 28 
cylindromatosis CYLD 3 
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malate dehydrogenase 1,NAD MDH1 5 
 
Metaplasia – 8 genes 
  name symbol abstract count 
alpha methylacyl CoA racemase AMACR 6 
tumor protein p73 like TP73L 16 
SRY box 2 SOX2 9 
catenin,delta 1 
CTNND
1 3 
jagged 1 JAG1 3 
v abl Abelson murine leukemia viral oncogene homolog 1 ABL1 22 
thrombospondin 1 THBS1 5 
CD83 molecule CD83 3 
 
WNT signaling pathway – 5 genes 
  name symbol abstract count 
fibroblast growth factor 10 FGF10 3 
catenin,delta 1 
CTNND
1 3 
jagged 1 JAG1 4 
SRY box 2 SOX2 3 
gap junction protein,alpha 1,43kDa GJA1 3 
  
cell motility – 11 genes 
  name symbol abstract count 
myosin X MYO10 5 
catenin,delta 1 CTNND1 21 
shroom family member 3 SHROOM3 9 
slit homolog 2 SLIT2 4 
T cell lymphoma invasion and metastasis 1 TIAM1 6 
abl interactor 1 ABI1 4 
thrombospondin 1 THBS1 17 
neuregulin 1 NRG1 10 
gap junction protein,alpha 1,43kDa GJA1 11 
v abl Abelson murine leukemia viral oncogene homolog 1 ABL1 26 
Fas APT1 11 
 
wound healing – 12 genes 
  name symbol abstract count 
epiregulin EREG 7 
collagen,type V,alpha 2 COL5A2 3 
fibroblast growth factor 10 FGF10 19 
thrombospondin 1 THBS1 62 
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matrix metallopeptidase 10 MMP10 19 
fibrillin 2 FBN2 3 
T cell lymphoma invasion and metastasis 1 TIAM1 3 
gap junction protein,alpha 1,43kDa GJA1 36 
cyclin dependent kinase inhibitor 2C CDKN2C 3 
jagged 1 JAG1 5 
catenin,delta 1 
CTNND
1 3 
tumor protein p73 like TP73L 3 
neuregulin 1 NRG1 4 
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